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Abstract 
The management of HIV-associated tuberculosis (TB) is complicated by the 
pharmacokinetic interactions between rifampicin (RMP) and co-administered 
protease inhibitors (PIs) and non-nucleoside reverse transcriptase inhibitors. 
Rifabutin (RBT) is an alternative rifamycin, preferred in patients requiring PIs. 
Recent studies suggest the current recommended dose of RBT in 
combination with boosted lopinavir (LPV/r) is suboptimal and there are 
insufficient pharmacokinetic data evaluating the interaction between RBT co-
administered with efavirenz (EFV) and nevirapine (NVP). Pharmacogenomic 
studies have shown that RMP concentrations are lower in patients from sub-
Saharan Africa with polymorphisms of the SLCO1B1gene but there is 
currently no data on the pharmacogenetic determinants of RBT exposure. 
 
 
The pharmacokinetics of RBT were evaluated at two different doses in HIV 
co-infected patients before and after the introduction of LPV/r, EFV and NVP-
based antiretroviral therapy (ART). After six weeks of standard TB therapy, 
RBT 300 mg daily was started for four weeks. Thereafter patients were 
randomized to receive either RBT 150 mg daily or RBT 150 mg three times a 
week (TPW) with LPV/r, RBT 300mg or 450mg with NVP or RBT- 450mg or 
600mg with efavirenz. After four weeks on the first RBT dose, patients 
switched to the alternate dose and continued until the end of TB treatment. 
Serial RBT and 25-O-desacetylrifabutin (dRBT) concentrations were 
measured during a dose interval before patients switched RBT doses.  
	   viii	  
 
 
 The median AUC0-24 and Cmax, of RBT in patients taking 150mg RBT TPW 
was significantly reduced when compared to the other treatment arms. 86% of 
patients whilst on this intermittent RBT arm had an AUC0-24 < 4.5 μg.h/mL, 
level that has been associated with acquired rifamycin resistance. Rifabutin 
exposure was maintained within the range of AUCs that have been shown to 
prevent acquired rifamycin resistance (ARR) with 150mg daily dosing in 
combination with LPV/r. In addition, the combination of RBT with NVP 300mg 
resulted in significantly increased exposure of RBT, with significantly higher 
exposure observed with 600mg RBT.  However, the combination of RBT 
450mg with EFV resulted in RBT exposure lower than 300mg RBT given 
alone in the same patients, whereas RBT 600mg plus NVP results in 
bioavailability of RBT equivalent to 300mg given alone.  
 
 
Rifabutin was well tolerated at all doses. Only three grade 4 laboratory 
toxicities, elevated transaminases, neutropenia, and uveitis, possibly related 
to RBT were reported in patients taking NVP. SLCO1B1 rs4149032 C>T 
polymorphism occurs frequently in African patients in Durban and may be 
associated with low RBT bioavailability. These findings support 
recommendations for the higher dose of RBT in combination with LPV and 
EFV but not with NVP. 
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Chapter 1. Introduction & Literature Review 
Section 1 Introduction 
1.1. Tuberculosis – a recurring epidemic 
The presence of tuberculosis (TB) in human remains from pharaonic Egypt indicates 
that it has plagued mankind since an early stage of human history. A large expansion 
of TB occurred in the early 1600s during the industrial revolution in Europe, as a result 
of over-crowding and unhygienic living conditions, and was subsequently spread to 
North America by European migration (Bates and Stead 1993). For decades preceding 
the discovery of antibiotics, TB was treated by lung collapse and thoracoplasty, 
confinement in a sanatorium, bed rest and exposure to fresh air (Ducati et al 2006) 
resulting in high case fatality rates (CFRs). The probability of death in patients 
diagnosed with pulmonary TB between 1925 and 1934 in Denmark was reported to be 
17-29% 1 year after diagnosis, 32-43% 3 years after diagnosis and 42-55% 5 years 
after diagnosis (Buhl and Ngboe 1925). An observational study of sputum-positive TB 
patients diagnosed between 1928 and 1938 by (Thompson et al 1943) reported that 
the probability of dying in the first year after diagnosis was 40%.  
 
The subsequent development of modern TB therapy during the 1950s and 1960s and 
the use of treatment regimens incorporating combinations of these drugs resulted in 
cure rates of over 90% (Fox et al 1999). However, an upsurge of the global incidence 







attributed to various factors including HIV. Globally, in 2010 there were an estimated 
8.8 million people infected with TB of which 1.1 million (13%) were also infected with 
HIV. The majority (82%) of TB-HIV co-infected people reside in sub-Saharan Africa 
(Figure 1.1). Tuberculosis was the cause of approximately 1.4 million deaths globally in 
2010, 0.35 million of which were also HIV co-infected. South Africa has the largest 
population of HIV infected people in the world, estimated at 5.9 million in 2009 with 
Kwa-Zulu Natal (KZN) being the most affected province in the country. Consequently 
South Africa has the highest incidence of TB-HIV co-infected patients among countries 





















1.2. Development of modern tuberculosis chemotherapy 
 Although Dr. Robert Koch discovered that infection with the bacillus, Mycobacterium 
tuberculosis, caused TB as early as 1882 (Koch 1882), effective treatment of TB 
began only after the discovery of streptomycin (SM; S) in 1943 (Waksman 1943). In 
fact, the very first clinical trial of TB therapy conducted in 1946 compared the efficacy 
of bed rest to the combination of bed rest and treatment with SM. Treatment with SM 
proved to be superior to bed rest alone thus SM was the first drug to be used for the 
treatment of TB (BMRC 1948). However, treatment with SM alone was associated with 
acquired resistance and the use of drug combinations was proposed when more anti-
TB drugs were introduced, namely P-aminosalicylic acid  (PAS; P) in 1948 and 
isoniazid (INH; H) in 1952. Subsequent clinical trials incorporating SM, INH and PAS, 
demonstrated almost complete suppression of acquired resistance by the addition of 
INH (Medical Research Council 1955). Thus a triple combination anti-TB regimen 
consisting of INH, SM and PAS for 2 or 3 months followed by INH and PAS for the 
remaining months of at least 12 months of treatment was developed and was used as 
standard chemotherapy for the treatment of TB for 20 years (International Union 
against Tuberculosis 1964).  
 
Short-course chemotherapy (SCC), was introduced in the early 1970s after the 
discovery of rifampicin (R; RMP). Following extensive in vitro studies in a murine model 
of TB which showed the unique sterilizing ability of RMP and PZA in combination with 







of 2 six-month regimens of daily chemotherapy, viz. SM, INH, RMP and SM, INH, PZA 
in the treatment of newly diagnosed extensive smear-positive pulmonary TB. In this 
study the relapse rate was reduced to 8% and 3% by the addition of PZA and RMP 
respectively (East African/ British Medical Research Councils 1973). Subsequent 
studies showed that adverse events were associated with SM but not with ethambutol 
(EMB; E) and chemotherapy with RMP and INH for 9 months supplemented in the first 
2 months by EMB was recommended as the treatment of choice for pulmonary TB in 
Britain (British Thoracic and Tuberculosis Association 1976). Further studies showed 
that treatment could be reduced to 6 months by combining RMP and PZA (British 
Medical Research Council 1978).  
 
The World Health Organization (WHO) currently recommends standard SCC for the 
treatment of all patients with active TB. Short course chemotherapy consists of 2 
months of an intensive phase of treatment with RMP, INH, PZA and EMB followed by 4 
months of a continuation phase of INH and RMP (World Health Organization Stop TB 
Department 2009). The aim of SCC is to shorten the treatment period by killing the 
bacterial population quickly and to prevent the emergence of drug resistance. The 4 
drug combination in the intensive phase ensures early bacterial and sterilizing activity 
and the prevention of drug resistance while the 2 drugs in the continuation phase 
continue with sterilizing activity to prevent relapse (Mitchison 1979; Jindani et al 1980).  
Various studies have shown the superiority of 6 months of RMP-based therapy for the 







Medical Research Council Tuberculosis Units in Africa, Singapore and India recorded 
2-year relapse rates of 0%-3% in patients taking RMP for the entire treatment period of 
6 months compared to 2-year relapse rates of 7%-18% in patients that took RMP for 
2/6 months of therapy (Fox et al 1999). A subsequent study confirmed that RMP-based 
therapy for 6 months was superior to 8-month EMB-containing regiments in HIV-
infected and HIV-negative patients. In this study, newly diagnosed, sputum smear-
positive TB patients were randomized to receive either 2 RHZE daily followed by 6EH 
daily, or 2 RHZE three times per week (TPW) followed by 6EH daily, while a control 
arm received 2 RHZE daily followed by 4RH daily. Sputum negative cultures 12 
months after the completion of therapy were highest for patients on the control regimen 
thus verifying that both 8-month EMB-based regimens were inferior to the 6-month 
RMP-based regimen (Jindani et al 2004). Similar observations were reported in a 
Ugandan study of 549 TB-HIV co-infected patients. After treatment with 2 RHZE, 
patients were randomized to receive either 4 months of RMP and INH, 6 months of 
RMP and INH or 6 months of EMB and INH TPW. After 2 months of treatment, more 
than 94% of patients had negative sputum mycobacterial cultures. However, during 
follow-up 26% of patients that took EMB-based therapy relapsed, compared to 7% and 
13% of patients that took RMP-based therapy for 6 and 4 months respectively (Okwera 
et al 2006).  
 
1.3. The Treatment of HIV-associated Tuberculosis  
In 2003, the WHO declared TB a global public health emergency and since 2004 has 







and treat TB in persons living with HIV. One of the recommended interventions is the 
provision of antiretroviral therapy (ART) to all persons living with HIV (World Health 
Organization 2004) and the WHO has since begun up scaling access to ART in 
resource poor countries. By the end of 2010, 6.65 million adults and children received 
ART in low and middle-income countries (World Health Organization 2011a). In many 
resource-limited countries with a high burden of TB, a large proportion of TB-HIV co-
infected patients present at TB clinics late and with advanced immunosuppression 
(Dean et al 2001; Manosuthi et al 2006) and thus require TB therapy and ART 
urgently.       
 
Antiretroviral therapy plays a key role in the prevention of HIV-associated TB. In 
patients taking ART, the risk of developing TB is reduced by 70 - 90% (Badri et al 
2002; Lawn et al 2005; Lawn et al 2009; Lawn et al 2011). However, the burden of TB 
among patients taking ART is still high (and above the background rates in HIV-
negative patients) in resource-limited settings, particularly in patients with more 
advanced immunodeficiency and incomplete or delayed immune restoration (Lawn et 
al 2005; Lawn et al 2006; Houlihan et al 2010; van Rie et al 2011; Gupta et al 2012). 
Bonnet et al (2006) investigated the incidence of TB in 5 countries with a high TB 
burden and reported that the incidence of TB among HIV-infected patients with CD4 
counts < 200 cells/µL ranged from 4.8/100 person-years in Cameroon to 17.7/100 
person years in Kenya. In a more recent cross-sectional survey of 24 ART treatment 
programs in Africa, Asia and Latin America, the rate of incident TB in the first year of 







patients on ART, TB may occur as unmasking of sub-clinical disease (TB present but 
not diagnosed at ART initiation), activation of latent TB or new infections.  
  
The WHO promotes the use of SCC and directly observed therapy (DOT) for the 
treatment of TB in HIV-positive patients and in patients without HIV co-infection (World 
Health Organisation Stop TB Department 2009). Studies have shown that this 
approach is effective, including in patients with advanced immunosuppression (Small 
et al 1991; Schurmann et al 1993; Kassim et al 1995; Perriens et al 1995; Chaisson et 
al 1996; El-Sadar et al 2001). However, some African countries that have used 
“standard” regimens that do not contain RMP have reported high rates of relapse and 
death (Perriens et al 1991; Hawken et al 1993; Elliott et al 2009). A review of CFRs in 
sub-Saharan Africa by Mukadi et al (2001) reports that mortality was higher in HIV-
infected TB patients compared to HIV-negative patients during the course of TB 
therapy and that countries that used non-RMP-based therapy or used RMP only in the 
intensive phase. A recent meta-analysis by Khan et al (2010) reported that patients 
treated with a rifamycin for only two months were more likely to experience relapse 
than those patients treated with 6 to 8 months of rifamycin based therapy.     
The benefits of concurrent antiretroviral (ARV) and TB therapy compared to sequential 
therapy in the treatment of HIV-infected TB patients with advanced 
immunosuppression were shown recently by various large studies. In the Starting 
Antiretroviral Therapy at Three Points in Tuberculosis (SAPIT) study in South Africa, 
TB-HIV co-infected patients with CD4 cell counts < 500 cells/mm3 were randomized to 







(sequential arm). This trial showed that starting ART therapy during TB therapy 
increased the survival of TB patients co-infected with HIV (Abdool Karim et al 2010). 
Data from the Multicenter Cohort of Patients with HIV infection in the Madrid South-
Eastern Metropolitan Crown (COMESEM) study showed that survival could be 
increased further if ART was started within 2 months of stating TB therapy (Velasco et 
al 2009). A subsequent study, the Cambodian Early versus Late Introduction of 
Antiretrovirals (CAMELIA) study investigated the timing of ART on the survival of ART-
naive TB-HIV co-infected patients with CD4 cell counts < 200 cells/mm3. . Enrolled 
patients on standard TB therapy were randomized to receive efavirenz (EFV)-based 
ART 2 weeks after starting TB therapy (earlier treatment) or 8 weeks after starting TB 
treatment (later treatment). Mortality was significantly lower in the earlier treatment 
group (18%) compared to the later treatment group (27%). Thus initiating ART within 2 
weeks of starting TB therapy significantly increases the survival of TB-HIV co-infected 
patients with CD4 cell counts ≤ 200 cell/mm3 (Blanc et al 2011). Another large open 
label multicenter randomized study compared immediate (within 2 weeks of TB 
treatment initiation) to early (8-12 weeks) ART among TB-HIV co-infected patients with 
CD4+ cell counts < 250 cells/mm3 and confirmed the results of Blanc and colleagues. 
In this study, in patients with CD4+ counts < 50 cells/mm3, AIDS defining illnesses and 
death were 42% lower in patients on immediate ART compared to early ART (Havlir et 
al 2011). The combined results from these studies have led to new treatment 
guidelines, which recommend that all TB patients receive ART soon after starting TB 








1.4. Current challenges in the treatment of HIV-associated TB 
1.4.1. Overlapping toxicities between anti-TB drugs and antiretrovirals 
Adverse drug reactions to anti-TB therapy and ART are similar and common in TB-HIV 
co-infected patients. The majority of adverse events occur within the first two months of 
starting therapy. Hepatotoxicity is a common adverse event in patients taking 
rifamycins, INH and PZA and may be compounded in patients taking concomitant non-
nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs). The 
risk of hepatotoxicity is increased further in patients with concomitant hepatitis C virus 
infection (Sterling et al 2010). Dean et al (2001) reported peripheral neuropathy, rash 
and gastrointestinal upset as the most common adverse events in TB-HIV co-infected 
patients taking concomitant anti-TB therapy and highly active anti-retroviral therapy 
(HAART). Peripheral neuropathy, rash and gastrointestinal upsets are reported with TB 
and HAART, however they are more common in TB-HIV co-infected patients (40%) 
compared to non-infected patients (26%) (Breen et al 2006).   
 
 
1.4.2. Immune reconstitution inflammatory syndrome (IRIS) 
Despite the benefits of starting ART soon after the start of TB therapy some patients 
experience a paradoxical worsening of symptoms or the onset of new symptoms which 
manifests as fever, rapidly enlarging lymph nodes, worsening pulmonary infiltrates, 
development of new plural effusions, appearance of a miliary pattern on chest x-rays 
and worsening central nervous system lesions. This worsening of the signs and 







reconstitution inflammatory syndrome (IRIS) (Narita et al 1998; Michailidis et al 2005; 
Lawn et al 2008). The initiation of ART stimulates the reconstitution of immune 
responses to mycobacteria, and cytokine secretion, particularly of interferon (IFN)-γ is 
boosted. It is believed that IRIS may be a result of this sudden boosting of previously 
diminished immune function (Schluger et al 2002; Elliott et al 2009). 
 
There are two types of IRIS presentation. The most common form, reported in 8 to 
43% of patients, occurs in patients on TB treatment who soon after starting ART 
experience a deterioration of the clinical manifestations of TB. The second form of IRIS 
is called “unmasking” of subclinical TB which occurs as immune function is reinstated 
by ART (Lawn et al 2008). Risk factors for IRIS include starting ART within the first two 
months of TB treatment, extra-pulmonary or disseminated TB; low CD4+ cell counts at 
the start of ART, a viral load greater than 105 log10 copies/mL and a good 
immunological and virological response during HAART. Death from IRIS is rare and 
management with short-term corticosteroids (without interrupting TB therapy) 
suppresses the enhanced immune response (Colebunders et al 2006). 
   
1.4.3. Malabsorption of anti-Tuberculosis drugs 
The malabsorption of anti-TB drugs, particularly RMP has been reported in TB patients 
with and without HIV infection (Peloquin et al 1993; Choudhri et al 1996; Peloquin et al 
1996; Sahai et al 1997; Gurumurthy et al 2004; Perlman et al 2005; Tappero et al 







populations sub-optimal RMP concentrations have been reported in 70-80% of co-
infected patients (van Crevel et al 2002; Tappero et al 2005). Lower rifamycin 
exposure may contribute to lower effectiveness of anti-TB treatment and acquired 
rifamycin resistance (ARR) (Spradling et al 2002; Li et al 2005; Weiner et al 2005a; 
Burman et al 2006 ).  
 
 There is evidence to suggest that the absorption of rifamycins is affected by certain 
disease states. In Indonesian patients with TB and type 2 diabetes, RMP exposure 
was decreased by 53% compared to patients with TB alone (Nijland et al 2006). Low 
plasma concentrations of RMP were also observed in patients with cystic fibrosis and 
mycobacterial disease (Gilljam et al 1999). In TB-HIV co-infected patients, lower 
plasma RMP concentrations are associated with advancing HIV disease (evidenced by 
lower CD4+ cell counts) (Sahai et al 1997; Gurumurthy et al 2004). Low bioavailability 
of anti-TB drugs has been associated with various factors such as alcohol use 
(Kimerling et al 1998), race (Tappero et al 2005), age (McIlleron et al 2006), gender 
(Sahai et al 1997; Ray et al 2003; McIlleron et al 2012), hypoalbuminaemia (Tappero 
et al 2005) and dose per kg of body weight (McIlleron et al 2006). HIV-associated 
alterations in gastro-intestinal structure and function may also be responsible for the 








1.4.4. Drug-drug interactions 
Pharmacokinetic (PK) drug-drug interactions occur when drugs that share a common 
metabolic or elimination pathway are administered together. In humans, approximately 
50% of all drugs are metabolized by cytochrome 450 (CYP450) isoenzymes. CYP 450 
is located in the gut wall (enterocyte) of the small intestine and in the liver. Cytochrome 
3A4 (CYP 3A4) is the most prominent form of CYP 450 involved in drug metabolism. 
Other forms of CYP 450 involved in drug metabolism include CYP2D6, 2C9, 2C19, 
1A2, 2B6, 2E1 and 2A6 (Bachmann et al 1993; Diliger et al 1999). Cytochrome 450 
metabolizes various drugs, including antiretrovirals (ARVs). Nevirapine and all PIs are 
metabolized predominantly by CYP3A4 (Erickson et al 1999; Riska et al 1999). 
Efavirenz is metabolized predominantly by hepatic CYP2B6 and partially by CYP3A4 
and CYP2A6 (Ward et al 2003; Desta et al 2007). Rifampicin is a strong inducer of 
CYP3A4 and CYP2B6 (Rae et al 2001). Rifampicin increases the expression of CYP 
3A4 and CYP2B6 by binding with the nuclear receptors, pregnane X receptor (PXR) or 
constitutive androstane receptor (CAR) which then form a heterodimer with the retinoid 
X receptor (RXR). The heterodimer interacts with the regulatory region of the CYP3A4 
and CYP2B6 genes thereby increasing the synthesis of CYP3A4 and CYP2B6. 
Rifampicin also induces the activity of phase II enzymes (Diliger et al 1999; Gallicano 
et al 1999) and membrane transporters such as P-glycoprotein (PGP) (Greiner et al 








1.5. Study Objectives and Scope of the thesis 
The general aim of this study was to investigate the pharmacokinetics of rifabutin 
(RBT) given alone and in combination with ART in African TB-HIV co-infected patients 
with advanced immunosuppression. The specific aims were to: 
1. Describe the pharmacokinetics of standard doses of RBT (300mg) in TB-HIV co-
infected African patients with advanced immunosuppression 
2. Investigate the pharmacokinetic interaction between two different doses of RBT and 
NNRTIs, viz. EFV and nevirapine (NVP) 
3. Investigate the pharmacokinetic interaction between two different doses of RBT and 
boosted lopinavir (LVP/r) 
4. Assess the frequency and severity of adverse drug events associated with the 
combination of RBT and ART 
5. Investigate the frequency of SNPs of SLCO1B1 in African TB patients co-infected 
with HIV and their influence on RBT exposure 
 
Section 2 Literature Review 
1.6. Discovery Of Rifabutin 
Rifabutin is a member of the rifamycin family of antibiotics. The rifamycins are closely 
related bactericidal antibiotics. During a routine screening exercise for new antibiotics 
by staff of the Lepetit Research Laboratories (Milan, Italy) in 1957, an organism was 







Streptomyces but later classified as Amycolatopsis) produced a supernatant containing 
several substances with activity against gram-positive bacteria and mycobacteria. 
Further studies on the individual components of the mixture revealed substances that 
were highly active against mycobacteria and gram-negative bacteria. Following 
collaborative research with Ciba-Geigy (Basel, Switzerland) to produce an anti-
mycobacterial agent with good oral bioavailability and potent activity against 
Mycobacterium tuberculosis, RMP was developed, followed by RBT and rifapentine 
(RPT).  
 
The first step in the discovery of the rifamycins was the identification of a substance 
(ME/83) with antibiotic activity against Gram-positive bacteria, produced by cultures of 
the organism (Sensi 1983). Biochemical analysis identified a mixture of 5 
microbiologically active substances collectively named rifamycins (Margalith and 
Pagani 1961). Further biochemical analysis led to the production of rifamycin B, which 
possessed extremely low toxicity, but was poorly active against gram-positive bacteria 
and converted spontaneously to rifamycin SV.  Rifamycin SV had higher antibacterial 
activity; therefore a decision was taken to investigate chemical modifications of 
rifamycin B. Rifamycin SV showed high antibacterial activity in vitro, particularly 
against gram-positive bacteria and Mycobacterium tuberculosis (M. tuberculosis) as 
well as low toxicity. Thus Rifamycin SV was the first rifamycin to be used clinically and 
was administered intravenously for the treatment of infections due to gram-positive 







in the treatment of TB because therapeutic drug levels in blood were not achieved as 
the drug was concentrated in the liver and rapidly excreted in bile (Sensi 1966).  
 
A new rifamycin was sought with better oral absorption, slower biliary excretion and 
better activity against M. tuberculosis than Rifamycin SV. Modifications of the aliphatic 
bridge, glycolic chain and chromophoric nucleus of rifamycin B were studied. The N,N- 
disubstituted hydrazone derivatives of rifamycin B exhibited the highest antitubercular 
activity and were chosen for more extensive evaluation. All the derivatives of this class 
showed high in vivo activity against staphyloccal infection in mice, possessed good 
oral absorption as well as low biliary excretion. The most active derivative of this class 
was the hydrazone with N-amino-N’-methylpiperazine which was named RMP (Sensi 
1966). Further biochemical modifications of the side chain at carbon-3 in rifamycin S 
produced 4-N-isobutylspiropiperidylrifamycin S (Sanfilippo et al 1980). This derivative 
of rifamycin S, RBT (initially named LM 427), showed remarkable activity against M. 
tuberculosis in vitro and in vivo. Further research by the Centre for Disease Control in 
Atlanta (USA) showed that LM 427 inhibited growth of a number of clinical strains of 
RMP-resistant M. tuberculosis and displayed potent activity against strains of 
Mycobacterium avium intracellulare complex (MAC) (Della Bruna et al 1983). 
 
1.7. Structure Of Rifabutin 
The rifamycins have closely similar chemical structures. A common feature of all 







bridge and an acetyl group at position 25 (Sensi et al 1966). The structural difference 
between the three rifamycins is due to a different functional group at Carbon 3 (shown 
by arrows in Figure 1.2). Although the rifamycins have similar chemical structures, they 
have different physio-chemical and biological properties. 
 
Rifabutin is a spiro-piperidyl rifamycin and has a unique structure in which positions 3 
and 4 are incorporated into an imidazoline ring bearing a spiro-piperidyl group while 
RMP and RPT have a piperazinyl iminomethyl group (Figure 1.2). The piperazinyl 
iminomethyl group is recognized by receptors on enzymes that catalyze the 
deacetylation of RMP and RPT. The absence of this group in the chemical structure of 
RBT gives RBT a more rigid ring structure that imparts steaic hinderance to the binding 
of RBT to receptors on enzymes that catalyze the deacetylation of the rifamycins and 
is probably the reason why the metabolism of RBT does not occur predominantly by 











Figure 1.2. Chemical structures of the rifamycins (Vernon 2004) 
 
1.8. Physio-chemical Properties of Rifabutin 
The molecular formula of RBT is C46H62N4O11 and its molecular weight is 847.02. The 
pKa of RBT is 6.9, hence it is highly lipid soluble. It is absorbed well after oral ingestion 
and distributes extensively in tissues. Rifabutin penetrates easily into 
polymorphonuclear leukocytes, lymphocytes and macrophages. High concentrations of 
RBT are attained in the liver and lung (Brogden and Fitton 1994). 
 
At physiological pH, RBT is mostly unionized while RMP exists as a mixture of 







of their different ionization states, RBT and RMP possess different distribution 
coefficients. Rifabutin has a higher octanol / water partition coefficient (logP) and lower 
water solubility than RMP. The solubility of RBT is pH dependant (stable at pH range of 
2-8), therefore dissolution occurs in the stomach and absorption occurs in the small 
intestine where pH is higher. Rifabutin is also more lipophilic than RMP; therefore 
uptake of RBT into intracellular tissues and macrophages is greater than that of RMP 
(Acocella et al 1978; Narang 1995). 
 
1.9. Mode Of Action 
The predominant biological activity of the rifamycins is the inhibition of gram-positive 
bacteria and mycobacteria. They exhibit selective toxicity against these pathogens, 
exerting their antibacterial activity by blocking the synthesis of bacterial RNA but not 
interfering with host RNA. The macrocyclic ring of the rifamycin binds with bacterial 
RNA forming a complex that inactivates RNA polymerase (Wehrli and Staehelin1971). 
Rifabutin also has a unique ability to inhibit bacterial DNA synthesis (Della Bruna et al. 
1983). This unique characteristic of RBT might be responsible for its effects against 
RMP-resistant strains (Olliaro et al 1995). 
 
 
1.10. Antimicrobial Actions Of Rifabutin 
Rifabutin is a broad-spectrum antibiotic, effective against both Gram-positive and 







Mycobacteria. Initial in vitro studies (Sanfilippo et al 1980) showed that the spiro-
piperidyl rifamycins demonstrated potent activity against M. tuberculosis, which 
increased as the number of carbon atoms in the linear side chain increased. In 
comparison to RMP, these rifamycins displayed better gastrointestinal absorption, 
lower plasma levels and higher concentrations in tissues. Further in vitro studies on the 
minimum inhibitory concentration (MIC) of RBT showed that RBT possessed greater 
anti-mycobacterial activity than RMP and that 31% of M. tuberculosis strains resistant 
to RMP were susceptible to RBT (Woodley et al 1982; Dickinson and Mitchison 1987).  
 
The MIC of RBT for M. tuberculosis was initially reported to be 0.003-0.06 mg/L in 
liquid media (eg. Bactec), 0.03 - 0.08 mg/L in solid media (eg. 7H10, 7H11), and 0.25-1 
mg/L in Loewenstein-Jensen and the MBC/MIC ratio for M.tuberculosis is 4 (Heifets et 
al 1988). A study by Breda et al (1992) in healthy volunteers showed that plasma 
concentrations of RBT above the MICs for RMP-resistant strains of M.tuberculosis are 
maintained for 12-24 hours with 150-300 mg daily. Recently, Rastogi et al (2000) 
compared the MICs of RMP, RBT and RPT in 7H11 agar medium and Bactec broth 
against members of the M.tuberculosis complex. The MIC90 of RBT was 0.063 mg/L 
and 16.0 mg/L in Bactec and 7H11 against drug-susceptible and RMP-resistant 
isolates of M.tuberculosis respectively. When compared with RMP and RPT, the 








Table 1.2. The minimum inhibitory concentrations of rifabutin, rifampicin and 
rifapentine in Bactec and 7H11 against members of the M.tuberculosis complex  
(from Rastogi et al 2000) 
 
 Rifabutin Rifampicin  Rifapentine 
Species Bactec 7H11 Bactec 7H11 Bactec 7H11 
M.tuberculosis* 0.063 0.063 0.25 0.25 0.063 0.125 
M.tuberculosis** 16.0 16.0 >32.0 >64.0 >32.0 64.0 
M.africanum 0.063 0.125 0.125 0.50 0.031 0.25 
M.bovis 0.125 0.125 0.125 0.125 0.063 0.125 
* = drug susceptible; ** = RMP-resistant  
 
 
1.11. Activity Of Rifabutin In Animal Models 
In in vivo studies of experimental mice TB, RBT was 2-3 times more potent than RMP 
(Sanfilippo et al 1980). In addition, RBT was effective against RMP-resistant M.avium 
intracellulare (Woodley et al 1982). Further studies by (Luna-Herrera et al 1995) on the 
in-vitro and intracellular activity of RBT on drug-susceptible and multi drug resistant 
(MDR) tubercle bacilli showed that the in-vitro activity of RBT was comparable to or 
greater than the activity of RMP as determined by the MIC, minimal bactericidal 
concentration (MBC), MBC/MIC ratios as well as continuous exposure and post-
antibiotic effect studies. The MICs of RBT with RMP susceptible strains were much 
lower than those of RMP (MIC90 for RBT was 0.06 mg/L and 0.25 mg/L for RMP). 
Intracellular activity of RBT in macrophages showed that RBT displayed equally high 
potency against M. tuberculosis (strain H37Rv) as well as RMP-resistant strains (strain 







after the drug was removed indicating a prolonged post-antibiotic effect of RBT against 
intracellular and extracellular organisms. In a murine model of TB (BCG-vaccinated 
and M. tuberculosis infected immunocompetent mice) comparing the pharmacokinetics 
and antimicrobial activities of RMP, RBT and RPT, Ji et al (1993) have shown that 
RBT displayed the lowest Cmax but RBT was more bactericidal than RMP and 
comparable to RPT. The activity of RMP was significantly reduced when dosage was 
reduced from daily to TPW whereas the bactericidal activity of RBT was strongly 
maintained at 10 mg/kg twice weekly. In another study by Jabes et al (1994), the 
efficacies of 12-week regimens of daily RBT or INH or intermittent combination of the 
two drugs were evaluated in a murine model of TB. Daily doses of RBT at 10mg/kg 
was highly effective as by 8 weeks of treatment all spleens were sterilized and the 
number of bacilli was significantly reduced in the lungs and bacilli were completely 
eradicated from the spleens and lungs of mice after 12 weeks of treatment. 
Furthermore, the combination of RBT 10 mg/kg plus INH 25mg/kg twice weekly was 
almost as effective as RBT daily but daily INH and once-weekly RBT were less 
effective. Thus data from this study showed that RBT given alone, daily or twice weekly 
in combination with INH was effective in the treatment of TB.   
 
The efficacy of an anti-bacterial is determined by the concentration of the drug, or the 
length of time bacteria is exposed to the drug. Consequently, antibiotics are usually 
classified as concentration-dependent or time-dependent (Craig 1998). The efficacy of 
a dose is determined by pharmacokinetic / pharmacodynamic (PK / PD) parameters 







MIC), the ratio of 24-hour area under the curve to MIC (AUC0-24 / MIC) or time above 
MIC (Craig 2001). Presently, rifamycin PK/PD studies in humans are limited and there 
is controversy over whether the AUC0-24 / MIC or Cmax/ MIC ratio correlates best with 
rifamycin anti-bacterial activity. Early studies in guinea pigs (Mitchison and Dickinson 
1971) and mice (Verbist 1969) suggested that RMP displayed concentration-
dependent anti-bacterial activity, which corresponded with a Cmax/ MIC ratio. 
Subsequently evidence from a mouse model of TB by Jayaram et al (2003) suggested 
that the antimicrobial activity of RMP correlated best with the AUC / MIC ratio and 
Gumbo et al (2007) confirmed this in an in vitro hollow fiber system. Gumbo et al also 
demonstrated that the prevention of resistance was related to Cmax/ MIC. 
Recently, Diacon et al (2007) investigated the effect of increasing doses of RMP on 
early bactericidal activity (EBA) in South African patients. Their results showed that as 
the dose of RMP increased, AUC, Cmax and EBA also increased. Clinical studies 
comparing higher doses of RMP to standard doses in pulmonary TB patients by 
Ruslami et al (2007) reported that increasing the RMP dose from 10 to 13 mg/kg was 
associated with increases in the mean AUC and Cmax of 65% and 49% respectively. 
However these studies were unable to clearly determine if the AUC and Cmax  were 








1.12. Pharmacokinetics of Rifabutin 
1.12.1. Dosage and Administration 
Rifabutin is available as 150 mg capsules and can be administered as a single daily 
dose of 300 mg, independent of meals, for the treatment of newly diagnosed 
pulmonary TB, chronic RMP-resistant pulmonary TB, atypical Mycobacterial infections 
and/or prophylaxis of MAC in HIV-infected patients with advanced immunosuppression 
(Pharmacia Upjohn Company). 
 
1.12.2. Absorption and Bioavailability 
Rifabutin was rapidly absorbed after administration of four oral doses (300, 600, 900 
and 1 200 mg/day) to HIV-infected male patients (Skinner et al 1989) and a single 270 
mg dose to healthy volunteers (Battaglia et al 1990). Maximum concentration in 
plasma (Cmax) was attained in 2-3 hours after drug ingestion and increased 
approximately proportionally as the dose increased (Skinner et al 1989). Peak plasma 
concentration (Cmax) of RBT after a 600mg oral dose is 0.4 – 0.6 μg/mL, which is 
approximately 10-fold lower than the Cmax of a 600mg dose of RMP (Blaschke et al 
1996). At the currently licensed dose of 300mg, the Cmax of RBT is reported to be 0.2 
to 0.9 mg/L in HIV-infected patients. Mean trough plasma concentrations (Cmin) 
obtained 24h after ingestion of 300 or 600mg doses were 0.05 mg/L  (Skinner et al., 
1989). The ingestion of RBT with food does not influence the Cmax but slows the rate of 









In one study (Skinner et al 1989), the AUC of RBT on the first day of administration 
was significantly higher than the AUC after 28 days (at steady state) for each of the 
four doses. This indicates that auto induction of RBT metabolism occurs. The reported 
bioavailability in this study was low (compared to that of RMP) and showed substantial 
inter-patient variability. Average bioavailability was approximately 20% and ranged 
from 3% to 42%. However, the factors influencing RBT bioavailability were not 
investigated. A subsequent study on the influence of gender on the pharmacokinetics 
of RBT by Colborn et al (1993) has shown that the extent of RBT absorption may be 
slightly greater in females due to its high lipophilic nature and given that females have 
a higher body fat composition compared to males.  
 
A formal study on the effect of HIV infection on the pharmacokinetics of RBT has to 
date not been reported. An initial report on pooled data from 5 Phase I studies on the 
prophylactic use of RBT for MAC showed that RBT absorption was not associated with 
the severity of immunosuppression in HIV-infected patients (Narang et al 1996). 
Subsequently (Gatti et al 1999), it was showed that RBT AUC0-24 and Cmax were similar 
in HIV-infected patients with and without wasting syndrome. A population 
pharmacokinetic study of RBT in HIV-infected patients confirmed this. The study did 
not show that RBT exposure was influenced by severity of disease or gastrointestinal 
function (Gatti et al 1998). However, a review on RBT pharmacology by Narang (1995) 
reported higher inter-patient variability among the HIV-infected patients and a 











The AUC curves of RBT show a clear distribution phase (Skinner et al 1989; Gatti et al 
1998) with a distribution half-life of approximately 2-3 hours. The large differences 
between peak and trough plasma concentrations on the first day and after chronic 
administration also indicate the presence of a distribution phase. The mean volume of 
distribution determined in five HIV-positive patients who were receiving RBT 
intravenously was 9.3 L/kg (Skinner et al 1989). 
 
The extent of RBT binding to plasma proteins is reported to be 71% (Skinner et al 
1989) and the predicted free serum peak concentration is 0.13 mg/L  (Burman et al 
2001). Rifabutin penetrates across clinically un-inflamed meninges and concentrations 
between 30 and 70% of those in plasma have been recorded in cerebrospinal fluid 
from HIV-infected patients treated with doses of 300 to 900 mg/day. Concentrations of 
RBT in bile and urine are reported to be more than 100 times greater than 
concentrations in plasma and tissue concentrations are approximately 8.5 times 
greater than plasma 5-12 hours after administration of a single 150 or 300mg dose to 









The primary pathway of RBT elimination is metabolism. Systemic clearance is reported 
to be 0.81L/h/kg in healthy volunteers after a single 150mg dose and the mean plasma 
elimination half-life varies between individuals and studies, ranging from 32 to 67 hours 
(Narang et al 1992; Brogden and Fitton 1994). In humans, RBT is metabolized 
extensively and eliminated by both urinary and fecal excretion (Battaglia et al 1990). 
Approximately 5% of the dose is excreted as unchanged drug in urine (Strolin 
Benedetti et al 1990). The major lipophilic metabolites identified in human urine are 25-
O-desacetyl-rifabutin (d-RBT), 31-hydroxyrifabutin and 32-hydroxy-rifabutin, 20-
hydroxyrifabutin and 27-O-desmethylrifabutin (Battaglia et al 1990; Utkin et al 1997; 
Iatsimirskaia et al 1997). The plasma concentration of d-RBT is approximately 5% that 
of the parent drug and its antibacterial potency is similar to the parent drug (Brogden 
and Fitton 1994; Blaschke and Skinner 1996). 
 
Studies on the enzyme systems involved in the metabolism of RBT were undertaken in  
by Iatsimirskaia et al (1997), Jamis-Dow et al (1997), and Trapnell et al (1997) and 
more recently by Prasad and Singh (2012). The study by Iatsimirskaia et al. (1997) 
showed that RBT was readily metabolized by CYP3A4 in both human enterocytes and 
liver microsomes with similar metabolic patterns and kinetic pathways. Furthermore, in 
both enterocytes and liver microsomes, RBT metabolism was inhibited by 
clarithromycin, fluconazole and ketoconazole, which are known inhibitors of CYP3A4, 
and unaffected by azithromycin. The inhibition of RBT metabolism was more 







interaction occurs in the intestine during concurrent drug absorption. In contrast, the 
study by Trapnell et al. (1997) employing human liver microsomes and recombinant 
human CYP450 demonstrated that RBT was not metabolized by CYP3A4 and that 
CYP3A4 was only responsible for the biotransformation of RBT to d-RBT. However, 
the recent study by Prasad and Singh establishes that RBT is extensively metabolized 
by CYP3A4. Prasad and Singh incubated RMP, RBT and RPT with recombinant 
CYP450 isoforms, CYP1A2, CYP2C19, CYP2D6 and CYP3A4. The metabolism of 
RBT by CYP3A4 was extensive (60-70%) compared to that of RMP and RPT (< 20%). 
CYP1A2, CYP2C19 and CYP2D6 had no significant effect of the metabolism of all 
three rifamycins. 
 
Studies by Iatsimirskaia (1997) and Jamis-Dow (1997) have also shown that RBT is 
deacetylated to d-RBT by microsomal cholinesterase (β-esterase). Cholinesterases 
are also located in the liver and intestinal mucosa as well as in the circulation. 
However, RBT was not deacetylated when incubated with human serum or whole 
blood by Iatsimirskaia et al. indicating that the metabolism of RBT occurs only in the 
liver and intestine. Consequently, in patients with impaired liver function the RBT AUC 
and half-life were significantly increased (Benedetti et al 1993), whereas a case report 
of RBT pharmacokinetics in a haemodialysis patient by Bassilios et al (2002) shows 
that the pharmacokinetics of RBT were not altered by renal insufficiency and that 








Rifabutin also induces its own metabolism after repeated administration, similar to that 
of RMP and RPT. Strolin-Benedetti et al (1990) studied the auto induction of RBT 
metabolism in 7 healthy male volunteers. Subjects were given RBT 450mg orally after 
fasting for 10 hours on day 1. From day 6 onwards they were given the same daily 
dose for 10 days. Plasma concentrations of RBT, d-RBT and 31-hydroxyrifabutin were 
measured after the single and last dose using HPLC with UV detection. Rifabutin 
AUC0-24 after the last (10th) dose was significantly lower than the AUC0-24 of the first 
dose. However, there was no significant change in the elimination half-life between the 
first and 10th doses. The Cmax of d-RBT decreased significantly after repeated 
administration while, the Cmax of 31-hydroxyrifabutin increased by about 54%. It is 
believed that the auto induction of RBT is stimulated by intestinal CYP 3A4. 
 
1.13. Pharmacogenomics  
Previous pharmacokinetic studies on RBT and RMP in healthy volunteers, TB patients 
and TB-HIV co-infected patients have observed a wide distribution of drug 
concentrations (Narang 1995; Skinner et al 1989; Peloquin et al 1997; Peloquin et al 
1999; Wilkins et al 2008). Pharmacokinetic variability has been associated with the 
emergence of resistance in patients (Weiner et al 2005a) and model systems 
(Strivastava et al 2012). At the other extreme, higher exposure to RBT has been 
associated with increased toxicity. However, the factors determining such variation in 








Pharmacogenomic studies in HIV-infected individuals have identified genetic 
differences and profiles that affect drug bioavailability and responses to ARVs (Haas et 
al 2005). For example, the ABCB1 (MDR 1) gene encodes PGP (an ABC transporter). 
P-glycoprotein is known to act on a broad range of drugs, therefore a number of 
studies have investigated the functional consequences of variation in the ABCB1 gene 
particularly the ABCB1 C3435T polymorphism.  Studies have shown an association 
with this variant and serum drug levels, and with responses to a number of drugs 
(Loeuillet et al 2007). Plasma concentrations of the PIs have been associated with the 
T allele at the MDR1 C3435T locus (Saitoh et al 2005). In addition LPV and RTV are 
substrates, and may also inhibit and / or induce ABCB1. Similarly, genetic differences 
in the MDR1 gene may also affect the exposure and disposition of anti-TB drugs. 
Rifampicin is also a substrate of PGP and a recent study (Davies et al 2008) has 
shown that in MDR1 C3435T CC homozygotes, the bioavailability of RMP was reduced 
by 33% but remained unchanged in the TT homozygotes. There are ethnic differences 
in the allele frequencies of MDR1. Various studies have shown that Africans have a 
higher frequency of the CC genotype (and lower frequency of the TT phenotype) 
compared to Caucasians (Ameyaw et al 2001; Kim et al 2001; Schaeffeler et al 2001). 
 
The organic anion transporting polypeptide 1B1 (OATP1B1) is an uptake transporter. 
The SLCO1B1 gene encodes OATP1B1 (Hagenbuch et al 2003) and SNPs have been 
identified in the SLCO1B1 gene, which may result in significant alteration of drug 
pharmacokinetics by decreasing the uptake activity of the corresponding OATP 







between different populations (Pasanen et al 2008).  A recent study has shown that 
RMP concentrations are lower in African American patients and in these patients the 
SLCO1B1 SNP rss11045819 (C463A) has been associated with reduced RMP 
exposure (Weiner et al 2010). In another South African study a different polymorphism, 
rs4149032 SNP, was reported in 70% of individuals and patients heterozygous and 
homozygous for this polymorphism had reductions of 18% and 28% respectively, in the 
bioavailability of RMP (Chigutsa et al 2011).  
 
Although a few studies have been done on the pharmacogenomics of RMP as cited 
above there are no studies reporting on the pharmacogenomics of RBT. Information on 
the pharmacogenomics of RBT may help with the design of treatment regiments for the 
treatment of TB-HIV co-infection especially in African populations.  
 
1.14. Human Studies on Rifabutin 
In humans, initial studies on RBT focused on the treatment of disseminated MAC 
infection in HIV infected patients (O’Brien et al1987). Two randomized double blind 
multi-center trials administered 300mg RBT or placebo daily to HIV infected patients 
with advanced immunosuppression (CD4+ cell count < 200 cells/mm3). In the first trial, 
MAC bacteremia developed in 17% of patients assigned the placebo and in 8% of 
patients assigned RBT. In the second trial, 18% of patients in the placebo group and 
9% of patients in the RBT group developed MAC bacteremia. Patients in the RBT 







1993). Rifabutin administered to HIV infected patients at doses of 150 – 600 mg/day as 
prophylaxis for MAC was well tolerated (Olliaro et al 1993) hence RBT has been 
recommended as prophylaxis to prevent disseminated MAC in HIV infected patients 
with advanced immunosuppression. 
 
Clinical data on the efficacy of RBT in the treatment of pulmonary TB in HIV co-
infected patients is limited. Data from 5 randomized control trials (RCTs) (Hong Kong 
Chest Service/British Medical Research Council 1992, Gonzalez-Montaner et al 1994, 
McGregor et al 1996, Schwander et al 1995) that assessed the efficacy of RBT in TB 
disease show that RMP and RBT are equally effective. However, TB-HIV co-infected 
patients were under-represented in the RCTs, comprising only 5% of the randomized 
patients. 
 
In a pilot study in Uganda, that compared the efficacy of a RBT-based regimen against 
a RMP-based regimen for the treatment of pulmonary TB, RBT and RMP showed 
comparable efficacy. However, patients treated with RBT had significantly more rapid 
clearance of acid-fast bacilli from sputum at 2 months and over the entire study period 
than patients treated with RMP (Schwander et al 1995). Another multi-centre clinical 
trial compared the efficacy of RBT- and RMP-based SCC in the treatment of TB-HIV 
co-infected patients. Newly diagnosed smear positive TB patients were treated with 
RBT 150mg daily, RBT 300mg daily or RMP 600mg daily and sputum smear 







Montaner et al 1994). Both these clinical trials have shown that RBT is effective in the 
treatment of pulmonary TB, however the trials enrolled a small number of patients and 
only one trial was conducted in HIV-positive patients. Collectively these trials provide 
no evidence that RBT is inferior to RMP, but none of them were sufficiently powered to 
show superiority of one rifamycin over another. A recent review on the use of RBT for 
the treatment of pulmonary TB suggests that there is insufficient data on the efficacy of 
RBT in the treatment of TB in HIV-co-infected patients and more studies are required 
(Davies et al 2007).  
 
1.15. Clinical Pharmacology of Rifabutin 
1.15.1. Drug Interactions With Non-ARVs 
HIV-positive patients are administered cotrimoxazole (CTX) prophylactic therapy 
according to WHO guidelines. Therefore many patients who require anti-TB therapy 
and are prescribed RBT will be taking RBT and CTX concurrently. Colborn et al (1996) 
have investigated the interaction between CTX and standard doses of RBT in 12 HIV-
infected patients. At steady state, RBT and d-RBT AUC0-24 and Cmax were not altered 
by concomitant CTX. 
 
Breda et al (1992) investigated the effects of RBT on INH pharmacokinetics and 
metabolism in 6 healthy volunteers. This study found no significant effect on the 
pharmacokinetics of INH or its metabolism by concomitant RBT, including patients that 







RBT on the pharmacokinetics of EMB in healthy volunteers. No statistically significant 
differences were found in the AUC, Cmax, Tmax, half—life and clearance of EMB.  
 
Due to the metabolism of RBT through CYP3A4, inhibitors of this enzyme are 
predicted to produce significant increases in RBT bioavailability. Jordan et al (2000) 
investigated the pharmacokinetics of RBT in the presence of fluconazole alone, 
clarithromycin alone, or both agents together in HIV-infected patients. Rifabutin AUC0-
24 increased by 76% when combined with either fluconazole or clarithromycin and 
152% when both drugs were given together with RBT. Plasma concentrations of d-
RBT were also significantly increased (fivefold higher) in the presence of combined 
RBT, fluconazole and clarithromycin. The incidence of leukopenia was 38% in patients 
receiving the drug combination and 19% in patients receiving RBT alone.  
 
In a phase I open label, crossover trial of concomitant RBT and fluconazole, the 
plasma concentrations of both RBT and d-RBT were significantly increased in 12 HIV-
infected patients (Trapnell et al 1996). Rifabutin AUC0-24 was increased by 82% and 
that of the metabolite was increased by 216%. A study by (Hafner et al 2001) reported 
no significant changes in the pharmacokinetics of either drug when RBT and 









1.15.2. Drug Interactions Between Rifabutin and ARVs 
1.15.2.1. NRTIs 
An initial study of 16 HIV-infected patients receiving concomitant zidovudine (ZDV) and 
RBT (either 300mg or 450mg), reported that concomitant RBT decreased ZDV Cmax 
and AUC by 48% and 32% respectively; and increased ZDV clearance by 43% 
(Narang et al 1992). However, a subsequent study found that the only significant 
interaction observed by the concomitant administration of RBT 300mg daily and ZDV 
was a 28% decrease in the terminal half-life of ZDV (Gallicano et al 1995). Therefore 
RBT can be used concurrently with ZDV in the treatment of HIV-positive patients. 
Sahai et al (1995) investigated the pharmacokinetic interaction between RBT (either 
300 or 600mg) and didanosine (ddI) in HIV-infected patients and found no significant 
pharmacokinetic interactions between the 2 drugs; and there were no adverse events 
associated with the combined administration of both drugs.  
  
1.15.3.1. Drug Interactions between Rifampicin and Nevirapine 
Studies from Africa, India, South-Asia and Europe have reported significant reductions 
in plasma NVP concentrations in the presence of RMP leading to sub-therapeutic NVP 
trough concentrations in a large proportion of patients. Reductions of 31 and 21% in 
NVP AUC0-12 and C12 respectively, have been reported in TB-HIV co-infected Spanish 
patients treated with concomitant NVP and RMP (Ribera et al 2001). In a South African 
study, NVP trough plasma concentrations were decreased to below the recommended 
level of 3.4 mg/L in 38% of patients (Cohen et al 2008). In Malawians and Ugandan 







60% of patients in the lead in phase of treatment with NVP in the presence of RMP 
(van Oosterhout et al 2007; Lamorde et al 2010).  
 
In an Indian study, NVP Cmax, C12 and AUC0-12 were decreased by 42%, 53% and 46% 
respectively in the presence of RMP and the C12 of NVP was sub-therapeutic in 8/13 
patients (Ramachandran et al 2006). In Thai HIV-infected patients, mean trough 
plasma NVP concentrations decreased by 17.7 % in patients taking RMP and NVP 
concomitantly (Manosuthi et al 2006) and subsequently increased by 16.7% after 
discontinuation of RMP therapy (Manosuthi et al 2007).   
 
In another study, Thai patients were investigated to see whether RMP co-
administration in clinical practice led to clinically relevant decrease of NVP plasma 
concentrations. They compared NVP pharmacokinetics in 74 patients receiving 
concomitant NVP and RMP with a control group matched for age, weight, gender, 
height and body mass index (BMI), receiving only NVP. In the group taking RMP, NVP 
C12 concentration was significantly lower in 10% of patients compared with the control 
group (Autar et al 2005).  
 
A population pharmacokinetic study has suggested increasing the NVP dose to 600mg 
daily to counteract the reductions in NVP plasma concentrations in the presence of 
RMP (Elsherbiny et al 2009) another study has shown that increasing the NVP dose to 







presence of RMP (Ramachandran et al 2006). However, a study in Thai patients 
comparing the effect of RMP on the pharmacokinetics of NVP 400mg and 600mg daily 
reported that while the NVP AUC0-12, Cmax and C12 for the 400mg dose was 26%, 25% 
and 31% lower respectively, compared with the 600mg dose, a hypersensitivity rash 
occurred in 25% of patients in the 600mg group, which was associated with high NVP 
trough concentrations. Four patients in the 600mg group discontinued the study 
prematurely due to NVP hypersensitivity (Avihingsanon et al 2008).  
 
1.15.3.2. Drug Interactions between Rifabutin and Nevirapine 
Current WHO ART guidelines recommend the combination of NVP (400 mg daily) with 
RBT (300mg daily) for the treatment of TB-HIV co-infected patients (World Health 
Organization 2010 revision), but clinical data supporting this recommendation are 
limited. In contrast to the many studies on the pharmacokinetic interaction between 
NVP and RMP, there is only one report (an abstract by Maldonado et al 1999) in the 
literature on the pharmacokinetic interactions between RBT and NVP. Maldonado et al 
(1999) investigated the pharmacokinetics of RBT and NVP in an open-label single arm 
trial of RBT alone and in combination with NVP. Nineteen HIV-infected patients with 
CD4 counts > 100 cells/mm3 were enrolled and given RBT 300mg for two weeks.  After 
a 2-week lead in period of NVP 200 mg daily, patients were given NVP 200 mg twice 
daily for another 2 weeks. At steady state, RBT co-administration resulted in only a 
slight enhancement of NVP clearance. Nevirapine AUC, Cmax and Cmin were reported to 
be 54.0 μg.h/mL, 5.8 μg/mL and 3.8 μg/mL respectively. The only adverse event 







medication. This study did not report on the effect of NVP on RBT pharmacokinetics. 
More studies in HIV co-infected patients on the pharmacokinetic interactions between 
NVP and RBT are needed, particularly African patients, to evaluate the combination of 
RBT and NVP for the treatment of TB-HIV co-infection. 
 
1.15.3.3. Drug Interactions between Rifampicin and Efavirenz 
There is substantial evidence of drug-drug interactions between RMP and EFV in 
Caucasian patients. Reduced plasma EFV concentrations have been reported in 
healthy volunteers (Benedek et al 1998) and in TB-HIV co-infected patients (Lopez-
Cortes et al 2002; Matteelli et al 2007). These two very similar studies in Italian and 
Spanish patients compared the plasma concentrations of EFV 600 and 800mg in 
combination with RMP and found significant reductions in plasma EFV concentrations 
for the 600mg dose in the presence of RMP (Lopez-Cortes et al 2002; Matteelli et al 
2007). A subsequent study (Stohr et al 2008) investigated the factors influencing 
plasma EFV concentrations in 339 patients and also found that concomitant RMP 
substantially decreased plasma EFV concentrations in Caucasians. This study showed 
clear associations between EFV concentrations and ethnicity. Plasma EFV 
concentrations were not significantly reduced by concomitant RMP in African, Thai and 
Indian patients. Further studies in these population groups support this finding. In a 
small study of TB-HIV co-infected South African patients taking RMP-based anti-TB 
therapy and EFV 600mg, trough EFV concentrations were highly variable in the 
presence of RMP (CV 157%) compared to after RMP discontinuation (CV 58%) 







decreases in EFV concentrations in patients taking 600 or 800mg EFV in the presence 
or absence of RMP and similar virological outcomes in both the groups (Orrell et al 
2011). In a randomized controlled trial of 84 Thai HIV-infected patients with active TB, 
plasma EFV levels after 600- and 800mg EFV daily in the presence of RMP were 
compared. Mid-dosing plasma EFV concentrations for both the 600 and 800mg groups 
were not significantly different and immunological and virological outcomes assessed 
at 48 weeks after initiating HAART in both groups were comparable (Manosuthi et al 
2005). An observational study from India (Patel et al 2004) also reported comparable 
immunologic responses in patients taking 600mg EFV with and without concomitant 
RMP.  
 
1.15.3.4. Drug Interactions between Rifabutin and Efavirenz 
An initial study on the pharmacokinetic interaction between RBT and EFV (Benedek et 
al 1988) reported that EFV reduced the AUC0-24 and Cmax of RBT by 38% and 32% 
respectively, while EFV pharmacokinetics were not affected in the presence of RBT. 
This study suggested that a 50% higher dose of RBT might be required for patients co-
administered both drugs. Subsequently, treatment guidelines issued by the American 
Thoracic Society/ Centres for Disease Control (CDC) recommended increasing the 
RBT dose from 300mg to 450 or 600mg for combined therapy with EFV (American 








Weiner et al (2005b) assessed this recommendation in a pharmacokinetic study of TB-
HIV co-infected patients with advanced immunosuppression. Fifteen patients were 
enrolled in the continuation phase of TB therapy while patients were receiving RBT 
300mg two times per week and INH. Blood samples for baseline RBT pharmacokinetic 
parameters were obtained after two weeks of therapy. Antiretroviral therapy was then 
initiated with EFV 600mg daily and 2 NRTIs. After a further two weeks of therapy, a 
second series of pharmacokinetic samples were obtained. Efavirenz pharmacokinetics 
was compared with a historical control group of 35 HIV-infected patients without TB. At 
steady state, RBT AUC0-24 was slightly higher in patients taking RBT 600mg compared 
with the same patients taking 300mg RBT alone. In TBTC Study 23 (Weiner et al 
2005a) it was determined that RBT AUC0-24 below 4.5 μg.h/mL was associated with 
treatment failure or ARR. In this study RBT AUC0-24 was below 4.5 μg.h/mL in 5/15 
patients and 11/15 patients administered RBT 600mg plus EFV and RBT 300mg 
without EFV, respectively. Rifabutin Cmax values were significantly higher in patients 
taking EFV co-therapy compared to patients taking RBT alone. The AUC0-24 d-RBT 
was significantly lower in the presence of EFV compared with RBT alone. There were 
no significant changes in EFV pharmacokinetics between the group of HIV-infected 
patients that took RBT and the group that took only EFV.  
 
The higher dose of RBT was well tolerated with grade 3 or 4 adverse events reported 
in only 3 patients. One case each of neutropenia and elevated pancreatic enzymes 
was reported which were probably associated with study drug although drug levels in 







virological and immunological outcomes were also achieved in this study. The HIV viral 
load decreased by 2.6 log10 copes/mL and the median CD4+ T cell count increased by 
41% after 21 days of EFV-based ART. This study demonstrated that RBT 600mg with 
standard doses of EFV was suitable for the treatment of TB-HIV co-infected patients 
with advanced immunosuppression. However, this approach has not been confirmed 
with a daily treatment regimen in African TB-HIV co-infected patients with advanced 
immunosuppression. 
 
1.15.3.5. Drug Interactions between Rifampicin and Protease Inhibitors 
The drug-drug interactions that occur between RMP and PIs are more severe than 
those that occur between RMP and NNRTIs because PIs are substrates of both CYP 
3A4 and PGP (Burman et al 2001). Trough concentrations of PIs have been 
associated with viral outcome (Kempf et al 1997) therefore it is essential to maintain 
trough concentrations of all PIs co-administered with RMP within their therapeutic 
ranges. Reductions of saquinavir (SQV) trough concentrations of 64.3% and 49.6% 
have been reported in TB-HIV co-infected patients (Ribera et al 2007). Indinavir (IDV) 
trough concentrations were reduced by 87% when IDV/r 800/100 mg twice daily in 
combination with 300 mg RMP was given to HIV-infected patients (Justesen et al 
2004). In healthy volunteer studies, reductions of up to 90% in atazanavir (ATV) trough 
concentrations were reported when ATV/r was combined with RMP (Burger et al 2006; 
Acosta et al 2007). In both studies sub-therapeutic ATV trough concentrations were 








The CDC has recommended increasing the dose of RTV to 400mg every 12h in 
combination with SQV or LPV or doubling the dose of LPV to maintain trough PI 
concentrations at therapeutic levels in the presence of RMP (Centres for Disease 
Control & Prevention 2007. Updated December 2007). However, studies in healthy 
volunteers (la Porte et al 2004; Nijland et al 2008) and HIV-infected patients (L'homme 
et al 2009; Decloedt et al 2011) have reported sub-therapeutic PI trough 
concentrations and a high incidence of adverse events with higher doses of SQV/r 
(Rolla et al 2006) and LPV/r  (either 800/200 mg twice daily or 400/400 twice daily) in 
combination with RMP when compared to the standard dose of LPV/r (400/100 mg 
twice daily) without RMP. In the presence of RMP, LPV trough concentrations 
decreased by 90% in patients taking LPV/r 800 / 200 mg and 93% in patients taking 
LPV/r 400/ 400 mg. Twelve subjects (31%) were prematurely withdrawn due to 
elevations in hepatic transaminases that occurred only after combining LPV and RMP. 
L'homme et al (2009) reported similar observations in HIV positive patients. Dose 
adjustment was associated with inferior exposure to LPV and virological failure, and a 
high proportion of patients on a recommended increased dose stopped the 
combination prematurely due to adverse events. In a recent South African study of 
HIV-infected adults on a LPV/r regimen with concomitant RMP, gradual increase of the 
LPV dose to twice the baseline dose showed no significant increase in LPV trough 
concentrations between baseline and double-dose LPV/r. Furthermore, a large 
proportion of patients reported sub-therapeutic LPV/r trough concentrations. (Decloedt 
et al 2011). Another option recommended by the CDC is to replace RMP with RBT in 
patients requiring anti-TB therapy and concomitant PI-based HAART (Centres for 








1.15.3.6. Drug Interactions between Rifabutin and Protease Inhibitors 
The pharmacokinetic interaction between RBT and PIs has been studied extensively in 
healthy volunteers (Polk et al 2001; Hamzeh et al 2003; Kraft et al 2004; Ng et al 2009; 
Sekar et al 2010). The combination of boosted protease inhibitors and RBT in healthy 
volunteers has resulted in significantly large increases in RBT exposure and more 
profound increases in the bioavailability of d-RBT. A high incidence of neutropenia was 
consistent in all of these studies and some studies were prematurely terminated due to 
the high incidence of adverse events. The relationship between d-RBT exposure and 
neutropenia in healthy volunteers is as yet uncertain. 
 
Narita and colleagues reported that RBT could be combined with PIs for the successful 
treatment of TB-HIV co-infected patents. In their study, TB-HIV co-infected patients 
were treated with standard TB treatment (replacing RMP with RBT 300 mg) co-
administered with IDV and/or nelfinavir (NFV). Nelfinavir was dosed at either 800mg, 
1000mg or 1200mg 8 hourly or 1200mg twice daily and IDV was dosed at 1000mg or 
1250mg twice daily, depending on treatment guidelines or adjustments for drug levels. 
Two weeks after the initiation of PIs, plasma RBT concentrations were significantly 
increased and approached the published therapeutic range while plasma NFV and IDV 
levels were not significantly decreased. Plasma concentrations of the PIs were 
maintained within therapeutic concentrations. HIV viral loads of < 500 copies/mL were 







related adverse events such as uveitis and neutropenia. The investigators have 
however not reported on specific pharmacokinetic data for RBT and the PIs in this 
study (Narita et al 2000). 
 
Another study in HIV-infected patients evaluated the plasma levels of RBT and d-RBT 
during concomitant therapy of intermittent RBT dosing regimens with a combination of 
RTV and SQV. All patients were receiving 400mg of RTV and SQV twice daily as part 
of standard ART and were randomized to receive RBT 300mg every 7 days or 150mg 
TPW. At steady state RBT Cmax was significantly decreased by 37% and trough levels 
were significantly increased in the group taking 150mg TPW compared with the group 
taking 300mg every 7 days. The co-administration of RBT with RTV and SQV resulted 
in increases in AUC and Cmax of both PIs but the differences from baseline levels were 
not statistically significant. However, there was a significant increase in RTV (27%) and 
SQV (39%) trough levels at 12 hours. Overall, the effect of RBT on the 
pharmacokinetics of both RTV and SQV was consistent at 4 and 8 weeks of 
concurrent therapy. The only adverse events reported in this study were two 
incidences of rash probably caused by RBT (Gallicano et al 2001).  
 
The pharmacokinetic interaction between SQV and RBT was investigated in fourteen 
TB-HIV co-infected patients. Patients enrolled into the study received RBT 300mg daily 
for 10 days. After a 14 day wash-out period, patients were randomized to receive either 
SQV 1200mg three times daily for 10 days or SQV 1200mg three times daily plus RBT 







study. Two patients were withdrawn prior to completion. One patient reported 
headache, pyrexia, nausea and vomiting during treatment and the other reported 
abdominal pain, arthralgia and night sweats. A higher incidence of adverse events was 
reported during the combined treatment of RBT with SQV.  The most commonly 
reported adverse events were headache, diarrhea and nausea. Most of these were 
considered to be mild. The AUC and Cmax of SQV decreased by 47% and 39% 
respectively when co-administered with RBT. In contrast, RBT AUC, Cmax and Cmin 
were increased by 19.6%, 20.5% and 86.6% respectively (Moyle et al 2002). 
 
Benator et al (2007) investigated the pharmacokinetic interaction between NFV and an 
intermittent dose of RBT in TB-HIV co-infected patients. Patients were administered 
RBT 300mg two times per week and HAART consisting of two 2NRTIs plus NFV 1250 
mg twice daily. In the presence of NFV, RBT AUC increased by 22% while Cmax 
remained unchanged. Rifabutin had no effect on the plasma concentrations of NFV. 
Two patients developed toxicity that was attributed to TB therapy. One patient 
developed grade 3 transaminase elevations two weeks after starting ART. This patient 
had very high plasma concentrations of RBT in the presence of NFV. The other patient 
developed grade 4 neutropenia two months after the start of ART. This patient had a 
moderate increase in plasma RBT concentration in the presence of NFV. 
 
Boulanger and colleagues investigated the pharmacokinetics of RBT administered in 







300mg TPW. After two weeks of treatment, steady state RBT concentrations were 
measured (Visit 1). Thereafter, patients were switched to RBT 150mg TPW and LPV/r 
400/100mg twice daily with tenofovir and emtricitabine. New steady state assessments 
were done after another week of treatment (Visit 2) as well as rapid RBT analysis 4h 
and 8h post-dose. If RBT Cmax values were below the published reference ranges, RBT 
was increased to 300mg TPW and steady state assessments were repeated two 
weeks later (Visit 3) (Boulanger et al 2009).  
 
The published reference Cmax for RBT is 300-900 ng/ml according to Peloquin et al 
(2002). The RBT Cmax values obtained in this study for RBT given on its own or in 
combination with LPV/r were below this range. At visit 1, when patients were given 
300mg RBT TPW, the median RBT Cmax value was at the low end of this range and in 
5 patients it was below the range. After changing the RBT dose to 150mg TPW plus 
LPV/r  (Visit 2) 7/10 patients had decreased Cmax values and only 3 patients had Cmax 
values greater than 450 ng/mL.  
 
In a previous study (Weiner et al 2005a), patients with RBT AUC0-24 values lower than 
4 500 ng.h/mL were associated with ARR. When RBT 300mg was given TPW, the 
median and maximum RBT AUC0-24 values obtained were close to the values 
associated with ARR in the study by Weiner and colleagues. Similar low RBT AUC0-24 
was observed when the RBT dose was changed to 150mg TPW in the presence of 







and the standard adjusted dose of RBT 150mg TPW with LPV/r are inadequate for 
HIV-positive patients. 
 
In addition to the studies detailed above, there are two short reports on the 
pharmacokinetic interaction between RBT and LPV/r in TB-HIV co-infected patients. 
The first report by (Bonora et al 2003) investigated the pharmacokinetics of RBT 150 
mg daily and LPV/r in five TB-HIV co-infected patients. The AUC and Cmax of RBT 
were below the reference range recommended by Peloquin et al (2002) in 4/4 and 3/4 
patients respectively. Khachi et al (2009) investigated the pharmacokinetic interactions 
between RBT 150mg TPW and LPV/r (400/100mg) in five TB-HIV co-infected patients. 
RBT plasma concentrations were found to be below the reference range in all 5 
patients. In two patients who deteriorated clinically, the RBT dose was increased to 
300mg TPW resulting in therapeutic RBT plasma concentrations in only one patient. 
Furthermore, relapse has been reported in 3 TB-HIV co-infected patients treated with 
an intermittent RBT regiment and ART (Jenny-Avital and Joseph 2009). 
 
1.16. Adverse Events Associated With Rifabutin 
Rifabutin is well tolerated in HIV-infected patients in doses ranging from 300 to 1 200 
mg / day. However, adverse events such as uveitis, corneal deposits, neutropenia, 
arthralgias and skin discoloration have been reported in patients taking high doses of 







such as macrolides, azole antifungals and protease inhibitors (Cato et al 1996; Benson 
et al 2000). 
 
An arthritis – arthralgia syndrome was associated with doses of 1 200 mg / day, in HIV-
infected (Torseth et al 1989). Neutropenia has been reported in healthy volunteers 
taking 300mg daily in clinical trials (Apseloff et al 2003).  and in patients taking 600-
900mg RBT daily (Torseth et al 1989).  Uveitis has been reported in patients taking 
RBT as prophylaxis for MAC, usually if RBT was given in combination with a macrolide 
(Havlir et al 1996).  
 
1.17. Clinical Use Of Rifabutin 
Current WHO and CDC guidelines recommend that all TB-HIV co-infected patients, 
irrespective of CD4 cell-count, should be started on ART as soon as possible after 
starting TB treatment (as early as 2 weeks or within 8 weeks) (World Health 
Organization 2010 Revision). Two NRTIs and EFV are recommended as first-line 
treatment for TB-HIV co-infected patients. In the event of first-line treatment failure or 
toxicity, the WHO recommends the use of RBT 150 mg TPW with LPV/r and two 
NRTIs as second-line treatment. If RBT is not available RMP is recommended with 
super-boosted PIs, LPV/r or ATV/r.  
 
Presently, the recommendation of using EFV in combination with anti-TB therapy for 







as EFV is contra-indicated for pregnant women and women of child-bearing age. 
Furthermore, in patients that require second-line therapy, RMP is poorly tolerated with 
PIs and super-boosted PIs have an additional risk of hepatotoxicity. Rifabutin is 
presently recommended at a dose of 150mg TPW in combination with PIs, but there 
are concerns that this dose may be sub-optimal in TB-HIV co-infected patients and 
current recommendations may require revision. 
 
The use of RBT is currently limited to developed countries mainly because it is more 
expensive than RMP and will be too costly to sustain in TB programs in high burden 
countries. However, the need for RBT-based therapy is increasing in resource-limited 
countries.  A recent review forecasted the need for RBT in the top 21 TB-HIV burden 
countries to be between 10 000 and 18 000 courses in 2012, representing a 20 -30% 
increase from 2010. Of these 21 countries, South Africa represented half of the 














Chapter 2. Materials and Methods 
2.1. Study design 
An open-label, three-period, crossover drug interaction study was undertaken to 
investigate the pharmacokinetics of RBT in African TB patients co-infected with HIV. A 
total of 48 HIV-positive patients with newly diagnosed pulmonary TB and who met all 
inclusion requirements were recruited. All enrolled patients commenced trial 
medication by replacing RMP with RBT 300mg daily in combination with INH, PZA and 
EMB. After 4 weeks of RBT therapy, serial blood samples were obtained in a dosing 
interval for assessment of plasma RBT concentrations. Patients were then randomized 
to one of three arms according to computer-generated sequence and received ART in 
combination with RBT at two different doses. The doses of RBT administered in 
combination with ART to patients in each of the 3 arms are discussed in more detail in 
section 2.3 below. Pharmacokinetic sampling took place after 4 weeks of ART 
treatment with each dose of RBT. The cross-over design in which all patients received 
3 full pharmacokinetic assessments with RBT alone and at two different RBT doses in 
combination with ART, allowed us to formally compare the two different dosing 
strategies of RBT in combination with ART, with the recommended TB treatment dose. 
The Biomedical Research Ethics Committees of the Universities of Kwa-Zulu Natal and 
Cape Town as well as the South African Medicines Control Council approved the 
study.  
 
2.2. Patient recruitment and Inclusion Criteria 
Patients were recruited from local TB clinics in Kwa-Zulu Natal (KZN), South Africa. 







pulmonary TB confirmed by microscopy or culture, HIV infection with CD4 lymphocyte 
count ≥ 50 and ≤ 200 cells/mm3, weight ≥ 50kg or a BMI ≥ 18, a Karnofsky score Q ≥ 
80% and no grade 3 or 4 clinical or laboratory findings according to DAID tables (AIDS 
Clinical Trials Group 2004). Only patients who completed and adhered to 6 weeks of 
standard intensive phase TB chemotherapy and had not received ART in the 
preceding 3 months were enrolled. Patients with a previous TB episode within 3 years 
prior to the current episode, a history of prior treatment for MDR TB, concomitant 
opportunistic infection requiring additional anti-microbial treatment, a formal 
contraindication to any trial medication, diabetes mellitus requiring treatment, 
recreational drug or alcohol abuse, interrupted TB therapy for more than a week or less 
than 90% adherent to the first six weeks of intensive phase chemotherapy, mental 
illness, total neutrophil count < 1200 cells/L, hemoglobin < 6.8 g/dL, or liver function 
tests > grade 2 according to DAID tables and pregnant or lactating women or women 
unwilling to use appropriate contraception were excluded.  
 
 
2.3. Treatments under study  
At enrollment, six weeks after starting standard intensive phase TB chemotherapy, 
RMP was switched to RBT 300 mg daily for two weeks. Then PZA and EMB were 
stopped and patients commenced the continuation phase of treatment with RBT 300 
mg daily in combination with INH 300mg. After two more weeks, patients were 
admitted to the pharmacokinetic facility for the first pharmacokinetic evaluation (PK1). 







RBT dose sequences together with daily doses of INH and ART (Refer to Figure 2.1 
below) comprising of 600mg EFV daily, 400mg NVP daily  (after a lead-in dose of 
200mg daily) or LPV/r (400/100 mg) plus lamivudine (150mg bd) and stavudine (30mg 
bd).  
Half the patients on the LPV/r arm received RBT 150 mg TPW for 4 weeks before 
being switched to RBT 150 mg daily after a second pharmacokinetic evaluation (PK2). 
They remained on this dose of RBT until completion of TB treatment. The remaining 
patients received the two RBT doses in a reverse sequence, starting with the 150 mg 
daily dose of RBT and switching after PK2 to the TPW doses of RBT for the rest of the 
continuation phase. The final pharmacokinetic evaluation (PK3) took place after 4 
weeks on the second RBT dose. Patients randomized to the EFV arm received either 
450mg RBT (low dose) first followed by 600mg RBT (high dose) or 600mg first 
followed by the 450mg dose. Patients randomized to receive NVP-based ART received 
either 300mg RBT first or 450mg RBT with NVP, stavudine and lamivudine. After 4 
weeks of therapy on the first RBT dose and PK2, patients were switched to the 
alternate dose of RBT.  
 
Physical examinations and laboratory investigations were done at every 
pharmacokinetic evaluation and at the penultimate trial visit to assess safety and 
adverse events. Pfizer (South Africa) supplied the RBT (Mycobutin®) 150mg capsules 
for oral administration. Stockrin® was donated by MSD (South Africa). Nevirapine, 
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Figure 2.1. Figure 1: Diagram showing the timing of the trial procedures relative 
to trial visits and treatments (Rmp = rifampicinn, Inh = isoniazid, PzA = 








2.3. Sample size   
The sample size was calculated on the basis that 16 enrolled participants (per arm) 
would result in a minimum of 12 evaluable subjects. Based on the variability of AUC0-24 
for RBT determined in previous studies it was estimated that a sample size of 12 
participants has a power of 80% to detect a 20% difference between the mean AUC0-24 
for the participants taking RBT without ART and the AUC0-24 for RBT when combined 
with ART.  
 
2.4. Pharmacokinetic sampling 
All patients were admitted to the pharmacokinetic facility the night before each 
pharmacokinetic occasion and were fasted from midnight. On the morning of the 
pharmacokinetic sampling day, an indwelling catheter was inserted into the forearm of 
each patient via which serial blood samples were obtained. The first blood sample (0h) 
was drawn prior to administration of study drugs. All study drugs were administered 
with water by a clinical trial nurse and none of the patients vomited their doses. 
Subsequent blood draws were done at 2, 3, 4, 5, 6, 8, 12, 24 and 48h after drug 
ingestion. A standard hospital breakfast (oatmeal porridge) was served immediately 
after the 2h blood was drawn.. The samples were placed on ice immediately and 
centrifuged at 3000 rpm at 400C for 10 minutes within 30 minutes of collection. 
Separated plasma was transferred to polypropylene tubes and stored immediately at -









2.5. Drug Analysis 
The extraction of RBT, EFV, NVP and LPV from plasma samples obtained from trial 
participants and the quantification of the plasma concentrations of each of these drugs 
were performed at the Division of Clinical Pharmacology, University of Cape Town. 
The laboratory participates in the International Interlaboratory Control Program of 
Stichting Kwaliteitsbewaking Klinische Geneesmiddelanalyse en Toxicologie (KKGT; 
Hague, The Netherlands) on an ongoing basis. 
 
2.5.1. Rifabutin 
Rifabutin and d-RBT were analyzed with a validated LC/MS/MS assay developed by 
the Division of Clinical Pharmacology, University of Cape Town. The samples were 
processed with a protein precipitation extraction method, using 50 µL plasma and 300 
µL acetonitrile. Rifaximin was used as internal standard, and was spiked into the 
precipitation solvent at a concentration of 100 ng/mL. Gradient chromatography was 
performed on a Phenomenex, Luna 5 μm PFP(2), 100 Angstroms, 50 mm × 2 mm 
analytical column, using acetonitrile and 0.1% formic acid as mobile phase, and was 
delivered at a flow rate of 500 µL /min.  An AB Sciex API 3200 mass spectrometer was 
operated at unit resolution in the multiple reaction monitoring (MRM) mode, monitoring 
the transition of the protonated molecular ions at m/z 847.4 to the product ions at m/z 
95.1 for RBT, the protonated molecular ions at m/z 805.4 to the product ions at m/z 
95.1 for d-RBT, the protonated molecular ions at m/z 786.3 to the product ions m/z 
151.1 for the internal standard. The accuracies  for RBT and d-RBT were between 







The precision (%CV) for RBT and d-RBT during inter-batch validation was less than 
9.2% at low, medium and high QC levels.  The calibration range for RBT was between 
3.91 ng/ml and 1000 ng/ml, and for d-RBT the calibration range was between 0.780 
ng/ml and 200 ng/ml. 
 
2.5.2. Antiretrovirals 
Plasma concentrations of NVP were determined by a validated LC/MS/MS method, 
which has been described previously by Chi et al (2002) and EFV and LPV were 
determined by a method previously described by Chi et al (2003). 
 
Nevirapine was extracted by addition of 50 µL acetonitrile containing 1 mg/L internal 
standard to 20 µL of each sample or control to precipitate protein. Samples were 
vortexed for 30s, centrifuged for 5 min at 750g and 2 µL of the supernatant was 
injected onto the column. The standard curve was linear in the range 0.2-20 mg/L. The 
lower limit of quantification (LLQ) was set at 0.2 mg/L. A Waters alliance 2690 HPLC 
coupled to a Waters/Micromass ZMD single quadropole mass spectrometer was used 
for mass spectral analyses. The mobile phase consisted of 50% acetonitrile in 4mM 
ammonium acetate and 0.1% trifluoroacetic acid. A 20 by 2.1mm Hypersil Gold C18 
column (Thermo) was used at a flow rate of 0.3 mL/min. Neostigmine served as 
internal standard. Detection in positive ionization mode of NVP was at 276.2 (m/z) and 








Lopinavir and EFV were extracted from thawed plasma samples from trial participants, 
quality control (QC) samples and calibration standards by transferring 100 µL aliquots 
to 1.5 ml microcentrifuge tubes.  200 µL of internal standard solution was added to 
each tube and mixed gently, followed by 400 µL acetonitrile.  Each tube was vortexed 
for 20 seconds at high speed. The tubes were then centrifuged at 12 000 x g (11,000 
rpm) for 5 minutes. The precipitated proteins formed a pellet at the bottom of the tube 
leaving a clear supernatant. Aliquots of supernatant were transferred to vial insets and 
placed in the autosampler tray and loaded on the LC column. The supernatant was 
eluted through the LC column with a linear gradient of 10 mM ammonium formate 
buffer (pH 4.10) and acetonitrile. 
 
An AB Sciex API 3200 mass spectrometer was used for mass spectral analyses. The 
calibration curve was linear over the range from 0.05 to 20 mg/L. If the LPV or EFV 
concentration of a particular sample was determined to be > 20 mg/L, the sample was 
diluted with drug-free plasma and re-analyzed. The LLQ of the LPV assay was 0.05 
mg/L. The LPV calibration curve was linear over the range from 0.05 to 20 mg/L. 
Accuracy ranged from 94.3% to 103.0%. The intraday and interday precisions ranged 
from 0.14% to 4.72% and from 1.61% to 4.22%, respectively. The calibration curve for 
EFV was linear over the range 0.1-15mg/L. Accuracy ranged from 98.3% to 103.7%. 
The intraday and interday precisions ranged from 0.97% to 3.27% and from 2.28% to 
4.98%, respectively. Any sample with a LPV or EFV concentration below the LLQ was 







2.6. Pharmacokinetic Analysis 
Concentration-time curves were plotted for each series of drug assays for each 
participant. The main pharmacokinetic measures for RBT, d-RBT, NVP, EFV and 
LPV/r were derived by noncompartmental analysis using Stata (StataCorp. 2009. Stata 
Statistical Software: Release 11. College Station, TX: StataCorp LP). The peak 
concentration (Cmax), and time to Cmax (Tmax) were obtained directly from the 
concentration-time profiles. Drug concentrations at the end of a dosing interval (trough) 
are reported as C24 for RBT and d-RBT and as C12 for each of the ARVs. Pre-dose 
(0h) concentrations on the day of pharmacokinetic evaluation are reported as C0. The 
steady-state AUC from time 0h to the last quantifiable sample within 24h (AUC0-24) for 
RBT and d-RBT and at 12h (AUC0-12) for each of the ARVs were calculated by the 
linear trapezoidal method. The apparent total oral clearance of RBT from plasma at 
steady state (CL/F) was calculated by dose/AUC. 
 
2.7. Statistics 
The steady state pharmacokinetic parameters  of RBT and d-RBT were determined at 
each of the 3 pharmacokinetic evaluations and the pharmacokinetic parameters of 
EFV, NVP and LPV/r were determined after the second and third pharmacokinetic 
evaluations.  
 
For statistical analysis and to test for an effect of sequence on RBT AUC0-24, the AUC0-
24 was log- transformed.  A linear mixed model of log AUC with 3 levels of dose 







id (patient identifier) was nested within sequence in order to adjust for the repeated 
measurements on individuals. Day was not included in the model because day was a 
function of sequence and dose. Using this model, a significant sequence effect was not 
obtained for the EFV and NVP arms therefore data for high and low RBT doses were 
pooled. However a significant sequence effect (p = 0.04) was obtained for the LPV/r 
arm. There were significant differences in baseline AUC0-24 values between patients 
randomized to high-low and low-high sequences in the LPV/r arm (p = 0.01), which 
could have accounted for the significant sequence effect. To test this, a linear mixed 
model with two doses (high and low), day (2 and 3), sequence and log AUC at 
baseline and id nested within sequence was used. In this model sequence was no 
longer significant (p= 0.2) confirming that baseline differences were driving the 
sequence effect. Therefore the two arms were pooled and the model was used to test 
the dose effect after adjusting for baseline differences. Inter-patient variability for each 
of the dosing periods per arm was measured by co-efficient of variation (%CV) which 
was calculated as {100 X (e(var est) -1)1/2}.  
 
To calculate geometric mean ratios (GMR) for AUC, log means and 90% confidence 
limits were back transformed and presented in their original units as geometric means. 
Geometric mean ratios for the AUC of RBT were computed for each arm as follows : 
a. EFV arm:  450mg daily with EFV / 300mg daily; 600mg daily with EFV/ 300mg daily 







b. NVP arm: 300mg daily with NVP / 300mg daily; 450mg daily with NVP / 300mg daily 
and 300mg daily with NVP / 450mg daily with NVP 
c. LPV arm: 150 mg daily with LPV/r / 300mg daily; 150 mg TPW with LPV/r 300mg 
daily and 150 mg daily with LPV/r / 150 mg TPW with LPV/r 
 
Paired t-tests were used to compare the AUC0-24 of two doses of RBT given with ART 
with the AUC0-24 of RBT 300mg given alone to the same patients in each of the three 
arms. In the LPV/r arm, the AUC0-48 of RBT150mg TPW was also compared with 2 x 
RBT AUC0-24 because the dosing interval for the TPW dose is 48 hours. Demographic 
data, baseline and final log viral loads and CD4+ counts were also compared using 
paired t-tests.  A P-value < 0.05 was considered significant.  
 
A stepwise regression model was used to select factors associated with the AUC0-24 
and Cmax and variables significant at the 0.05 level were included and then factors such 
as sex and weight which have been shown in the literature to be associated were 
included in the model. 
  
2.8. Pharmacogenomics 
2.8.1. Study participants and Sample Acquisition  
Of the 48 patients who were recruited for the main pharmacokinetic study as described 
in section 2.2.2., 42 patients provided additional written informed consent for the 







tubes. Whole blood was aliquoted into 2ml samples and frozen immediately at -70oC. 
Genotyping was done at the Department of Molecular and Clinical Pharmacology, 




Total genomic DNA was isolated from whole blood using the QIAamp DNA mini kit 
according to manufacturer’s instructions. Purity was assessed following the extraction, 
by comparing the A260 and A280 ratio and the DNA was then normalized to 20 ng/µL. 
Genotyping for SLCO1B1 rs4149032, rs2306283, rs4149056 and rs11045819 was 
performed by real-time P.C.R. allelic discrimination by standard methodology (95˚C for 
15 min, followed by 40 cycles of 95˚C for 15 sec and 60˚C for 1 min). The Applied 
Biosystems assay IDs for the first three SNPs were C_1901709_10, C_1901697_20 
and C_30633906_10, respectively. For rs11045819, the forward primer, reverse 
primer, VIC probe and FAM probe were 
5΄CAGTGATGTTCTTACAGTTACAGGTATTCTAA3΄, 
5΄GAAGACTTTTTACTGTCAATATTAATTCTTACCTTTTCC3΄,     5΄-
ACTATCTCAGGTGATGCT-VIC, and 5΄-CACTATCTCAGTTGATGCT-FAM, 
respectively. 
2.8.3. Non-compartmental analysis 
Rifabutin AUC0-24 and Cmax for each patient were computed as described in 2.6 above. 







according to genotype. To achieve normality the AUC0-24 and Cmax was log 
transformed. The AUC0-24 and Cmax between the different genotype groups were 
compared, respectively using t-tests. Simple linear regression was used to determine 
the association between each SNP. Due to us not finding more than one significant 
relationship with an SNP, multiple regressions was not pursued. 
2.8.3. Statistics 
The Shapiro-Wilk test was used to test for normality. AUC was analyzed on th e log 
scale. ANOVA was used to determine whether AUC and Cmax differed between the 








Chapter 3. The Pharmacokinetics of Rifabutin 300mg in African TB-HIV co-
infected patients with advanced immunosuppression 
	  
Summary 
The pharmacokinetics of RBT 300mg was investigated in 44 African TB-HIV co-
infected patients with advanced immunosuppression. The median RBT AUC0-24, Cmax, 
C 24 and CL/F obtained were 2 790.8 ng.h/mL, 284 ng/mL, 48.0 ng/mL and 107.5 L/h 
respectively. Peak plasma concentration was attained 3 hours post-dose. Large 
interpatient variability (CV = 36%) was observed for RBT AUC0-24. The AUC0-24, of d-
RBT was approximately 10% of the parent drug and the drug concentration-versus-
time profile of d-RBT mimicked the profile of RBT. 
 
In comparison to previous Phase I studies in healthy volunteers (3390ng.h/mL- 4659 
ng.h/mL) the AUC0-24 of RBT obtained in this study (2 790.8ng.h/mL) is lower (Table 
3.1). However, the median AUC0-24 of RBT obtained in this study is comparable to the 
median AUC0-24 of RBT obtained in previous studies in TB-HIV co-infected patients 
(Table 3.2). The AUC0-24 of d-RBT obtained in this study was slightly higher than in 
healthy volunteers and lower than that previously reported in a study in TB-HIV co-
infected patients (Boulanger et al 2009). 
  








Rifabutin is currently prescribed for the treatment of TB and MAC at 300mg daily. 
However, the concentrations required for effective RBT therapy are only partially 
known and detailed PK-PD data from human studies are limited. A recent 
pharmacokinetic study reported that a RBT AUC0-24 of < 4.5 ug.h/mL was associated 
with treatment failure and ARR (Weiner et al 2005a) and TDM studies of anti-TB drugs 
recommend that peak RBT concentrations should fall between 300 and 900 ng/mL for 
the treatment of M tuberculosis (Peloquin et al 2002). Previous healthy volunteer 
(Table 3.1) and treatment studies (Table 3.2) show large variability in RBT AUC0-24 and 
Cmax concentrations. The objective of this chapter is to describe the enrollment of 
patients into the clinical trial and the clinical pharmacokinetics of RBT 300mg daily in 
African patients with TB-HIV co-infection. The pharmacokinetic analysis of RBT in 
combination with ARVs in these patients is described in subsequent chapters. 
 
Table 3.1. Pharmacokinetic parameters of rifabutin 300mg daily obtained from 
previous studies in healthy volunteers 




Hamezh, 2003 17 3 980 470.0 
Sekar, 2010 15 4 659 565.2 











Table 3.2. Pharmacokinetic parameters of rifabutin 300mg daily obtained from 








Cmax   
(ng/mL) 
Sahai, 1995 9 5 023.0 525.0 
Jordan, 2000 10 3 109.0 244.9 
Trapnell, 1996 12 3 025.0 - 
Blaschke and Skinner, 1996 75 5 324.0 381.0 
Colborn, 1996 12 2 663.0 352.0 
Narang, 1996 48 4 054.0 348.0 
Narang, 1995 8 2 539.0 265.0 
Moyle, 2002 14 3 007.0 308.0 
Ford, 2008 22 3 050.0 313.0 
Boulanger, 2009 10 2 700.0 280.0 
Hafner, 1998 34 4 000.0 430.0 
Li, 1996 8 3 400.0 400.0 
Weiner, 2005a 102 5 220.0 450.0 
· UNK = unknown 
 
 
3.2. Patient Enrollment Information 
In total, 176 patients were screened of which 128 patients failed screening, mainly 
because they did not fulfill all inclusion criteria. The first 48 patients to pass screening 
were enrolled and treated. These patients formed the intent-to-treat (ITT) population 
and form the group of patients in whom the safety analysis is based (Chapter 6). The 
ITT population is defined as all the patients that were enrolled into the trial and 
received trial medication; and includes patients that were non-compliant on trial 
medication and patients that were prematurely withdrawn as well as treatment failures. 
Forty-six patients completed pharmacokinetic analysis for RBT 300mg without ART. 







withdrawn after PK1, due to uveitis, elevated transaminase and TB meningitis. The 
data of 2 patients were excluded from the pharmacokinetic analysis. One patient 
reported non-compliance to trial medication and the other patient was hospitalized for 
cryptococcal meningitis and administered fluconazole intravenously.  
 
3.3. Trial Completion and Subject Withdrawal  
Of the total of 48 enrolled patients, sixteen were randomized to arm 1(EFV), fourteen 
were randomized to arm 2 (NVP) and sixteen were randomized to arm 3 (LPV/r) as 
described in section 2.3. All enrolled patients received 4 weeks of RBT before 
randomization to one of three ARV regimens, Two enrolled patients were not 
randomized. One patient died before reaching the randomization visit and another 
patient started ART at a local clinic prior to his randomization visit. Five patients 
discontinued the trial prematurely. The reasons for discontinuation were uveitis 
experienced after day 28 (arm 3), elevated transaminases experienced on day 42 
(NVP arm), meningitis diagnosed after day 42, MDR TB confirmed after day 56 (EFV 
arm) and neutropenia diagnosed on day 84 (EFV arm). These are described in more 














3.3. Patient Demographics and Baseline Characteristics 
The baseline mean and standard deviation of the demographic data for the ITT 










Table 3.3. Baseline demographic data of the ITT population. Values are the mean 
with standard deviation in brackets.  
Parameter 
All 
n = 48* 
Arm 1 
n = 16 
Arm 2 
n = 14 
Arm 3 
n = 16 
Age at screening, years 33.1 (5.8) 31.8	  (4.7)	   36.1 (6.6) 31.6 (5.5) 
Height, cm 159.8 (7.6) 159.1 (8.4) 159.5 (7.5) 160.1 (7.1) 
Weight, kg 58.3 (9.0) 59.4 (9.8) 57.2 (8.2) 59.0 (9.4) 
BMI, kg/m2 23.0 (3.6) 23.7 (5.2) 22.4 (2.8) 22.9 (2.6) 
Gender, n (%) 
  Female 









CD4+ cell count, 
cells/mm3 123.2 (43.5) 118.8 (47.1) 105.6 (29.4) 147 (43) 
Viral load, log10 
copies/mL 5.3 (0.1) 5.2 (0.84) 5.3 (0.68) 5.4 (0.68) 
*2 patients were not randomized 
 
There were no significant differences between the three randomized arms with regard 
to any of the demographic parameters. All patients were from the Black race group. 
Thirty were male (65.5%). All patients had a mean (sd) Karnofsky Q score of 100 
(100). 
             
Physical examination at screening did not reveal any relevant differences between the 
three arms. An overview of specific symptoms and active disorders at screening is 
presented in Tables 3.4 and 3.5 respectively. The most commonly reported diseases 
active at screening were related to the respiratory system (reported in 7 patients in the 







system (reported in 11 patients each in EFV and NVP arms and 14 patients in the LPV 
arm.   
 
 
Table 3.4. Specific symptoms present at screening. Conditions were graded 
according to DMID tables and Grade 0 corresponds to the absence of the 
condition 
 
Symptom Arm 1 Arm 2  Arm 3 
Cough        
 Grade 0 0 2 2 
 Grade 1 9 6 5 
 Grade 2 7 6 9 
Chest Pain       
 Grade 0 13 10 12 
 Grade 1 2 4 4 
 Grade 2 2 0 0 
Haemoptysis       
 Grade 0 13 11 14 
 Grade 1 3 3 2 
 Grade 2 0 0 0 
Night sweats       
 Grade 0 3 4 6 
 Grade 1 10 9 5 
 Grade 2 3 1 5 
Weight Loss       
 Grade 0 13 13 11 







 Grade 2 3 1 5 
Eye Pain       
 Grade 0 13 11 14 
 Grade 1 3 3 1 
 Grade 2 0 0 1 
Red Eye       
 Grade 0 14 12 14 
 Grade 1 2 2 2 
 Grade 2 0 0 0 
Light Sensitivity       
 Grade 0 13 12 14 
 Grade 1 3 2 2 
 Grade 2 0 0 0 
Blurred vision       
 Grade 0 15 12 15 
 Grade 1 1 2 1 
 Grade 2 0 0 0 
Joint Pain       
 Grade 0 13 12 11 
 Grade 1 1 1 2 
 Grade 2 2 1 3 
Muscle Pain       
 Grade 0 16 13 16 
 Grade 1 0 1 0 












Table 3.5. Active Concomitant Disease (by Body System Class) at Screening 
 
Body System Arm 1 Arm 2 Arm 3 
	  
	   Normal Abnormal Normal Abnormal Normal Abnormal 
ENT 
	  
16 0 14 0 15 1 
Eyes 
	  
14 2 12 2 15 1 
Cardiovascular 
	  
16 0 14 0 15 1 
Chest & lungs 
	  
9 7 1 13 5 11 
Abdomen 
	  
16 0 12 2 12 4 
Nervous sys 
	  
16 0 13 1 15 1 
Musculo-skeletal 
	  
13 3 10 4 13 3 
Skin and Mucosa 
	  
11 5 9 5 9 7 
Periph Vasc 
	  
16 0 13 1 15 1 
Lymphatic 
	  
5 11 3 11 2 14 
 
 
Of the 46 randomised patients, only 8 patients were taking any concomitant medication 
at screening. The most frequently used concomitant medication was pyridoxine 25mg 
daily (4 patients). The concomitant medication taken by all enrolled patients is 
tabulated in Table 3.6 below. Only three patients were taking cotrimoxazole at 










Table 3.6. Concomitant non-TB medication taken by all enrolled patients at 
screening  
Drug Arm 1 Arm 2 Arm 3 
No concomitant medication 13 11 14 
Pyridoxine (25 mg od) 1 3 0 
Allergex 2 (4mg bd) 1 0 0 
Co-trimoxazole (2T daily) 1 0 2 
Total 16 14 16 
 
 
3.4. Response to treatment 
Of the 48 patients enrolled there were 6 withdrawals at weeks 1, 6, 8 (two patients) 13 
and 18. Episodes of poor adherence were documented in two patients. Both patients 
were from the LPV/r arm. The microbiology, virology and immunology results of 
patients are shown below. 
 
3.4.1. Microbiology Results 
The microbiology results for all patients enrolled in the trial are shown in Table 3.7. 
Patients were enrolled after 6 weeks of standard intensive phase chemotherapy. After 
2 weeks of RBT substitution, a sputum sample was provided for drug sensitivity test 
(DST) Of the 48 patients enrolled, M. tuberculosis was isolated from 5 patients at visit 
2 and from 2 patients at visit 7. Only 2% were culture positive at visit 7. One patient 
was found to be MDR on DST at visit 2, although the results only became available 
after visit 7. A second patient was diagnosed with MDR TB from the visit 7 DST result. 







diagnosed with MDR were the only two patients who remained sputum culture positive 
at visit 7. 
 
 
Table 3.7. Microbiology results for all enrolled patients  
  Visit 2 Visit 7 
Smear   
Positive 10/46 2/46 
MIGIT   
MTB isolated (n) 8/46 2/46 
7H11 (n, %)   
MTB isolated  3.0 (6.3) 2.0 (4.30 
Drug resistance (n, %)   
Rifampicin 1.0 (2.1) 2.0 (4.3) 
Isoniazid 1.0 (2.1) 2.0 (4.3) 
Ethambutol 1.0 (2.1) 1.0 (2.1) 




3.4.2. Viral Loads 
There was a significant decrease in viral load in 42/46 patients after 16 weeks of ART 
(p < 0.05). The baseline mean (sd) viral loads for these patients was 5.3 (0.73) log10 







At the end of TB treatment, there were 7 patients who had a viral load of >1000.  A 
genotypic resistance test was carried out on samples from each of these patients. 
Resistance mutations were discovered in only one patient (from the NVP arm). The 
mutations detected in viral DNA from this patient were V901, K103N and G190AG. 
This patient was male and baseline genotypic results were not available. 
 
3.4.3. CD4 counts 
There was a significant increase in the mean CD4+ counts of 42/46 patients at the end 
of TB therapy (p < 0.05). In these patients, the mean baseline CD4+ count increased 
from 125.6 (43.4) cells/mm3 at screening to 209.7 (119.2) cells/mm3 at the end of TB 
treatment.  
 
3.5. Pharmacokinetics  
The pharmacokinetic analysis of RBT 300mg (displayed in Tables 3.8 and 3.9) is 
based on the pharmacokinetic data of 44 patients prior to the administration of ARVs. 
Of the 46 enrolled patients, one patient reported non-compliance to trial medication 
therefore his pharmacokinetic data was excluded from the data set. Another patient 
was hospitalized for meningitis and administered oral fluconazole 200mg daily. The 
patient was discharged on fluconazole prophylaxis therapy. Although the patient did 
not interrupt her trial medication, her pharmacokinetic data was excluded from the 
analysis. The main pharmacokinetic parameters for RBT and d-RBT for 44 patients are 








Table 3.8. Pharmacokinetic parameters of Rifabutin 300mg daily and d-RBT for 
44 patients from non-compartmental analysis 
Rifabutin (n = 44) 
  
Parameter Median IQR 
  AUC0-24 (ng.h/mL) 2 790.8 2 171.2 - 3324.9 
  Cmax (ng/mL) 284.0 198.5 - 372.5 
  Tmax (h) 3.0 3.0 - 4.0 
  C0 (ng/mL) 65.0 49.2 - 80.5 
  C24 (ng/mL) 48.0 39.5 - 62.6 
CL/F (L/h) 107.5 90.3 – 138.5 
25-Desacetyl-Rifabutin (n = 44) 
   
Parameter Median IQR 
  AUC0-24 (ng.mL/h) 232.3 191.8 - 317.9 
  Cmax (ng/mL) 25.4 18.8 - 37.8 
  Tmax (h) 3.0 3.0 - 3.0 
  C0 (ng/mL) 5.0 3.5 - 7.7 
  C24 (ng/mL) 3.6 2.9 - 5.0 














Table 3.9. Pharmacokinetic parameters of rifabutin 300mg daily and 25-O-
deacetylrifabutin according to arm from non-compartmental analysis. Data are 
presented as medians and IQR 
Rifabutin         Arm 1 (n = 14)       Arm 2 (n= 14)     Arm 3 (n = 16) 
AUC0-24 (ng.h/mL) 2647.6 (2065  - 3510.4) 2487.5 (2007.1 - 3120.1) 3052.85 (2650.2 - 3431.5)  
Cmax (ng/mL) 
 
245.5 (194.0 – 336.0) 246.0 (193.0 - 414.0) 291.5 (250.0- 377.0) 
Tmax (h) 3.0 (3.0 - 4.0) 3.0 (3.0 - 3.0) 3.0 (3.0 - 4.0) 
C0 (ng/mL) 62.7 (44.1 – 82.8) 73.6 (63.1 – 83.2) 59.0 (36.4 - 78.6) 
C24 (ng/mL) 25.2 (38.3 – 58.0) 45.8  (37.6 – 56.0) 60.7 (40.6 - 68.8) 
CL/F (L/h) 113.8 (85.5 - 145.3) 120.0 (96.1 - 149.5) 98.3 (87.4 - 113.2) 
    d-RBT       
AUC0-24 (ng.h/mL) 216.9 (182.9 - 339.2) 193.7 (154.0 – 236.9) 273.3  (235.7- 344.1) 
Cmax (ng/mL) 22.4 (18.9 – 45.5) 21.6 (16.7 – 28.8) 32.5 (25.2 - 37.7) 
Tmax (h) 3.0  (3.0 – 3.0) 3.0 (3.0 – 4.0) 3.0 (3.0 – 4.0) 
C0 (ng/mL) 4.4  (4.0 – 7.1) 5.8 (3.4 – 7.9) 5.1 (2.7 - 6.6) 
C24 (ng/mL) 3.5 (2.8 – 4.7) 3.2  (2.2 -4.2) 5.0  (3.4 - 5.8) 
CL/F (L/h) 1386.4 (884.5 - 1640.3) 1548.9 (1213.6 - 1949.0) 1098.6 (871.9 - 1272.6) 
	  	   	  	     	  	  
d-RBT = 25-O-deacetylrifabutin; AUC = area under the concentration-time curve; Cmax = maximum concentration in 
plasma; Tmax = time at which maximum concentration in plasma attained; C0 = pre-dose concentration; C24= trough 








Figure 3.2. Median (IQR) concentration-time profile of rifabutin 300mg daily 
(blue) and 25-O-desacetylrifabutin (red) for 44 patients 
The area-under-the-plasma-concentration vs time curve (AUC) (Figure 3.2) shows that 
an oral dose of RBT 300mg reaches a median peak plasma concentration of 284.0 
ng/mL (IQR, 198.5 - 372.5 ng/mL) in African patients co-infected with TB-HIV. Peak 
plasma concentration was obtained 3 hours after the dose was taken. Median trough 
concentration (C 24) attained was 48.0 ng/mL (IQR, 39.5- 62.6 ng/mL). Trough 
concentration was 6-fold lower than peak concentration indicating a large volume of 
distribution. The median RBT AUC0-24 obtained in this study was 2 790.8 ng.h/mL. 
Individual AUC0-24 concentrations ranged from 1 088.5 ng.h/mL to 5 892.9 ng.h/mL. 
Inter-patient variability for AUC0-24 and Cmax was 36 and 43% respectively. Individual 
AUC0-24 plots of the 14 and 16 patients enrolled to the NVP, EFV and LPV arms 
respectively, (Figure 3.3 A,B&C) shows heterogeneous absorption. Peak concentration 







peaks occurred. For 5 patients with Cmax values below the published reference (range 
108 - 207 ng/mL), 2-hour and 6-hour post-dose concentrations were roughly the same 





Figure 3.3 A. Individual concentration-time profiles of rifabutin 300mg for 14 








Figure 3.3 B. Individual concentration-time profiles of rifabutin 300mg for 16 
patients randomised to the efavirenz arm 
  
Figure 3.3 C. Individual concentration-time profiles of rifabutin 300mg for 16 







The median AUC0-24 and Cmax of d-RBT was 232.3 ng.h/mL and 25.4 ng/mL 
respectively. Maximum plasma concentrations of the metabolite were attained in 3 
hours. The ratio of the AUC0-24 of parent drug to metabolite was 12 : 1. The metabolite 
reached peak concentrations of approximately 10% of the parent drug and 
demonstrated a similar plasma decay curve.  The main pharmacokinetic parameters 
for 25-O-desacetylrifabutin are displayed in Table 3.7.   
 
Based on previously published reference ranges there are 41/44 (93%) and 26/44 
(59%) patients with low AUC0-24 and Cmax values, respectively. To identify the 
determinants of RBT plasma concentrations, the effects of weight, height, gender, 
CD4+ count, hemoglobin, neutrophil count, platelets, aspartate aminotransferase (AST) 
and alanine aminotransferase (ALT) were tested in a univariate and multivariate 
logistic regression model. Rifabutin AUC0-24 concentrations were log transformed prior 
to analysis. Mean (sd) values for RBT AUC0-24, log AUC0-24, Cmax, C24 and all 













Table 3.10.  Mean (sd) values for rifabutin AUC0-24, log AUC, Cmax, C24 and various 
covariates for 44 patients on rifabutin 300mg 
Variable n mean sd median min max 




























































In univariate analysis female sex, weight and CD4+ count were significantly associated 
with AUC0-24 and female sex, hemoglobin and weight were significantly associated with 
Cmax. However, with multivariate analysis only female sex and weight were significantly 
associated with Cmax. As body weight increased RBT Cmax decreased. There were no 





















Table 3.11. Determinants of rifabutin serum concentrations by univariate and 
multivariate analysis 
 Univariate (n=44) Multivariate (n = 44) 
   β coefficient 
 
    (95%CI) 
P value   β coefficient  
 
    (95%CI) 
P value 
log AUC0-24     
Female sex       0.205132 
 
(-0.00523 - 0.415496) 
0.05         0.148507 
 
 (-0.06207 - 0.359086) 
0.16 
Weight      - 0.01353  
 
(-0.0252 - -0.00185) 
0.02          - 0.00944 
 
 (-0.02148 - 0.002608) 
0.12 
CD4 count 0.002245  
 
(-0.00012 - 0.004608) 
0.06          0.001876  
 
  (-0.0004 - 0.004157) 
0.1 
Cmax     
Female sex       125.756 
  
(55.61095-195.901) 
0.001  104.1372  
 
(33.08654 - 175.1879) 
0.01 
Weight       -5.81287 
 
(-9.97138 - -1.65436) 
0.007       - 4.03424 
  
(-8.04543 - -0.02305) 
0.04 
Hemoglobin      - 22.9306  
 
( -45.6179 - -0.24322) 
0.04          5.7  









Low bioavailability of anti-TB drugs has been reported frequently in patients co-infected 
with TB and HIV (van Crevel et al 202; Choudhri et al 1996; Peloquin et al 1996; Sahai 
et al 1997; Gurumurthy et al 2004; Perlman et al 2005; Tappero et al 2005; McIlleron et 
al 2006) and these studies report that of the commonly used anti-TB drugs, RMP is the 
most common drug with reduced bioavailability. Although initial studies reported no 
association between HIV and plasma RBT concentrations (Narang et al 1996; Gatti et 
al 1998; Gatti et al 1999), there is more recent evidence that RBT absorption is also 
decreased in TB-HIV co-infected patients and contributes to ARR (Weiner et al 2005a; 
Holland et al 2009). The median AUC0-24 and Cmax values for RBT 300mg obtained in 
this study are comparable to values obtained in a previous study of RBT 
pharmacokinetics in TB-HIV co-infected patients by (Boulanger et al 2009). However, 
in comparison to a Phase I single dose study of RBT 300mg daily in HIV-infected 
patients without TB (Skinner et al 1989), the bioavailability of RBT in our study is lower. 
Furthermore, the RBT AUC0-24 and Cmax values in this study are also lower than those 
obtained in healthy volunteers studies (Strolin-Benedetti et al 1990, Narang et al 1992, 
Polk et al 2001, Hamezh et al 2003, Sekar et al 2010). In contrast, the AUC0-24 d-RBT 
was higher than values previously reported in healthy volunteers but lower than values 
reported by Boulanger et al. This may indicate increased metabolism of RBT in TB-HIV 
co-infected patients. 
 
Rifabutin also undergoes autoinduction, which may account for its decreased oral 







300mg. In a study by Strolin-Benedetti et al (1990) in healthy volunteers, RBT and d-
RBT AUC0-24 was significantly decreased after 10 consecutive doses whereas half-life 
remained unchanged. This pattern of elimination is characteristic of drugs with a high 
hepatic extraction ratio (Rowland and Towser 1995). However, the hepatic extraction 
ratio of RBT is presently unknown due to a lack of pharmacokinetic studies following 
i.v. administration of RBT to healthy volunteers. Strolin-Benedetti et al (1990) have 
estimated the hepatic extraction ratio of RBT from available i.v data in HIV-infected 
patients to be 0.16. Consequently, RBT is not a high hepatic extraction ratio drug 
suggesting that RBT is metabolized extensively in the gut after oral dosing leading to 
its low oral bioavailability. 
 
Analysis of individual time-concentration graphs suggest that delayed absorption 
accounted for the decreased exposure of RBT in a very small proportion of patients, 
suggesting that the bioavailability of RBT may be determined by various other factors. 
The bioavailability of anti-TB drugs have been associated with various factors such as 
alcohol use (Kimerling et al 1998), race (Tappero et al 2005), age (McIlleron et al 
2006), gender (Sahai et al 1997; Ray et al 2003; McIlleron et al 2006), 
hypoalbuminaemia (Tappero et al 2005) and dose per kg of body weight (McIlleron et 
al 2006). In this study peak RBT plasma concentration was associated with body 
weight and patients who were males by multivariate logistic regression analysis. Males 
had lower Cmax than females (p = 0.06). This is in agreement with a previous study 
comparing RBT pharmacokinetics in males and females. Females had higher 







distribution in tissues is expected to take place in females who have a higher fat 
content than males (Colborn et al 1993). Approximately 66% of the patients in this 
study were males, which may have contributed to the overall low bioavailability. A 
recent South African study conducted in a similar cohort to this study reported that 
male patients have lower RMP bioavailability (McIlleron et al 2012).  
 
A significant difference in RBT bioavailability was shown between male and female 
patients. Females showed higher RBT bioavailability, consistent with a previous study 
(Colborn et al 1993). Gender differences in RMP pharmacokinetics has been reported 
recently in a study of TB-HIV co-infected patients recruited in Kwa-Zulu Natal 
(McIlleron et al 2012). In this study, females showed greater RMP bioavailability 
compared to males.  Differences in drug pharmacokinetics between males and female 
may also be due to differences in the activity of drug metabolizing enzymes and drug 
transporters. Studies in normal human liver samples have suggested that women have 
higher CYP3A4 and 2-fold lower PGP activity compared to men (Schuetz et al 1995; 
Meibhom et al 2002). However, hepatic PGP and CYP3A4 work together to increase 
drug elimination from the liver. Therefore, in women, intracellular accumulations of 
PGP substrates occur, which consequently increase competitive drug interactions 
between PGP and CYP3A4, ultimately delaying drug elimination (Chiou et al 2000; Lan 








Physiological differences such as generally lower body weight and organ size, higher 
percentage of body fat and different gastric motility in women compared to men could 
also account for the differences in bioavailability (Meibhom et al 2002). Greater body 
fat in women may account for greater volume of distribution of lipophilic drugs such as 
RBT and oral bioavailability of CYP3A substrates are higher in women compared to 
men (Schwartz 2003). 
 
Significant weight loss is one of the first signs and a symptom of TB and HIV infection 
and malnutrition is common in TB-HIV co-infected patients (Harries et al 1985; 
Onwubalili et al 1988). Reduced RMP bioavailability has been reported in patients with 
malnutrition (Polasa et al 1984) and there is evidence from patients without TB that 
malabsorption of antimycobacterial drugs increases with advancing HIV disease (as 
determined by decreasing CD4 cell counts) (Sahai et al 1996). Low serum albumin 
levels have also been reported in TB patients (Onwubalili et al 1988; Tappero et al 
2005). Low serum albumin levels reduce intravascular oncotic pressure, which could 
lead to edema, thickening of the intestinal wall, and impaired drug absorption. Rifabutin 
exhibits high affinity for plasma proteins. The extent of RBT binding to plasma proteins 
is reported to be 70 - 90% (Skinner et al 1989; Brogden and Fitton 1994). Therefore 
when serum albumin levels are low, less RBT is bound with plasma proteins and more 
is available in the circulation thereby increasing hepatic clearance and decreasing 
bioavailability.  However, in this study there were no malnourished patients as the 








 Gastro-intestinal malfunction is common in patients with HIV-infection (Smith et al 
1992; Lambi et al 1996). Rifabutin absorption may be decreased in TB-HIV patients by 
the presence of gastrointestinal disorders, which reduce the intestinal absorptive area 
or alter the absorptive processes. The D-Xylose tolerance test is used in clinical 
practice to assess small intestine function (Rolston et al 1989). A low D-Xylose level 
indicates poor mucosal absorption or the presence of bacteria in the small intestine 
that metabolize the xylose before it can be absorbed. Altered D-Xylose kinetics was 
observed in patients infected with HIV (Ehrenpreis  et al 1991; Carlson et al 1994) and 
who had severe weight loss and diarrhoea in the absence of intestinal pathogens and 
histologic abnormalities, suggesting that lymphatic obstruction produces the 
malabsorptive state (Ehrenpreis et al 1992). Two previous studies that investigated the 
absorption of anti-TB drugs in TB patients with HIV infection and the concurrent 
absorption of D-Xylose in the same patients found that the AUC of D-Xylose correlated 
with the reduced AUC of RMP and PZA (Choudhri et al 1996; Sahai et al 1997). Thus 
there is evidence of altered drug absorption taking place in the small intestines of HIV-
infected patients. 
 
Differences in RBT bioavailability among patients can also be due to different rates of 
metabolism. Rifabutin is metabolized to d-RBT by β-esterases (Jamis-Dow et al 1997) 
in the liver and by CYP3A4 in the gastrointestinal tract and liver (Iatsimirskaia et al 
1997). However, there is presently no data on the effect of β-esterase gene 







10-fold variation among individuals in the extent to which RMP induces CYP3A4 
expression in humans (Watkins 1989; Kolars 1992). Whether such variation in 
induction of CYP3A4 expression by RBT also exists is unknown; and likewise variable 
induction of CYP3A4 by RBT may account for the inter-individual variation in RBT 
bioavailability. In addition, various physiological and environmental factors such as 
hormonal homeostasis, disease status, age and diet are also responsible for the 
individual variability in CYP3A4 induction (Tang et al 2005). 
 
 
The bioavailability of RBT 300mg is low in TB-HIV co-infected patients in this study. 
However, the metabolite is also microbiologically active and the combination of parent 
drug and metabolite may provide adequate antimicrobial activity in TB-HIV co-infected 
patients. More studies are required to determine whether a revision of RBT dosing in 
African TB-HIV co-infected patients is required. 







Chapter 4: The Pharmacokinetic Interaction between Rifabutin and Non-
nucleoside Reverse Transcriptase Inhibitors 
	  
Summary 
The combination of RBT 300mg daily plus NVP maintains RBT Cmax and AUC0-24 in 
line with currently recommended ranges for the treatment of M. tuberculosis and the 
prevention of ARR respectively. When RBT 600mg is combined with EFV, the AUC0-24 
and Cmax of RBT is similar to the AUC0-24 and Cmax of RBT 300mg daily in the same 
patients. The administration of EFV and NVP in combination with RBT to TB-HIV co-
infected patients was well tolerated by patients in both treatment arms. There was one 
report of grade 4 hepatotoxicity in the NVP arm, one report each per arm of grade 4 
neutropenia and one patient in the NVP arm reported grade 4 uveitis after 24 weeks of 
TB treatment.  
 
4.1. Introduction 
Treatment options for TB-HIV co-infected patients living in resource-limited countries 
are few because of limited access to ART and the high cost of treatment. Efavirenz is 
currently prescribed with RMP-based ART, according to WHO ART treatment 
guidelines, on the basis of evidence of greater drug interactions occurring between 
RMP and NVP. Pozniak et al (1999) have suggested that when TB is diagnosed in 
patients taking NVP, NVP should be stopped and the patients switched to an 
alternative regiment. However, in resource-limited countries NVP is the more widely 







alternate rifamycin recommended for the treatment of TB-HIV co-infected patients 
requiring PI-based therapy but clinical data on the pharmacokinetic interactions 
between RBT and first line ART are limited. This study investigated the 
pharmacokinetic interactions between standard doses of EFV and NVP administered 
with two different daily doses of RBT in severely immunocompromised African patients 
co-infected with TB-HIV. 
 
 
4.2. Patient enrolment  
In total 14 patients were randomized to the NVP arm and 16 to the EFV arm. Three 
randomized patients were excluded from the pharmacokinetic analysis, leaving 14 
patients in the EFV arm and 13 patients in the NVP arm.  One patient in the EFV arm 
was withdrawn after completing one pharmacokinetic visit due to TB meningitis. 
Another patient was hospitalized for cryptococcal meningitis where she was 
administered fluconazole and discharged on secondary prophylaxis with fluconazole. 
One patient in the NVP arm developed grade 4 elevated transaminases two weeks 
after starting NVP therapy and was subsequently withdrawn from the trial.  
 
4.3.  Results 
4.3.1. Baseline patient demographics 
The baseline demographic data of patients randomized to the EFV and NVP arms are 
comparable (Table 4.1). The mean age, weight, height, BMI, CD4+ counts and viral 







kg/m2, 117.6 cells/mm3 and 5.2 log 10 copies. In the NVP arm the mean age, weight, 
height, BMI, CD4+ counts and viral load was 34.8 years, 54.4 kg, 158.6 cm, 22.3 
kg/m2, 99.0 cells/mm3 and 5.3 log 10 copies.  
 
Table 4.1. Baseline demographic data for patients randomized to the efavirenz 
and nevirapine arms. Data presented are means with standard deviation in 
brackets 
 
Parameter EFV Arm 
(n = 16) 
NVP Arm 
(n = 14) 
Age at screening, years 31.8 (4.7) 36.1 (6.6) 
Height, cm 159.1 (8.4) 159.5 (7.5) 
Weight, kg 59.4 (9.8) 57.2 (8.2) 
BMI, kg/m2 23.7 (5.2) 22.4 (2.8) 
Gender, n (%) 
  Female 






8 .0 (57) 
CD4+ cell count, cells/mm3 117.6 (44.4) 107.3 (30.0) 
Viral Load 5.2 log10 5.3 log10 










4.3.2. Response to treatment 
At randomization there were a total of 6 patients who were AFB sputum smear 
positive, one of whom was also sputum culture positive for M. tuberculosis.  At the end 
of TB treatment, 2 patients remained sputum culture positive for M. tuberculosis one 
each from the EFV and NVP arms. Both these patients’ drug susceptibility testing 
(DST) results at randomization, available after completion of pharmacokinetic visits, 
revealed multi-drug resistant (MDR) M. tuberculosis. In addition there was one patient 
on the EFV arm who remained sputum smear positive but sputum culture negative at 
the penultimate trial visit. Both patients diagnosed with MDR-TB were initiated on 
standardized second-line MDR-TB treatment according to South African Department of 
Health guidelines.  All patients in both arms reported 100% compliance to trial 
medication. 
 
There were significant increases in the CD4+ counts of patients randomized to both 
arms, by the end of TB treatment. Baseline CD4+ count increased from 110.5 
cells/mm3 to 182.5 cells/mm3 (p < 0.01) in the EFV arm and from 99.0 cells/mm3 to 
202.8 cells/mm3 (p = < 0.01) the NVP arm. There was also a significant decrease in log 
viral load in both arms. In the EFV arm, mean viral load decreased significantly from 
5.3 log10 copies to 1.9 log10 copies (p  < 0.01) and from 5.3 log10 copies to 2.3 log10 
copies (p < 0.01) in the NVP. This corresponded to a mean change of 3.3 log10 in the 
EFV arm and 2.9 log10 in the NVP arm.  After 16 weeks of ART in combination with 
RBT, there were two patients with viral loads greater than 1 000, both from the NVP 







copies/mL. Only the latter patient had genetic evidence of NNRTI resistance. 
Genotyping of viral DNA showed the presence of V90I, K103KN and G190AG 
mutations.  
 
4.3.3. Pharmacokinetic analysis 
The median AUC0-24 of RBT 300mg was comparable between the EFV and NVP arms 
(Table 4.2 and Table 4.5). The AUC0-24 of RBT 300mg was 2 647.6 ng.h/mL in the EFV 
arm and 2 487.5 ng.h/mL in the NVP arm. The median Cmax values of RBT 300mg 
were similar between the two arms, 245.5 ng/mL in the EFV arm and 246.0 ng/mL in 
the NVP arm. However, RBT trough concentration (C24) in the NVP arm was almost 
double the value obtained in the EFV arm. There were no significant differences in the 
oral clearance of RBT between patients randomized to the two arms.  
 
Large inter-patient variability was noted for AUC0-24 and Cmax in both arms. In the EFV 
arm, RBT AUC0-24 ranged from 1 483.1 ng.h/mL to 5764.5 ng.h/mL and Cmax ranged 
from 108.0 ng/mL to 526.0 ng/mL. Similar interpatient variability in RBT AUC0-24 and 
Cmax values as in the EFV arm were observed in the NVP arm. Rifabutin AUC0-24 
ranged from 1 572.4 ng.h/mL to 5 892.9 ng.h/mL and Cmax ranged from 116.0 ng/mL to 
589.0 ng/mL. The inter-patient variability expressed as coefficient of variation (%CV) 
for AUC0-24 and Cmax was 42 and 48% respectively in the EFV arm and 43% and 50%, 








The main pharmacokinetic parameters of RBT given alone and in combination with 
EFV are displayed in Table 4.2 and the median concentration-time profile of RBT 
before and after EFV-based ART is shown in Figure 4.1. The median RBT AUC0-24 for 
300mg RBT daily given alone and 450mg RBT daily plus EFV in the same patients 
was 2 647.6 and 1 967.8 ng.h/mL respectively, representing a decrease of 26%. 
However, the median AUC0-24 of RBT 300mg daily was similar to the median AUC0-24 
of RBT 600mg plus EFV in the same patents. The median AUC0-24 of RBT 600mg plus 
EFV was 2 567.7 ng.h/mL compared to 2 647.6 ng.h/mL for RBT 300mg given alone in 
the same patients. The difference in AUC0-24 between the two dosing periods was 3%.  
 
The median Cmax of RBT 450mg decreased in the presence of EFV while that of RBT 
600mg increased in comparison to 300mg RBT given alone, but the differences were 
not significant (p = 0.6 and 0.5 respectively). Large inter-patient variation in RBT Cmax 
was observed for all three dosing periods. The inter-patient variability (%CV) was 
equal for 300mg RBT given alone and 600mg RBT plus EFV, 42% and 43% 
respectively, and 52% for 450mg RBT plus EFV. There were no significant changes in 
median Tmax values between the three dosing periods indicating that absorption of RBT 
was not affected by the presence of EFV. However the oral clearance of RBT 450mg 
plus EFV was significantly higher when compared to the clearance of RBT 300mg 
given alone (p = 0.01). The clearance of RBT 600mg was not increased in the 


























Period 1 Mean 2 901.4 279.6 3.4 81.3 54.0 118.9 
RBT300mg SD 1 211.3 135.0 1.0 65.5 25.2 44.1 
 
Median 2 647.6 245.5 3.0 62.7 25.2 113.8 
 
IQR (25) 2 065.0 194.0 3.0 44.1 38.3 85.5 
 
IQR (75) 3 510.4 336.0 4.0 82.8 58.0 145.3 
 
GM 2 697.5 250.8 3.3 67.2 49.4 111.2 
 
Min 1 483.1 108.0 2.0 35.7 22.9 52.0 
 
Max 5 764.5 526.0 6.0 282.0 107.0 202.3 
 
CV% 42 48 29 81 47 37 
        
        Period 2 Mean 2 057.4 257.2 3.1 42.7 31.8 195.3 
RBT450mg SD 1072.5 150.3 0.8 33.9 21.5 115.0 
+EFV Median 1967.8 209.0 3.0 34.3 26.6 152.5 
 
IQR (25) 1091.6 137.0 2.0 18.6 19.0 103.3 
 
IQR (75) 2903.5 406.0 3.0 59.4 43.9 274.8 
 
GM 1788.4 216.5 3.0 28.8 26.0 167.8 
 
Min 676.8 78.1 2.0 2.0 7.3 76.2 
 
Max 3936.0 544.0 5.0 113.0 81.8 443.3 
 
CV% 52 58 26 79 68 59 
        
        Period 3 Mean 2 655.8 328.3 2.9 55.6 43.7 145.2 
RBT600mg  SD 1148.5 183.0 1.1 20.1 18.0 89.3 
+EFV Median 2567.7 309.5 3.0 51.2 43.1 117.0 
 
IQR (25) 1977.8 171.0 2.0 45.1 26.9 79.7 
 
IQR (75) 3765.5 426.0 3.0 73.4 54.0 151.7 
 
GM 2378.2 273.7 2.8 51.8 40.0 126.1 
 
Min 866.5 71.1 2.0 23.4 18.4 72.2 
 
Max 4154.7 662.0 6.0 85.1 76.0 346.2 
 
CV% 43 56 38 36 41 62 
                
RBT = rifabutin; EFV = efavirenz; AUC = area under the concentration-time curve; Cmax = maximum concentration in 
plasma; Tmax = time at which maximum concentration in plasma attained; C0 = pre-dose concentration; C24= trough 










Figure 4.1. Median (IQR) concentration-time profiles for rifabutin (RBT) 300mg 




The pharmacokinetic parameters and median concentration-time profile of d-RBT are 
displayed in Table 4.3 and Figure 4.2 respectively. The median AUC0-24 and Cmax of d-
RBT when 300mg RBT was given alone was 216.9 ng.h/mL and 22.4 ng/mL 
respectively. However, when 450mg RBT was given in combination with EFV in the 
same patients, the AUC0-24 and Cmax were 139.0 ng.h/mL and 18.3 ng/mL respectively, 
which corresponded with a 1.5-fold decrease in d-RBT exposure in the presence of 
EFV. In contrast, median AUC0-24 and Cmax values of d-RBT were similar for RBT 







were 216.9 ng.h/mL and 22.4 ng/mL and 222.1 ng.h/mL and 24.6 ng/mL for RBT 
300mg and RBT 600mg plus EFV respectively. Oral clearance of d-RBT was higher for 
RBT 450mg and 600mg  plus EFV compared to RBT 300mg given alone in the same 
patients, but only significant for the 450mg dose (p = 0.01). The median combined 
exposure of the active moiety (parent plus metabolite) was highest for RBT 300mg (2 
859.3 ng.h/mL) compared to the other dosing periods (2 107.2 ng.h/mL for 450mg RBT 





Figure 4.2. Median (IQR) concentration-time profiles of 25-O-deacetylrifabutin (d-
RBT) for rifabutin 300mg daily (green), rifabutin 450mg plus efavirenz (blue) and 







Table 4.3. Pharmacokinetic parameters of 25-O-desacetylrifabutin before and 


















Period 1 Mean 316.6 34.0 3.1 8.7 4.7 1228.4 
RBT 300mg SD 224.9 24.8 0.9 11.4 3.5 474.6 
 
Median 216.9 22.4 3.0 4.4 3.5 1386.4 
 
IQR (25) 182.9 18.9 3.0 4.0 2.8 884.5 
 
IQR (75) 339.2 45.5 3.0 7.1 4.7 1640.3 
 
GM 270.8 28.1 3.0 6.0 3.9 1108.0 
 
Min 173.7 14.5 2.0 3.1 1.8 319.1 
 
Max 940.1 98.8 6.0 46.6 13.7 1727.6 
 
CV% 71 73 29 131 74 39 
        
        Period 2 Mean 160.0 21.4 3.1 3.4 2.0 3262.4 
RBT 450mg  SD 118.5 15.4 1.0 4.0 2.0 2734.5 
+ EFV Median 139.0 18.3 3.0 1.9 1.6 2161.2 
 
IQR (25) 66.6 8.4 3.0 0.4 0.9 1530.3 
 
IQR (75) 196.0 28.1 3.0 4.0 1.7 4501.8 
 
GM 122.9 16.5 3.0 1.8 1.4 2441.6 
 
Min 32.0 4.4 2.0 0.4 0.4 670.8 
 
Max 447.2 56.5 6.0 13.3 7.2 9370.6 
 
CV% 74 73 32 118 100 84 
        
        Period 3 Mean 205.6 27.3 4.4 3.5 2.6 2228.9 
RBT 600mg  SD 119.5 17.4 5.7 2.5 1.5 1780.4 
+ EFV Median 222.1 24.6 3.0 3.1 2.4 1350.7 
 
IQR (25) 124.7 13.9 2.0 2.1 1.7 1235.3 
 
IQR (75) 242.9 37.8 3.0 3.9 2.8 2405.4 
 
GM 170.4 21.0 3.2 2.9 2.2 1760.9 
 
Min 43.8 2.7 2.0 0.5 0.4 689.4 
 
Max 435.2 58.7 24 9.4 6.4 6852.3 
 
CV% 58 64 133 71 58 80 
                
RBT = rifabutin; EFV = efavirenz; AUC = area under the concentration-time curve; Cmax = maximum concentration in 
plasma; Tmax = time at which maximum concentration in plasma attained; C0 = pre-dose concentration; C24= trough 








 The pharmacokinetic parameters of EFV administered with two different doses of RBT 
are displayed in Table 4.4 and the corresponding median concentration-time profile of 





Figure 4.3. Median (IQR) concentration-time profile of efavirenz (EFV) in the 
presence of rifabutin 450mg (blue) and 600mg (red) daily 
 
The median EFV AUC0-12 when EFV was given with 450mg RBT was similar to the 
median EFV AUC0-12 when EFV was given with 600mg RBT (86.3 ng.h/mL). 
Comparison of the median EFV trough (C12) concentrations for the two dosing periods 
showed no differences (3.0 ng/mL and 2.7 ng/mL for the 450mg and 600mg doses of 
RBT respectively). However, inter-patient variability of EFV trough concentrations was 







Trough concentrations ranged from 1.3 ng/mL to 24.4 ng/mL when patients took 
450mg RBT plus EFV and from 1.1 ng/mL to 16.5 ng/mL when the same patients took 
600mg RBT plus EFV. In this study there were no patients with EFV trough levels 
below 1.0 ng/mL, however 5 and 4 patients had EFV trough concentrations above 4 
ng/mL for the 450 and 600mg doses of RBT, respectively. Trough EFV concentrations 
were notably high in one patient (24.2 ng/mL for 450mg RBT plus EFV and 16.5 ng/mL 
for 600mg RBT plus EFV). However, adverse events such as CNS toxicity, which have 
been associated with such high EFV concentrations (Marzolini et al 2002) were not 
reported in this study.  
 
In most patients, secondary peaks were observed for EFV in combination with RBT 
450 and 600mg approximately 6 hours after the ingestion of EFV. The second peak 
















Table 4.4. Summary pharmacokinetics for efavirenz in the presence of rifabutin 

















Mean 142.6 7.4 5.6 5.5 5.5 
EFV +  SD 133.4 6.0 5.9 5.2 6.2 
RBT Median 86.3 5.2 3.0 3.4 3.0 
450mg IQR (25) 62.3 4.1 3.0 2.3 1.8 
 
IQR (75) 235.1 11.7 6.0 7.9 8.6 
 
GM 103.7 5.9 4.2 3.9 3.6 
 
Min 35.7 2.4 2.0 1.1 1.3 
 
Max 524.0 24.2 24 20.6 24.2 
 
CV% 94 81 105 95 113 
       
       EFV +  Mean 123.4 6.7 4.1 5.3 4.5 
RBT SD 97.4 4.9 3.0 5.0 4.2 
600mg Median 86.3 4.9 3.5 3.5 2.7 
 
IQR (25) 57.6 3.6 2.0 2.3 1.9 
 
IQR (75) 178.8 9.6 5.0 7.8 6.6 
 
GM 97.6 5.5 3.8 3.8 3.3 
 
Min 32.8 1.9 0.0 0.7 1.1 
 
Max 381.4 20.2 12.0 20.22 16.5 
 
CV% 79 73 73 94 93 
	  	   	  	   	  	   	  	   	  	   	  	   	  	  
RBT = rifabutin; EFV = efavirenz; AUC = area under the concentration-time curve; Cmax = maximum concentration in 
plasma; Tmax = time at which maximum concentration in plasma attained; C0 = pre-dose concentration; C12= trough 













The pharmacokinetic parameters of two different doses of RBT in the presence of NVP 
were compared with the pharmacokinetics of RBT 300mg given without NVP. The 
pharmacokinetic parameters of RBT before and after NVP-based ART are displayed in 
Table 4.5 and the corresponding median concentration-time profile is displayed in 
Figure 4.4.  
 
 
Figure 4.4. Median (IQR) concentration-time profiles for rifabutin (RBT) 300mg 










The RBT AUC0-24 of RBT 300 and 450mg plus NVP was significantly higher than the 
AUC0-24 of RBT 300mg given alone in the same patients (p = 0.003 and 0.0002 
respectively). The median RBT AUC0-24 was 2 487.5 ng.h/mL for 300mg RBT alone, 
increased by 46% to 4 443.3 ng.h/mL for the same dose in the presence of NVP and 
increased further by 60% to 6 214.0 ng.h/mL with the 450mg dose. One patient in the 
NVP arm had significantly higher RBT AUC0-24 values compared to concentrations of 
the remaining patients. Her RBT AUC0-24 was 2760.5 ng.h/mL for 300mg RBT, 8 373.5 
ng.h/mL for 300mg plus NVP and 9550 ng.h/mL for 450mg RBT plus NVP respectively. 
This patient developed grade 4 uveitis after 26 weeks of RBT therapy.    
 
The Cmax of RBT 300 and 450mg plus NVP were also significantly higher than the Cmax 
of RBT 300mg given alone (p = 0.004 and 0.002 respectively). A median Cmax value of 
500.0 ng/mL was obtained with RBT 300mg in combination with NVP. Increasing the 
RBT dose to 450mg achieved a higher Cmax value of 668.0 ng/mL. However the 
difference in Cmax for high and low doses of RBT were not statistically significant (p= 
0.2). There were no significant changes in Tmax between baseline and high and low 
doses of RBT in the presence of NVP. However, oral clearance of RBT 300mg and 
450mg was significantly lower in the presence of NVP (p = 0.01) compared to 300mg 




























Period 1 Mean 2 848.5 291.9 3.4 74.9 55.4 120.0 
 RBT 300mg SD 1 213.1 146.9 1.3 16.1 30.7 40.4 
 
Median 2 487.5 246.0 3.0 73.6 45.8 120.6 
 
IQR (25) 2 007.1 193.0 3.0 63.1 37.6 96.2 
 
IQR (75) 3 120.1 414.0 3.0 83.2 56.0 149.5 
 
GM 2 655.3 259.6 3.2 73.3 49.8 113.0 
 
Min 1 572.4 116.0 2.0 50.3 28.6 50.9 
 
Max 5 892.9 589.0 6.0 111.0 132.0 190.8 
 
CV% 43 50.3 38 21 55 34 
        Period 2 Mean 5 350.8 550.2 3.3 133.2 116.9 68.2 
RBT 300mg  SD 2444.7 277.3 0.9 76.9 67.8 31.3 
+NVP Median 4 443.2 500.0 3.0 91.8 103.0 67.5 
 
IQR (25) 3 937.8 356.0 3.0 69.4 71.1 40.9 
 
IQR (75) 7 338.0 642.0 3.0 208.0 155.0 76.2 
 
GM 4 853.8 493.6 3.2 112.6 102.5 61.8 
 
Min 2 438.8 196.0 3.0 46.8 46.8 28.9 
 
Max 10 370.5 1 270.0 6.0 263.0 299.0 123.0 
 
CV% 46 50 27 58 58 46 
        Period 3 Mean 6 579.5 621.1 3.6 204.8 140.5 53.3 
RBT 450mg  SD 2 475.9 254.0 1.0 101.5 70.2 24.3 
NVP Median 6 214.0 668.0 3.0 181.0 136.0 48.3 
 
IQR (25) 4 980.3 440.0 3.0 157.0 91.4 35.8 
 
IQR (75) 8 387.5 841.0 4.0 228.0 157.0 60.2 
 
GM 6 116.2 564.6 3.5 183.5 124.5 49.1 
 
Min 2 713.2 198.0 3.0 84.8 42.1 28.9 
 
Max 10 385 935.0 6.0 395.0 280.0 110.6 
 
CV% 37 41 28 50 50 46 
                
RBT = rifabutin; NVP = nevirapine; AUC = area under the concentration-time curve; Cmax = maximum concentration 
in plasma; Tmax = time at which maximum concentration in plasma attained; C0 = pre-dose concentration; C24= 








The AUC0-24 and Cmax of d-RBT increased significantly in the presence of NVP 
compared to when RBT 300mg was given alone. The AUC0-24 of d-RBT increased by 
four- and five-fold when RBT 300mg and 450mg was combined with NVP respectively, 
compared to when RBT 300mg was given alone.  The pharmacokinetic parameters of 
d-RBT in the presence and absence of NVP are displayed in Table 4.6 and the 
corresponding median concentration-time profile of d-RBT is displayed in Figure 4.5 
below. The combined median exposure of the active moiety (parent plus metabolite) 
was 2 677 ng.h/mL for 300mg RBT, 5 182.2 ng.h/mL for RBT 300mg plus NVP and 7 
334.2 ng.h/mL for RBT 450mg plus NVP. 
 
 
Figure 4.5. Median (IQR) concentration-time profiles of 25-O-deacetylrifabutin (d-
RBT) for rifabutin 300mg daily (blue), rifabutin 300mg daily plus NVP (red) and 







Table 4.6. Pharmacokinetic parameters of 25-O-desacetylrifabutin before and 

















	   	   	   	   	   	   	   	  Period 1 Mean 262.0 28.9 3.5 6.1 4.5 1501.5 
RBT 300mg SD 209.9 22.2 1.2 2.8 4.6 579.6 
 
Median 193.7 21.6 3.0 5.8 3.2 1548.9 
 
IQR (25) 153.9 16.7 3.0 3.4 2.2 1266.6 
 
IQR (75) 236.9 28.8 4.0 7.9 4.2 1949.0 
 
GM 221.2 23.8 3.4 5.4 3.4 1355.9 
 
Min 120.5 12.3 2.0 2.6 1.3 328.1 
 
Max 914.2 91.5 6.0 10.0 18.7 2490.5 
 
CV% 80 77 34 46 102 37 
        
        Period 2 Mean 945.0 92.5 3.3 23..5 20.6 466.2 
RBT 300mg  SD 640.9 51.0 0.9 21.0 21.4 293.1 
+NVP Median 739.0 85.3 3.0 12.4 13.2 406.0 
 
IQR (25) 528.3 59.7 3.0 10.4 10.1 250.3 
 
IQR (75) 1 198.8 123.0 3.0 26.3 21.8 567.9 
 
GM 775.9 79.7 3.2 16.8 14.7 386.7 
 
Min 289.6 27.7 3.0 4.7 3.9 122.3 
 
Max 2 454.0 123.0 6.0 67.5 83.8 1035.9 
 
CV% 68 55 27 89 103 63 
        
        Period 3 Mean 1 081.6 92.4 3.9 28.6 30.5 361.0 
RBT 450mg  SD 643.3 42.4 1.3 20.05 39.3 176.0 
+NVP Median 910.3 82.5 3.0 20.4 15.2 329.6 
 
IQR (25) 627.1 73.0 3.0 17.1 12.4 267.8 
 
IQR (75) 1 120.2 91.1 4.0 35.4 26.7 478.4 
 
GM 939.1 84.4 3.8 23.6 19.2 319.5 
 
Min 404.1 36.7 3.0 7.6 4.4 118.6 
 
Max 2 530.2 181.0 6.0 78.9 151.0 742.3 
 
CV% 59 46 33 70 128 49 
                
RBT = rifabutin; NVP = nevirapine; AUC = area under the concentration-time curve; Cmax = maximum concentration 
in plasma; Tmax = time at which maximum concentration in plasma attained; C0 = pre-dose concentration; C24= 








The median AUC0-12 and Cmax of NVP was higher in the presence of 300mg RBT 
compared to 450mg RBT but the difference was not statistically significant. The main 
pharmacokinetic parameters of NVP in the presence of two different doses of RB are 
displayed in Table 4.7 and the corresponding median time-concentration profile is 
shown in Figure 4.6. The median NVP trough concentration (C12) for the 300mg and 
450mg RBT doses was 5.46 ng/mL and 5.35 ng/mL respectively. There was only one 
patient with a NVP trough concentration less than 3.1 ng/mL for both doses of RBT. 
His NVP C12 was 1.65 ng/mL when he was on the 300mg dose and 1.31 ng/mL when 
he took the 450mg dose of RBT with NVP. This patient also had a detectable viral load 
of 188 000 cells/mL after 16 weeks of ART and genotyping of viral DNA showed the 
presence of NNRTI resistance mutations. For most patients, secondary peaks were 
observed 5 h after the ingestion of NVP as has been described in previous studies 










Figure 4.6. Median (IQR) concentration-time profile of nevirapine (NVP) in the 












Table 4.7. Summary pharmacokinetics for nevirapine in the presence of rifabutin 















NVP + Mean 95.3 10.6 2.8 8.0 7.3 
300mg  SD 81.5 9.3 1.5 8.7 7.2 
RBT Median 72.4 8.0 3.0 5.8 5.5 
 
IQR (25) 62.6 5.8 2.0 4.7 4.4 
 
IQR (75) 107.3 11.5 4.0 8.8 7.2 
 
GM 76.2 8.2 2.7 5.0 5.7 
 
Min 20.7 2.4 0.0 0.1 1.7 
 
Max 347.2 35. 5.0 35.6 30.2 
 
CV% 86 88 54 109 99 
       
       NVP + Mean 80.2 8.1 3.6 6.7 6.1 







RBT Median 69.6 7.0 2.0 6.3 5.4 
 
IQR (25) 55.1 5.2 2.0 3.9 4.2 
 
IQR (75) 96.4 8.8 5.0 8.0 7.3 
 
GM 66.4 6.6 3.1 4.5 5.1 
 
Min 12.6 1.3 0.0 0.1 1.3 
 
Max 232.2 25.1 12.0 21.7 16.8 
 
CV% 67 72 86 81 64 
	  	   	  	   	  	   	  	   	  	   	  	   	  	  
RBT = rifabutin; NVP = nevirapine; AUC = area under the concentration-time curve; Cmax = maximum concentration 
in plasma; Tmax = time at which maximum concentration in plasma attained; C0 = pre-dose concentration; C24= 








Table 4.8 Comparison of geometric mean ratios (GMR) for rifabutin when 
rifabutin 300 or 450mg is administered with nevirapine vs 300mg daily without 
rifabutin and when rifabutin 450 or 600mg is administered with efavirenz vs 
300mg daily  
 
 GMR (90% CI) 







NVP/RBT 300mg daily NVP/RBT 300mg daily 
AUC0-24 1.8 (0.9 – 3.0) 2.3 (1.3 – 2.1) 
 RBT 450mg plus 
EFV/RBT 300mg daily 
RBT 600mg plus 
EFV/RBT 300mg daily 
AUC0-24 0.7 (1.2 - 2.6) 0.9 (1.2 – 1.9) 
RBT = rifabutin; NVP = nevirapine; EFV = efavirenz; AUC = area under the concentration-time curve; GMR = 













Although previous studies have shown that RBT is as effective as RMP in the 
treatment drug susceptible TB (Schwander et al 1995; Gonzalez-Montaner 1994), the 
RBT concentrations required for effective therapy are only partially known and detailed 
PK-PD data from human studies are lacking (Davies et al 2007). Peloquin et al. (2002) 
recommend that peak RBT concentrations should fall between 300 to 900 ng/mL in the 
treatment of M. tuberculosis and in TBTC study 23 RBT AUC0-24 < 4.5 ug.h/mL was 
associated with ARR (Weiner et al 2005a).   
 
In this arm of the study, the median AUC0-24 and Cmax for RBT 300mg administered to 
27 HIV-infected TB patients before the start of ART was considerably lower than the 
AUC0-24 and Cmax of RBT 300mg reported previously, and is discussed in detail in 
Chapter 3. However, in the presence of NVP, the AUC0-24 and Cmax of RBT 300 and 
450mg is significantly higher than 300mg RBT given alone. Similar respective 
increases in the bioavailability of d-RBT were also observed in the presence of NVP. 
The increases in RBT and d-RBT bioavailability may be due to a reduction of their 
metabolism in the presence of NVP. Rifabutin and its metabolite are metabolized by 
intestinal and hepatic CYP3A4 (Strolin-Benedetti et al 1990; Trapnell et al 1997; 
Prasad and Singh 2012). In humans, CYP3A4 is responsible for the metabolism of a 
vast majority of drugs and particular classes of drugs such as PIs and NNRTIs 
modulate their activity. Efavirenz and NVP stimulate the activity of CYP3A4 (Mouly et 
al 2002; Back et al 2003) thus accelerating the metabolism of drugs that are substrates 







CYP3A4 activity has reduced plasma concentrations of concomitantly administered 
CYP3A4 substrates, indinavir, nelfinavir, saquinavir and methadone by 20-60% (Merry 
et al 1998; Barry et al 1999; Altice et al 1999; Piscitelli et al 2001). However, in this 
study of HIV-infected TB patients, NVP has inhibited the metabolism of concomitantly 
administered RBT. Similar inhibition of CYP3A4 by concomitant NVP has been 
reported in previous studies in HIV-infected patients (Mouly et al 2006; Kredo et al 
2011). Whether the alteration in CYP3A4 activity with regard to NVP is a consequence 
of HIV-infection; or gender and race related is not known. Large interindividual 
variability in hepatic CYP3A4 activity in HIV-infected patients has been reported 
previously (Slain et al 2000; Mouly et al 2006). Significantly lower CYP3A4 activity in 
HIV-infected Caucasian males compared to females, before the administration of 
HAART has been reported by Eap et al (2004) and Fellay et al (2005). Previous 
studies have also shown race and gender differences in CYP3A4 activity in African 
(Mouly et al 2006) Caucasian (Min et al 2000) and Asian (Zhu et al 2003) HIV-infected 
patients and healthy volunteers. 
 
Nevirapine plasma concentrations obtained in the presence of RBT were comparable 
to data from previous studies in patients taking NVP with (Maldonado et al 1999) and 
without RBT (Manosuthi et al 2009). There was only one patient with NVP trough 
concentrations < 3.1mg/L for both dosing periods. A sample from this patient showed 








Previous studies on RMP and NVP interaction have reported significant decreases in 
NVP trough concentrations in African (Cohen et al 2008; Lamorde et al 2010), Indian 
(Ramachandran et al 2006) and Thai patients (Autar et al 2005; Avihingsanon et al 
2008). While increasing the NVP dose to 600mg daily has been suggested 
(Ramachandran et al 2006; Elsherbiny et al 2009) to compensate for the decreased 
NVP exposure in the presence of RMP, a study comparing the pharmacokinetics and 
efficacy of NVP 400mg daily versus 600mg daily in HIV-co-infected patients receiving 
concomitant RMP, reported that 25% of patients on 600mg NVP developed NVP-
associated rash which was correlated with high NVP trough concentrations (range 5.6 
-11.02 mg/L) and there was no significant difference in the efficacy of viral suppression 
between the two doses after 24 and 48 weeks of treatment (Avihingsanon et al 2008). 
The use of RBT in combination with NVP would therefore be a more rational option in 
the treatment of TB-HIV co-infected patients. 
 
In contrast to NVP, plasma concentrations of RBT and d-RBT were significantly 
reduced when 450mg RBT was combined with EFV. This interaction between RBT and 
EFV has been reported previously (Benedek et al 1998), as EFV is an inducer of 
CYP3A4 and consequently accelerated the metabolism of RBT and d-RBT, which are 
also CYP3A4 substrates. However, increasing the RBT dose to 600mg in combination 
with EFV resulted in higher RBT and d-RBT concentrations, which were similar to 
concentrations obtained with 300mg RBT given alone. These observations are in 







RBT to 600mg in combination with EFV as per current treatment guidelines might be 
appropriate in TB-HIV co-infected African patients with advanced disease. 
 
Efavirenz plasma concentrations are subject to substantial inter-patient variability 
(Csajka et al 2003) and consistently higher plasma EFV concentrations have been 
observed in female and non-Caucasian patients (Burger et al 2005). The currently 
proposed range of acceptable EFV trough concentrations is 1- 4 mg/L. Concentrations 
below 1 mg/L are associated with virological failure and concentrations above 4 mg/L 
are associated with CNS toxicity (Csajka et al 2003; Marzolini e al 2001). There were 
no patients in this study with trough EFV concentrations below 1 mg/L. We also 
observed high interpatient variability in trough efavirenz concentrations (CV 113% for 
450mg and CV 93% for 600mg RBT). However, there were no patients with virological 
failure in the EFV arm nor were there any reports of EFV-associated CNS toxicity in 
this arm. The second peak in EFV concentrations may be due to delayed absorption or 
as a consequence of circadian variations in gastric acid secretion, gastric emptying 
time and gastrointestinal and hepatic blood flow (Bruguerolle 1998). These findings 
imply that it may be possible to substitute RBT 600mg for RMP in treatment regimens 
incorporating EFV. This may not be difficult to implement in a clinical setting as may 










Chapter 5. Pharmacokinetics of Different Rifabutin Doses in African HIV-infected 
Tuberculosis Patients on Lopinavir/ritonavir-based Antiretroviral Therapy 
	  
Summary 
The pharmacokinetics of RBT was evaluated at two different doses in HIV co-infected 
African patients before and after the introduction of LPV/r (tablet formulation 400/100 
mg 12 hourly)-based ART. Serial RBT and d-RBT concentrations were measured 
during a dose interval after 4 weeks of RBT 300 mg daily, after 4 weeks of 150 mg 
RBT daily with ART and after 4 weeks of RBT 150 mg 3 times a week (TPW) with 
ART. The median AUC0-48 and Cmax, of RBT in patients taking 150mg RBT TPW was 
significantly reduced when compared to the other treatment arms. 86% of patients on 
this intermittent RBT arm had an AUC0-24 < 4.5 μg.h/mL, which has been associated 
with ARR. A daily 150 mg dose of RBT in combination with LPV/r safely maintained 




	  Rifabutin is an alternative rifamycin, preferred in patients requiring PIs. Despite recent 
studies suggesting that the current recommended dose of RBT in combination with 
LPV/r is suboptimal, there are insufficient pharmacokinetic data evaluating the 
interaction in patients treated with the film-coated tablet formulation of LPV/r. The 







RBT (150mg TPW and 150mg daily) in HIV-positive TB African patients initiating ART 
with LPV/r. 
 
5.2. Patient enrolment information 
A total of 16 patients received LPV/r therapy with RBT. One patient was withdrawn 
from the study due to uveitis, five days after the initiation of ART. Another patient was 
withdrawn from the pharmacokinetic analysis due to documented non-compliance on 
trial medication. Thus the pharmacokinetic evaluation was based on 14 patients. All 




5.3.1. Patient Demographics 
 The evaluable subjects’ mean (SD) age was 31.5 (5.8) years, weight was 59.9 (9.7) 
kg, height was 160 (7.7) cm, BMI was 23.3 (2.6), Karnofsky score Q was 100 % (100) 
and CD4+ lymphocyte count was 150.9 (12.1) cells/mm3. 
 
5.3.2. Response to TB/HIV Treatment  
Amongst the 14 patients, 3 were sputum culture positive after 2 months of TB therapy 
and all of these patients were culture negative for TB at the end of therapy. The mean 







was significantly higher (p = 0.03) than the mean CD4 count of 150 (12.1) cells/mm3 at 
baseline. Before the initiation of ART the mean (sd) viral load was 5.4 (0.7) log10 
copies. Of the fourteen patients who participated in the pharmacokinetic analysis, 8 
patients had viral loads > 500 cells/L. Genotypic testing was performed on isolates 
from all 8 patients. None of these isolates demonstrated HIV protease mutations with 
resistance. After fourteen weeks of ART the mean (SD) viral load dropped significantly 
(p < 0.001) by 2.7 log10 copies to 2.9 (1.3) log10 copies. 
 
5.3.3. Pharmacokinetic Analysis 
5.3.3.1. Rifabutin 
The steady state pharmacokinetics of RBT and d-RBT were evaluated when RBT was 
given alone and at two different doses in combination with LPV/r The main 
pharmacokinetic parameters for RBT and d-RBT for each of the dosing periods are 
summarized in Tables 5.1 and 5.2 respectively. 
 
The AUC0-24 of RBT 150 mg daily with LPV/r was significantly higher when compared 
to the AUC0-24 of RBT 300 mg daily in the absence of LPV/r in the same patients (P = 
0.004). In contrast, the AUC0-24 of RBT 150 mg TPW with LPV/r was lower than the 
AUC0-24 of RBT 300 mg daily (P = 0.2) and the AUC0-24 of RBT 150mg daily with LPV/r 
(P = 0.0001). The differences in the AUC0-48 were more pronounced between the three 
groups. The AUC0-48 of RBT 150 mg TPW with LPV/r was significantly lower than the 
AUC0-48 of RBT 300 mg daily (p = 0.0001) and the AUC0-48 of RBT 150mg daily was 







Wide inter-patient variability was observed in RBT AUC for all three doses (Table 5.2).  
The %CV was 24% for the 300mg dose, 46% for RBT 150 mg daily plus LPV/r and 
52% for RBT 150mg TPW plus LPV/r. 
 
  
Figure 5.1. Median (IQR) concentration-time profiles for rifabutin 300mg (green), 
rifabutin 150mg thrice weekly plus lopinavir/ritonavir (blue) and rifabutin 150mg 
daily plus lopinavir/ritonavir (red) 
 
The Cmax of RBT 150 mg TPW with LPV/r was also significantly lower when compared 
to the 150 mg daily dose with LPV/r  (P = 0.01) and the 300 mg daily dose without 
LPV/r (P = 0.01). The median C12 for RBT 300mg was 60.7 ng/mL (IQR, 40.6-68.8 
ng/mL). The C12 values increased in the presence of LPV/r with daily dosing of RBT to 







dose. For the 150 mg TPW dose, the median C24 and C48 were 70.7 ng/mL (IQR, 45.7-
96.6 ng/mL) and 37 ng/mL (IQR, 26.6-70 ng/mL) respectively. Rifabutin clearance was 
significantly reduced in the presence of LPV/r (p= 0.001 for daily and p = 0.002 









Table 5.1. Main pharmacokinetic parameters median (interquartile range) for 
rifabutin derived by non-compartmental analysis for each of the study 










* calculated by 2 X AUC0-24 
RBT = rifabutin; LPV/r = lopinavir/ritonavir; TPW = three times per week; AUC = area under the curve; Cmax = 
maximum concentration in plasma; Tmax = time at which maximum plasma attained; CL/F = clearance; C0 = pre-
dose concentration; Cmin = trough concentration 
 
Treatment period Rifabutin 300mg 
(n = 14) 
Rifabutin 150 mg 
TPW plus LPV/r 
(n=14) 
Rifabutin 150 mg 
daily plus LPV/r 
(n=14) 












Cmax (ng/mL) 291.5 (250.0-377.0) 167.5 (87.8-294.0) 311.0 (258.0-376.0) 
 
Tmax (h) 3.0 (3.0-4.0) 3.5 (3.0-5.0) 3.0 (3.0-4.0) 
 
C0 (ng/mL) 59.0 (36.4 - 78.6) 49.1 (27.7-58.9) 176.5 (149.0 – 195.0) 
 
Cmin 24h (ng/mL) 60.7 (40.6 -68.8) 70.7 (45.7 – 96.6) 133.0 (105.0 – 191.0) 
 
Cmin 48h (ng/mL) - 37.0 (26.6-70.0) - 
 







 (2424.6 – 6772.7) 
8753.0 







Table 5.2. Main pharmacokinetic parameters for 25-O-desacetylrifabutin before 












Period 1 Mean 316.7 34.2 3.7 5.3 5.2 
 300mg SD 129.7 15.4 1.3 3.0 2.4 
 
Median 273.3 32.5 3.0 5.1 5.0 
 
IQR (25) 235.7 25.2 3.0 2.7 3.4 
 
IQR (75) 344.1 37.7 4.0 6.6 5.6 
 
GM 297.7 31.6 3.6 4.2 4.8 
 
Min 193.6 17.9 3.0 0.4 2.6 
 
Max 677.3 77.1 6.0 11.7 11.4 
 
CV% 41 45 35 57 46 
       
       Period 2 Mean 1712.4 88.5 6.6 47.7 67.0 
RBT 150mg  SD 877.0 44.4 5.6 29.2 33.9 
TPW   Median 1565.5 77.2 5.0 44.6 63.9 
+ LPV/r IQR (25) 1105.5 58.6 4.0 31.7 42.7 
 
IQR (75) 2567.3 128.0 6.0 68.9 101.0 
 
GM 1454.7 76.0 5.3 25.6 58.1 
 
Min 345.9 19.7 2.0 0.4 16.7 
 
Max 2888.7 152.0 24.0 105.0 126.0 
 
CV% 51 50 85 61 51 
       
       Period 3 Mean 3904.0 210.8 4.1 165.3 136.4 
RBT 150mg SD 1731.2 80.3 2.0 73.2 78.0 
 daily + LPV Median 4118.0 236.5 4.0 186.0 155.0 
 
IQR (25) 2678.2 159.0 3.0 115.0 53.6 
 
IQR (75) 5405.5 274.0 3.0 232.0 206.0 
 
GM 3327.6 187.6 4.1 138.6 106.3 
 
Min 589.5 33.7 0.0 17.1 22.7 
 
Max 5761.5 321.0 8.0 244.0 239.0 
 
CV% 44 38 49 44 57 
              
RBT = rifabutin; LPV/r = lopinavir/ritonavir; AUC = area under the concentration-time curve; Cmax = maximum 
concentration in plasma; Tmax = time at which maximum concentration in plasma attained; C0 = pre-dose 
concentration; C24= trough concentration; SD = standard deviation; IQR= interquartile range; GM = geometric mean; 








Table 5.3. Summary pharmacokinetics for lopinavir/ritonavir in the presence of 












LPV  Mean 129.5 14.2 2.6 8.4 7.4 
RBT   SD 45.0 4.3 0.9 5.9 3.4 
150 mg Median 139.5 15.8 2.0 9.8 7.4 
TPW IQR (25) 103.7 12.9 2.0 3.5 4.5 
 
IQR (75) 163.9 17.1 3.0 14.0 10.0 
 
GM 118.2 13.3 2.5 4.0 6.2 
 
Min 26.5 3.9 2.0 0.1 0.8 
 
Max 185.4 19.1 5.0 15.3 12.0 
 
CV% 35 30 35 70 46 
       
       LPV  Mean 161.8 17.4 2.6 12.0 10.1 
RBT   SD 40.1 4.0 0.9 5.1 3.2 
150 mg Median 160.1 18.1 2.0 11.4 9.4 
daily IQR (25) 129.1 14.5 2.0 9.9 7.2 
 
IQR (75) 181.9 19.6 3.0 15.2 11.6 
 
GM 157.5 17.0 2.5 10.9 9.6 
 
Min 102.5 10.6 2.0 3.6 6.1 
 
Max 25.8 27.4 5.0 23.1 15.5 
 
CV% 25 23 35 43 32 
              
RBT = rifabutin; LPV/r = lopinavir/ritonavir; AUC = area under the concentration-time curve; Cmax = maximum 
concentration in plasma; Tmax = time at which maximum concentration in plasma attained; C0 = pre-dose 
concentration; C24= trough concentration; SD = standard deviation; IQR= interquartile range; GM = geometric mean; 












Table 5. 4.  Comparison of geometric mean ratios (GMR) for rifabutin when 
rifabutin 150 mg is administered three times per week (TPW) or daily with 
lopinavir/r vs. rifabutin 300 mg daily without lopinavir/ritonavir and comparison 













 GMR (90% CI) 
 RBT 150 TPW 
with ART/RBT 
300 mg daily 
without ART 
RBT 150 mg daily 
with ART/RBT 
300 mg daily 
without ART 
RBT 150 mg 
daily with ART/ 
RBT 150 mg 
TPW with ART  
AUC0-24 
0.8 (0.7 – 0.9) 0.6 (0.5 – 0.7) 0.4 (0.5 – 0.5) 
AUC0-48 0.6 (0.5 – 0.7) 0.6 (0.7  - 0.5) 
 










Figure 5.2. Median (IQR) concentration-time profiles of 25-O-deacetylrifabutin (d-
RBT) rifabutin 300mg (blue), rifabutin 150mg thrice weekly plus 
lopinavir/ritonavir (green) and rifabutin 150mg daily plus lopinavir/ritonavir (red) 
 
In the absence of LPV/r, d-RBT concentrations were approximately 11 % of the parent 
drug. In the presence of LPV/r, plasma d-RBT concentrations increased 5-fold with 
intermittent RBT dosing and 15-fold with daily doses of RBT (Figure 5.2). The total 
antimicrobial moiety (combined AUC0-24 of RBT and d-RBT) for RBT at 150mg TPW 
was 1.2 times greater than that for 300mg RBT and at 150mg daily the total 
antimicrobial moiety was 2.6 times greater than that at 300mg RBT and 2.2 times 
greater than that at 150mg TPW. The ratios of parent drug : metabolite were 11:1 at 









Figure 5. 3. Median (IQR) concentration-time profile of lopinavir (LPV) when 
lopinavir/ritonavir was administered as part of antiretroviral treatment with 
rifabutin (150 mg daily (blue) and 150mg thrice weekly (red) and isoniazid 
	  
The main LPV pharmacokinetic measures are summarized in Table 5.3 and the 
concentration-time curves are shown in Figure 5.3. In both dosing arms, median LPV 
trough (C0) concentrations at steady state were above the recommended lower limit for 
ART-naïve patients of 1 µg/mL (la Porte 2006). Although there was a trend to higher 
LPV concentrations with the once daily dosing of RBT compared to the TPW dose, the 
differences in AUC0-12 and Cmax between the two doses were not statistically 
significant. Double peaks were observed in the LPV concentration-time profile with 









The current recommended dose of RBT for the treatment of pulmonary TB is 300mg 
daily but there are few pharmacokinetic data from HIV infected African TB patients 
treated at this dose. The median RBT AUC0-24 for patients randomized to receive LPV-
based ART in this study was 3 052.9 ng.h/mL (IQR, 2 650.2 – 3 431.5 ng.h/mL) which 
was comparable to previous studies of RBT 300mg daily in HIV-infected patients 
(Colborn et al 1996; Li et al 1996: Moyle et al 2002; Boulanger et al 2009). The AUC0-24 
in these studies ranged from 2 663 ng.h/mL to 5 324 ng.h/mL. Similiarly the Cmax from 
the current study was 291.5 ng/mL again comparable to the range of values (244.9 to 
525.0 ng/mL) reported from previous studies.  
 
Previous studies of the pharmacokinetic interaction of RBT with LPV/r in HIV infected 
individuals have been small case series or involved an adaptive design in which only 
selected patients were exposed to the higher dose of RBT. In addition, no previous 
studies have reported on the RBT pharmacokinetics in combination with the tablet 
formulation of RTV boosted LPV (Aluvia), now the most widely used formulation of a PI 
in global HIV programs. A cross-over design in which all patients received 3 full 
pharmacokinetic assessments with RBT alone and at two different RBT doses in 
combination with LPV/r was adopted allowing a formal comparison to be made 
between the two different dosing strategies of RBT in combination with LPV/r at the 
recommended TB treatment dose. In this study the AUC0-48 and Cmax of RBT when 
150mg was given intermittently with the PI was significantly lower than when 300mg 







LPV/r was significantly higher than that obtained with the 300mg daily dose. This 
confirms previous reports that the 150mg intermittent dose of RBT with LPV results in 
potentially suboptimal TB therapy. The changes in AUC and CL/F of RBT are 
completely different according to whether RBT is dosed daily or intermittently (Table 
5.1) despite the dose of LPV/r remaining unchanged. This is rather peculiar and may 
implicate other pathways in the metabolism of RBT besides CYP3A4. Previous studies 
have shown that the rifamycins are also metabolized by β-esterases. However, the 
exact role of β-esterases in RBT metabolism are not completely understood.   
 
The pharmacodynamic-pharmacokinetic relationship for RBT has not been 
comprehensively studied so it is not clear how the reduced bioavailability of the 150mg 
intermittent dose would impact on TB treatment outcomes. There is still controversy 
over whether Cmax or AUC is the critical pharmacodynamic measure for rifamycins in 
general. Initial studies in guinea pigs by Mitchison and Dickinson (1971) and (Verbist 
1969) were consistent with a Cmax/MIC being the critical pharmacokinetic parameter. 
Subsequent studies in a murine model (Jayaram et al 203) and a hollow fibre model 
(Gumbo et al 2007) found that the AUC0-24/MIC ratio of rifamycins was a superior 
parameter and this has also been found in an early bactericidal activity of RMP in 
humans  (Diacon et al 2007). The only efficacy trial comparing the 300mg and 150mg 
daily doses of RBT found there was no difference in bacterial conversion rates 
between the regimens, but the study was in HIV negative patients and was 
underpowered to assess differences in tuberculosis relapse rates (Gonzalez-Montaner 








Although there is a lack of conventional efficacy data in support of a particular dose of 
RBT, there is convincing evidence that intermittent rifamycin therapy is associated with 
TB relapse and ARR. Various studies have reported this association of ARR with 
intermittent RMP and RBT especially in subjects with low CD4 counts (Spradling et al 
2002; Nettles et al 2004; Li et al 2005) [28-30]. In TBTC study 23 (Weiner et al 2005a), 
TB-HIV co-infected patients who had lower plasma concentrations of RBT were at risk 
of ARR. 83% of patients with an AUC0–24 of < 4.5 μg.h/mL who relapsed or failed 
therapy developed ARR as opposed to 33% who had AUC’s above this threshold 
value. In this study 71% patients on RBT 150mg daily versus 14% on RBT TPW had 
AUC0-24 values > 4.5 μg.h/mL. Similarly the trough values of RBT 48hours after dosing 
in the intermittent RBT arm in this study are significantly lower than the trough values 
for either of the other two arms, which may also be a pertinent pharmacokinetic 
parameter associated with selection of resistance. 
 
The AUC0-24 and Cmax of d-RBT were significantly increased in the presence of LPV/r in 
keeping with previous treatment studies (Hamzeh et al 2003; Benator et al 2007) and 
in healthy volunteers (Polk et al 2001; Ford et al 2008; Sekar et al 2010). On daily 
dosing of RBT, ritonavir caused a 50% increase in parent exposure but a 1000% 
increase in metabolite exposure. Furthermore on intermittent dosing the parent 
exposure decreased while the metabolite exposure increased five-fold. Ritonavir is a 







with daily dosing of RBT is expected. However, the five-fold increase in metabolite 
exposure with intermittent dosing is unexpected and may imply bidirectional 
interactions with other CYP450 isoenymes as well as the participation of alternate 
metabolic pathways. Furthermore, the patients in this study were severely 
immunocompromised which may have altered the normal functioning of many 
processes and pathways including those involved in drug metabolism. 
 
25-O-desacetylrifabutin is known to have significant antimycobacterial activity and 
could contribute to the regimen efficacy. Interestingly when the combined RBT and 
metabolite AUC0-24 are compared between all three arms of the study only the 150mg 
daily dose with LPV/r was significantly different from the other arms. The therapeutic 
index of d-RBT is unknown and it is possible that elevations of the metabolite could 
affect adverse drug reactions. We were unable to show a significant association 
between plasma RBT and d-RBT concentration and adverse events such as 
neutropenia or elevated transaminases although the numbers of patients are few. 
Using a random effects model, no association between AUC0-24 and Cmax of RBT, 
dRBT and RBT+dRBT and neutrophil levels was found. 
 
In view of the high NVP concentrations observed when NVP is combined with RBT 
300mg and 450mg and significant increases in d-RBT when RBT 150mg daily is given 







adverse events related to RBT in this study were few, more studies are required to 
investigate RBT toxicity at the exposures observed in this study. 
 
Various clinical studies involving PIs have shown that their activity is influenced by 
their concentrations in plasma (Kempf et al 1997). We were therefore keen determine 
the pharmacokinetics of LPV in our cohort especially as the heat-stable current 
formulation has not been previously evaluated. The median LPV AUC0-12, Cmax, C0 and 
C12 obtained in this study when LPV was administered with two different doses of RBT 
are comparable to a recent study by Matteelli et al (Matteelli 2010) and consistent with 
historical control data (Crommentuyn et al 2004). Secondary peaks were observed in 
the time-concentration profiles of LPV, usually within 4 hours of drug ingestion, similar 
to patterns observed in other studies. In both dosing arms, median LPV trough (C0) 
concentrations at steady state were above the recommended lower limit for ART-naïve 
patients of 1 µg/mL la Porte et al (2006) and therapeutic LPV trough (C0) and Cmin (C12) 
concentrations were achieved in all patients with both doses of RBT.  
 
This study supports an alteration to the current guidelines for the dosing of RBT in 
combination with boosted LPV. The high proportion of patients on the 150mg TPW arm 
who failed to establish a serum drug concentration that can prevent the emergence of 
drug resistance is very concerning. Although escalating the RBT dose after therapeutic 
drug monitoring is a viable option in resource rich settings it is impractical in many 







treatment of HIV-associated TB recommend that treatment is given daily throughout 
the intensive and continuation phases of TB treatment (World Health Organisation 
Stop TB Department 2009). Giving RBT as a daily dose is in line with these 
recommendations. This would also facilitate the important programmatic issue of 
combining RBT with other anti-TB medications as a fixed-dose combination pill to be 







Chapter 6. Safety 
  
Summary 
The safety of combining RBT with ART was investigated in this chapter. There were 
nine reports of SAEs. There were three patients with grade 4 laboratory toxicities. The 
remaining SAEs were clinical and not related to RBT. One patient died two weeks after 
enrolment of disseminated TB. There were no grade 4 adverse events in the LPV/r 
arm. The most common clinical adverse events reported in the LPV arm were skin 
infections (three patients) and diarrhea (four patients). Uveitis (grade 2) was reported 
in one patient after four weeks of RBT therapy. Grade 3 neutropenia occurred on six 
occasions in four patients. In the EFV and NVP arms there were six grade 4 and 10 
grade 3 adverse events, equally distributed per arm.  The most common adverse event 
was neutropenia, two grade 4s (1 each per arm) and three grade 3s. There was one 
grade 4 elevated transaminases in the NVP arm and there were two grade 3 elevated 
amylase (one per arm). Grade 3 clinical adverse events were MDR TB, headache with 
associated nausea and vomiting and weight loss. Grade 4 uveitis was reported in one 




In previous chapters, the pharmacokinetics of RBT in African TB patients with 
advanced immunosuppression was described. The study went on to investigate the 







discuss the toxicity of RBT particularly when it is combined with ART in severely 
immunocompromised patients. The adverse events associated with ART and anti-TB 
therapy is well documented and their effects may to be compounded in combined 
treatment regiments. Previous studies on RBT have raised concerns about the 
association between high RBT plasma levels and neutropenia, uveitis and 
hepatotoxicity. In this chapter the adverse events associated with combined RBT and 
ART are described and their association with RBT is discussed. 
 
6.2. Methods 
Safety was evaluated by means of adverse event  (AE) reporting, clinical laboratory 
tests, vital signs, screening for specific symptoms and physical examinations. All 
events were coded using the Division of AIDS Table for Grading the Severity of Adult 
and Pediatric Adverse Events (December, 2004) (AIDS Clinical Trials Group 2004). 
Type (body system) and incidence of all adverse events (AEs) from screening up to 
and including trial termination visit are tabulated in Table 6.3 per arm. A separate 
tabulation of Grade 3 and 4 AEs and drug relationship of the AEs is presented in Table 
6.4. The serious adverse events (SAEs) are described below.  
 
6.3. Results 
6.3.1. Serious Adverse Events 
Serious adverse events were reported according to standard clinical trial procedures 
and definitions. There were a total of 9 AEs all in different patients and these are 







and were clinical conditions recognized as complications of HIV or TB infection. 
However there were three that were possibly or probably related to RBT.  
 
Table 6.1. List of Serious Adverse Events 








144 2a Elevated 
transaminases 
84 Possible Withdrawn 
157 1b Cryptococcal 
meningitis 
68 Not related Resolved 
166 3b Meningitis 147 Not related Resolved 
184 1a TB Meningitis 66 Not related Withdrawn 
234 Disseminated TB 85 Not related Death 
188 2a Uveitis 127 Probable Resolved 
250 3a Pyelonephritis 133 Not related Resolved 
241 1a Neutropenia 180 Possible Withdrawn 
257 1b MDR TB 175 Not related Withdrawn 
 
	  
6.3.1.1 Serious Adverse Events Related to Rifabutin 
Patient NHM 144 2a, a 41-year-old male was enrolled in the trial after taking rifampicin 
for six weeks. Upon enrollment, he commenced RBT 300mg. At a routine trial visit 4 







increased (grade 1). The patient was asymptomatic and clinically well at this visit and 
commenced ART the next day. He was given stavudine 30mg bd, lamivudine 150mg 
bd and NVP 200mg daily. The patient returned to the clinic 2 weeks later for dose 
escalation and routine LFT analysis for patients on the NVP arm. The patient was 
asymptomatic and clinically well. There was no evidence to suggest liver pathology. 
There was also no history of alcohol or traditional medication ingestion. The LFTs 
revealed grade 4 AST and ALT. The LFTs were repeated and the results were 
confirmed. A hepatitis screen was negative.  This clinical presentation of hepatotoxicity 
after two weeks of initiating ART, and specifically NVP, is well documented and was 
the most likely cause of the transaminitis in this case. RBT levels were not elevated in 
this patient. 
 
All study drugs were subsequently withdrawn and the patient withdrawn from the trial. 
He was hospitalized for further investigations. An abdominal ultrasound revealed no 
abnormalities. Serial LFTs revealed an improvement in elevated transaminase levels 
hence he was re-introduced to anti-TB drugs one at a time at weekly intervals with 
weekly LFT monitoring. As his LFTs returned to baseline values the patient was 
discharged from hospital with Rifanah, 2 tablets daily and referred to the local ARV 
clinic for re-commencement of EFV based therapy.  
 
Patient NNL 188 2a, a 35-year-old female progressed well in the trial without any 







with associated light sensitivity and blurred vision that reached maximal intensity on 
day 106. She referred herself to the Eye Clinic of a local hospital where an 
ophthalmologist diagnosed viral uveitis. The patient was started on topical steroids and 
oral acyclovir. At a subsequent follow-up visit at the Eye Clinic, the patient reported a 
continuation of painful red eyes since the last visit, suggesting drug-related uveitis.  
The patient was admitted for treatment and RBT was stopped. At this point in the trial 
the patient had already completed 24 weeks (6 months) of anti-TB treatment. 
 
On admission, pan uveitis and syphilis were diagnosed on the basis of positive 
treponemal serolgoy. The following treatment was commenced and prescribed for 10 
days: penicillin 4mg 6 hourly iv, with prednisone forte 1 drop every hour in both eyes, in 
addition to atropine 1 drop 8 hourly in both eyes. She was discharged with prednisone 
40mg daily orally for two weeks. The patient was seen at subsequent follow up visits at 
which there were no residual symptoms or signs of severe uveitis. The patient was 
completely asymptomatic and reported that she was compliant on ART. 
Plasma RBT levels for patient NNL, in contrast to patient NHM, was high at all three 
PK visits. Her RBT concentrations were 2 760.5 ng.h/mL for 300mg RBT alone, 8373.5 
ng.h/mL for 300mg RBT plus NVP and 9550 ng.h/mL for 450mg RBT plus NVP. The 
patients’ plasma RBT concentrations in the presence of NVP were above the IQR for 
both the 300 and 450mg doses. This would suggest that the uveitis was definitely drug 








Patient BBM 241 1a, a 30-year-old male progressed well in the trial but on day 84 was 
found to have a grade 4 neutropenia (0.39 x 109 /L). The test was repeated and the 
neutropenia confirmed (0.24 x 109 /L). Anti-TB medication was stopped immediately 
while ART was continued. Serial FBCs were subsequently done and when the 
neutrophil count had normalized, the patient was restarted on anti-TB treatment (RBT 
600mg and INH 300mg daily). The patient was reviewed a week later and the FBC 
revealed a grade 1 neutropenia. The FBC was repeated 4 days later and the grade 1 
neutropenia was confirmed. The patient was therefore withdrawn and was referred to 
the local TB clinic for continuation of TB therapy (RMP and INH) and ART therapy. The 
recurrence of neutropenia after a re-challenge with RBT would strongly support that 
neutropenia in this patient was drug related. The RBT AUC0-24 and Cmax, respectively 
for this patient were 2 472.7 ng.h/mL and 208 ng/mL for 300mg RBT, 1091.6 ng.h/mL 
and 109 ng/mL for RBT 450mg plus EFV and 1977.8 ng.h/mL and 242 ng/mL for RBT 
600mg plus EFV.  
 
6.3.1.2 Serious adverse event NOT related to Rifabutin 
Patient MS 257 1b, a 26-year-old male, was found to be 3+ smear positive after 2 
months of TB treatment. Sputum smear was repeated one month later and was found 
to be 1+ positive. Subsequently the initial sputum was found to be culture positive and 
resistant to INH, RMP, EMB, SM and ethionamide. The patient remained clinically well 
and was referred to the local MDR treatment centre. He was started on MDR treatment 
in the form of ofloxacin 800mg daily, amikacin 830mg daily, pyrazinamide 1.5g daily, 







months later and was found to be clinically stable and adherent to therapy. The onset 
of MDR-TB was detected at the randomization visit. This was the first visit at which the 
patients received a sputum drug susceptibility test in the trial and occurred after 2 
weeks of trial medication. The trial was designed like this so that the sputum 
corresponded to the 2 monthly sputum analysis, which is standard in TB control 
programs, including in South Africa. This patient had no previous drug susceptibility 
testing as this is not required in smear positive patients, with an initial episode of TB. It 
is theoretically possible that 2 weeks of trial medication could have resulted in acquired 
drug resistance, but it is more likely that the patient had MDR-TB at the time of entry 
into the trial. Of note is that the patient’s M. tuberculosis isolate was resistant to SM as 
well as other drugs and SM is not part of the trial treatment regimen.      
 
 
Patient TS 157 1b a 34-year-old female was hospitalized with crytptococcal meningitis 
21 days after enrollment. Crytptococcal meningitis is a common opportunistic infection 
associated with HIV infection and therefore the event was considered not related to 
trial medication. The patient was discharged on fluconazole 400mg daily for 10 weeks, 
thereafter fluconazole 200mg daily for life so her subsequent pharmacokinetic studies 
could not be included in the study analysis due to the potential drug-drug interactions.   
 
Two further patients were diagnosed with meningitis. Patient WTS 166 3b, a 44-year-







treatment and returned to complete the study.  Patient SM 184 1a, a 40-year-old male, 
was also hospitalized with a provisional diagnosis of TB meningitis. The patient was 
withdrawn from the trial and started on standard RMP based chemotherapy for TB. 
 
Patient PED 234, a 36-year-old male was hospitalized 2 days after enrollment with a 
problem of respiratory distress. Study personnel visited the patient in hospital and he 
disclosed that he had not taken any trial medication since his enrolment. He 
subsequently deteriorated and died.  His death certificate indicated disseminated TB 
as the cause of death, and there was no indication that study medication was 
implicated in the cause of this SAE. 
Patient PNS 250 3a, a 24-year-old female was hospitalized 16 days after enrolment 
giving a history of acute lower abdominal pain associated with vomiting since the 
morning of day of admission. Trial medication was continued in hospital and after 5 
days of treatment, the patient was completely asymptomatic and was discharged. The 
condition was diagnosed as pyelonephritis based on urine microscopy and culture and 
therefore this SAE was considered as not related to trial medication. 
 
6.3.2. Adverse Events 
The occurrence of adverse events was reviewed at each study visit and each was 
graded according to DAIDS tables. A summary of the number of AEs by trial arm is 







Most AEs were grade 1(52%) and grade 2 (33%) in severity. The most common AEs 
according to body systems were gastro-intestinal (41%) and hematology (20%). 
 
Table 6.2. Summary of Reported Adverse Events per arm 
AE Grade Arm 1 
(n = 14) 
Arm 2 
(n = 16) 
Arm 3 
(n = 16) 
Total 
Grade 1 36 42 34 113 
Grade 2 27 15 30 72 
Grade 3 5 5 12 23 
Grade 4 3 4 0 7 


















Table 6.3. Incidence of All Reported Adverse Events by Body System and by 




(n = 14) 
Arm 2 
(n = 16) 
Arm 3 






Loss of appetite 


































































































































Upper respiratory tract infection 













































































































































































Grade 3 AEs (10%) were reported in all 3 arms with arm 1 and 2 reporting 5 each and 
arm 3 reporting 12. Grade 4 AEs were reported in arm 1 and arm 2 only. A full listing of 
AEs by clinical system is shown in table 6.3. This was largely accounted by the higher 
occurrence of neutropenia in this group, but the mean changes from baseline were not 























Table 6.4. Grade 3 and 4 Clinical AEs according to body system and relationship 
to study drug 
 
Body System 
Incidence of AE 
Any Grade 3, 4 AE 














   Grade 3 
   Grade 4 
 Amylase increased 
   Grade 3 
Loss of weight 
   Grade 3 
Vomiting 
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 Grade 3  
 Grade 4 
Cryptococcal meningitis 




































































































6.3.3. Safety Laboratory Evaluation 
6.3.3.1. Treatment Emergent Changes in Transaminases and Neutrophil Count  
The co-administration of tuberculosis chemotherapy and ART is associated with a 
number of overlapping toxicities including hepatotoxicity and neutropenia.  Descriptive 
statistics of the actual laboratory values and changes from baseline are provided in 







initiation of trial medication but at a time when the patients were receiving intensive 









































Hemoglobin  (g/dl) 
Arm 1  
Arm 2  





















Neutrophils  (x 109 /L) 
Arm 1  
Arm 2  





















ALT (units/L)   
Arm 1  
Arm 2  
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There was a significant drop in neutrophil count at day 28 compared to baseline 
values, in all 3 arms. Thereafter, neutrophil count remained constant. 
 AST levels increased significantly at day 28 in arm 1 and thereafter remained 
constant. There were no significant changes in AST levels in arm 2. In arm 3, AST 








There was a significant increase in ALT levels in arm 1 at day 56 compared to baseline 
values. The increase in ALT levels, continued until day 112, but the increase was not 
significant. In arm 2, ALT levels dropped at day 28 (not significant) and from day 56 
onwards increased to match baseline levels. In arm 3, ALT levels increased at day 28 
(non significant) dropped at day 56 (not significant) and then increased to above 
baseline levels (significant only at day 112 of the trial).  
 
6.3.3.2. Laboratory grades 
Laboratory tests were evaluated using the DAIDS grading scale. A summary table of 
the number of subjects with treatment-emergent laboratory results per grade is 
provided in Table 6.6 below. Most treatment-emergent abnormalities were grade 1 or 2 
in severity. Grade 3 or 4 abnormalities occurred in hemoglobin, neutrophils, AST, ALT, 





Table 6.6. Treatment-Emergent Graded Laboratory Abnormalities (Worst 

























































































































































































































































6.3.4. Cardiovascular Safety 
Examination of vital signs included pulse, systolic blood pressure, diastolic blood 
pressure and respiration rate measurement at every trial visit. No treatment emergent 
adverse events related to vital signs were reported for any patients for the duration of 
the trial. 
 
6.3.5. Physical Examination 
A Physical examination was performed at all visits throughout the trial. There were no 








6.3.6. Specific Symptom screening 
Specific symptom screening was performed at every trial visit. Grade 2 red eye was 
reported in one patient in arm 1 on day 84 of the trial. There was one report of grade 3 
red eye, light sensitivity and blurred vision in a patient in arm 2 at day 112 of the trial. 
 
6.4. Discussion 
The commonest adverse event reported in all 3 arms of this study was neutropenia. 
Neutropenia is a common adverse event in patients taking RBT and has been reported 
predominantly in previous studies on healthy volunteers (Apseloff 2003). There were 
2/46 reports of grade 4 neutropenia in this study, one each in the EFV and NVP arms. 
Although there was a significant fall in the neutrophil count during the course of the trial 
most of this decline occurred in the first few weeks of RBT therapy prior to the initiation 
of ART and we did not find a significant association between neutropenia and plasma 
RBT concentrations. Neutropenia is also the most common side effect of cotrimoxazole 
therapy in HIV-infected patients (Moh 2005) and all patients in the present study were 
prescribed cotrimoxazole 960 mg daily as prophylaxis. The majority of the patients 
started cotrimoxazole at enrollment and this could have contributed to the declining 
neutrophil count seen in this study. None of the patients interrupted their study 
medication because of a decline in neutrophil count. 
 
One patient in the NVP arm developed grade 4 uveitis after 24 weeks of RBT therapy. 
The RBT plasma concentrations of this patient in the presence of NVP were higher 







patients in that arm. Another patient in the LPV/r arm developed grade 2 uveitis on day 
84 of the trial which coincided with the start of ART. Plasma RBT concentrations of this 
patient were not significantly higher than concentrations of the other patients. Uveitis is 
a common ocular complication occurring in up to 80% of HIV-positive patients with 
advanced disease (Cunningham 2000). . However, in HIV-positive patients taking RBT 
uveitis has been associated with high plasma concentrations of the drug, usually in the 
presence of CYP 450 inhibitors such as PIs, and azithromycin (Havlir et al 1996; Lin et 
al 2007; Bazewicz et al 2011). It is therefore difficult to attribute uveitis uniquely to 
RBT, although it was treatment emergent in this case. In the absence of a control 
group it is impossible to determine exactly the increased risk of uveitis in this patient 
group 
 
There was only one patient with grade 4 elevated transaminases. He was randomized 
to the NVP arm.  Hepatotoxicity is also a common adverse event in patients taking 
ART with and without concomitant RBT. Therefore the elevation in hepatic 
transaminases cannot be attributed solely to the use of RBT. Although the numbers in 
this trial are small, a single grade 4 event would suggest that hepatotoxicity is not 
going to be a limiting factor in RBT combined with ART when compared to rifampicin. 
 
There has been a reluctance to recommend a higher dose of RBT partly based on 
early experience with RBT and CYP3A4 inhibitors (Griffith et al 1995; Apseloff et al 
1996; Griffith et al 1996; Shafran et al 1996; Shafran et al 1998; Apseloff et al 2003). 







allowing a safety evaluation to be made over a longer duration. In this study the 
combinations of RBT and ART were generally well tolerated with no grade 4 toxicities 
in the LPV/r arm apart from 2 clinical serious adverse events unrelated to RBT, one 
report each of grade 4 neutropenia in the NVP and EFV arms and one report of grade 
4 elevated transaminases in the NVP arm. 
 
This study is too small to address all concerns about the toxicity of the higher dose 
RBT with ART, most notably the decrease in neutrophil count, which requires further 
evaluation. However the higher doses of RBT were well tolerated and the concerns 












Chapter 7. Pharmacogenomics 
Summary 
This study was undertaken to investigate the frequencies and influence of SNPs of 
SLCO1B1, on the pharmacokinetics of RBT. Data were analyzed by non-
compartmental methods. According to non-compartmental analysis, patients with the 
rs4149032 CT genotype had significantly higher RBT AUC and Cmax than patients with 
TT and CC genotypes.  
 
7.1. Introduction 
The pharmacokinetics of RBT shows substantial inter-patient variability in accordance 
with previous reports (Narang 1995; Skinner et al 1989). Various factors can affect the 
bioavailability of drugs, viz. age, weight (McIlleron et al 2006), HIV infection (Sahai et al 
1997; Perlman et al 2005) and genetic polymorphisms (Davies et al 2008). 
Polymorphisms in genes encoding drug metabolizing enzymes or drug transporters 
can affect the absorption, volume of distribution and hepatic clearance of a drug. The 
effect of various co-variates on the pharmacokinetics of RBT has been studied 
previously (Gatti et al 1998) but there is currently no data on the pharmacogenomic 
determinants of RBT exposure. Therefore, the present study was undertaken to 
investigate the frequencies of SLCO1B1 SNPs rs4149032, rs2306283, rs4149056 and 
rs 11045819 and their relationships to the pharmacokinetics of RBT in HIV-infected 







7.2. Patient enrolment information 
Forty-four patients provided pharmacokinetic data, of which 27 (61%) were male. Of 
the 44 patients that provided pharmacokinetic data, 6 were unavailable for provision of 
a sample for genetic analysis, which was only initiated after some patients had 
completed therapy. For two patients no result was obtained for one polymorphism 
(rs4149032). All patients were of black African ethnicity. 
	  
7.3. Results 
7.3.1. Patient Demographics 
The patient demographics have been previously described. The mean (sd) weight, 
height, age, BMI, Karnofsky score and CD4+ count of the patients were 58.01(8.3) kg, 
159.7(7.7) mm, 33.1 (6.0) years, 23.0 (3.3), 100 (100) and 126.1 (44.0) cells/mm3 
respectively. In chapter 3 only sex and weight were associated with RBT Cmax. 
 
7.3.2. Allelic Frequency and Non-compartmental analysis 
The allelic frequencies were determined using quantitative rtPCR as described in 
chapter two. The results are shown in table 7.1. The frequency of the SLCO1B1 
rs4149032 polymorphism was high in this study population. Nineteen individuals (53%) 
were homozygous and 12 (33%) were heterozygous for the reported variant allele, 
which is a C to T substitution. These were comparable to a previous study from South 







allele therefore this SNP was not included in the analysis. All polymorphisms were in 
Hardy-Weinberg equilibrium. 
 
Table 7.1. Allele frequencies among patients with SLCO1B1 SNPs 
 
SNP Genotype (number of patients, %) 
rs4149032 TT (19, 53) CT (12, 33) CC (5, 14) No data (8) 
rs4149056 CC (37) CT (1)  No data (6) 
rs2306283 GG (29, 76) AG (9, 24)  No data (6) 
rs11045819 CC (33, 87) AC (5, 13)  No data (6) 
 
 
The results of non-compartmental analysis are displayed in Table 7.2. below. 
According to non-compartmental analysis, patients with the rs4149032 CC genotype 
had significantly lower RBT AUC0-24 and Cmax than patients with CT polymorphism 
.There are 12 patients in the study with the CT polymorphism and in all 12 patients 
RBT AUC0-24 were below the AUC0-24 previously associated with ARR (Weiner 2005a). 











Table 7.2. Rifabutin pharmacokinetic parameters from non-compartmental 
analysis among patients with SLCO1B1 rs4149032, rs2306283 and  rs11045819 
single nucleotide polymorphisms 
SNP	   Mean	  	   Standard	  Deviation	  	   Confidence	  Interval	  	   	  	   P-­‐value	  
SLCO1B1	  rs4149032	   	  	   	  	   	  	   	  	   	  	  
Log	  AUC0-­‐24	   	   	   	   	   	  
CC(5)	   7.8	   0.1	   (7.6-­‐	  7.2)	   mean(CT)	  vs	  mean(TT)	   0.07	  
CT	  (12)	   8.0	   0.2	   (7.9	  -­‐	  	  8.1)	   mean(CC)	  vs	  mean(TT)	   0.9	  
TT	  (19)	   7.8	   0.4	   (7.6	  -­‐	  	  8.0)	   mean(CC)	  vs	  mean(CT)	   0.01	  
	  	  
	   	   	   	   	  Cmax	  
	   	   	   	   	  CC	  (5)	   210.2	   56.0	   (159.3	  -­‐	  	  261.1)	   mean(CT)	  vs	  mean(TT)	   0.08	  
CT	  (12)	   344.5	   87.5	   (293.2	  -­‐	  395.8)	   mean(CC)	  vs	  mean(TT)	   0.5	  
TT	  (19)	   256,8947	   148.9	   (187.5	  -­‐	  	  326.3)	   mean(CC)	  vs	  mean(CT)	   0.007	  
	  	  
	   	   	   	   	  SLCO1B1	  rs2306283	  
	   	   	   	   	  log	  AUC0-­‐24	  
	   	   	   	   	  AG	  (9)	   7.8	   0.4	   (7.5	  -­‐	  	  8.1)	  
	   	  GG	  (29)	   7.9	   0.3	   (7.8	  -­‐	  	  8.0)	   mean(AG)	  vs	  mean(GG)	   0.6	  
	  	  
	   	   	   	   	  Cmax	  
	   	   	   	   	  AG	  (9)	   271.3	   116.	   (181.8	  -­‐	  	  360.9)	  
	   	  GG	  (29)	   287.0	   135.4	   (235.5	  -­‐	  	  	  338.5)	   mean(AG)	  vs	  mean(GG)	   0.8	  
	  	  
	   	   	   	   	  SLCO1B1	  rs11045819	  
	   	   	   	   	  log	  AUC0-­‐24	  
	   	   	   	   	  AC	  (5)	   8.1	   0.4	   (7.5	  -­‐	  	  8.7)	  
	   	  CC	  (33)	   7.8	   0.3	   (7.7	  -­‐	  	  8.0)	   mean(AC)	  vs	  mean(CC)	   0.1	  
	  	  
	   	   	   	   	  Cmax	   	  	   	  	   	  	   	  	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	  
AC	  (5)	   323.8	   164.7	   (119.3	  -­‐	  	  528.2)	   	  	   	  	  
CC	  (33)	   277.2	   125.7	   (232.6	  -­‐	  	  321.7)	   	  mean(AC)	  vs	  mean(CC)	   0.5	  
	  	   	  	   	  	   	  	   	  	   	  	  














This study shows that the SLCO1B1 rs4149032 polymorphism (C to T) occurs 
frequently in African patients in Durban. This polymorphism has been reported to occur 
more frequently in Africans (75%) compared to Caucasians (29%) and Asians (56%) 
(http://www.ncbi.nlm.nih.gov/progects/SNP/snp_ref.cgi?rs=4149032).   A previous 
South African study has found that thirty-one individuals were homozygous (52%) for 







the common allele. This study showed that both the heterozygous and homozygous 
variant allele genotypes were associated with reduced RMP bioavailability (Chigutsa et 
al 2011).  
Whilst the allele frequencies are very similar in this study the associations with RMP 
bioavailability were not found to be statistically significant. Although the AUC0-24 and 
Cmax of the homozygotes for the variant allele (TT) were lower than the heterozygotes, 
and close to statistically significant, in line with the study by Chigutsa, The PK 
parameters of homozygotes for the common allele were also lower and statistically so. 
This could be due to low numbers and variability in this patient group. Another 
possibility is linkage disequilibrium with other loci determining RBT bioavailability. None 
of the other SNPs evaluated in this study were found to be associated with RBT 
bioavailability. 
Another recent study has shown that the presence of SNP rs 11045819 C463A 
reduced RMP exposure by 36% in a mixed cohort of Africans and Caucasions (Weiner 
et al 2010). However, this allele was not common in this study population and no 
significant associations were found with this allele and RBT AUC0-24 or Cmax.  
 
Previous studies on the pharmacogenomic determinants of RMP exposure suggest 
that a dose increase of RMP should be considered for South African patients. This 
study has shown that RBT bioavailability is low in South African patients and there may 
be a genetic association with RBT bioavailability. However, more studies are needed to 







Chapter 8. Conclusion and Future Recommendations 
This study investigated the pharmacokinetics, pharmacodynamics and 
pharmacogenomics of RBT in severely immunosuppressed TB-HIV co-infected 
patients, in the absence and presence of ART and has provided important information 
on how the complex management of co-infected patients can be improved. 
 
This study has shown that the bioavailability of RBT is low in African TB patients co-
infected with HIV. However, when RBT 150mg daily is co-administered with LPV/r in 
the same patients, RBT exposure increases and is in line with concentrations required 
to prevent ARR in co-infected patients. Another interesting observation in this study 
was the approximately 1000-fold increase in d-RBT exposure with daily dosing of RBT 
despite the LPV/r dose remaining unchanged. Previous studies have reported that a 
high incidence of toxicity is associated with high plasma concentrations of d-RBT. 
However, in this study, adverse events were few and there were no deaths related to 
RBT. Nevertheless, the results of this study should be interpreted with caution and 
more studies in a larger cohort are required to confirm theses findings.   
 
The combination of RBT 300mg and 450mg daily with NVP results in significantly 
higher exposure of RBT compared to 300mg RBT given alone in the same patients. 
This observation was completely unexpected, as NVP is a CYP 3A4 inducer an in 
combination with RBT is expected to accelerate RBT metabolism. More studies are 







such high exposure in TB-HIV co-infected patients. This study has reported few 
adverse events but more studies in a larger cohort are required. However, if RBT is 
well tolerated by severely immunosuppressed co-infected patients at 300mg with NVP 
then this has implications for current policy on the management of TB-HIV co-infected 
patients. Presently most ART programs in resource-limited countries use EFV-based 
ART in the treatment of co-infected patients. Nevirapine is a cheaper ARV and its 
incorporation into a combined TB-HIV regiment might be more suitable than the EFV-
based regiment. 
 
The combination of RBT 450mg with EFV produced RBT exposures lower than the 
exposure of RBT 300mg given alone in the same patients. Therefore increasing the 
dose of RBT to 600mg daily with EFV, produces RBT plasma concentrations above 
and/or equivalent to 300mg RBT daily given alone in the same patients. This confirms 
current dosing recommendations for the combined use of RBT and EFV 
 
More studies are required to confirm the results of this study. A recent study in Vietnam 
(NCT 01259219) has compared the pharmacokinetics of RBT 150mg TPW plus LPV/r 
with RBT 150mg daily plus LPV/r in TB-HIV co-infected patients with CD4+ cell counts 
< 200/mm3. The results of this study are eagerly awaited, as it will provide further 
evidence of the most suitable dose of RBT to use in combination with LPV/r in the 







The pharmacogenomics study investigated various SNPs and their relationships to 
RBT exposure. A major limitation of this study was the small sample size. However, 
this study has shown that there may be a genetic association with RBT bioavailability 
in African patients. These observations are similar to previous studies that have found 
a genetic association with RMP bioavailability in South African patients. Thus a larger 
pharmacogenomic study will be able to provide more evidence on the genetic influence 
on rifamycin exposure in South African patients particularly when it is believed that the 
dosing of RMP should be increased in African patients. 
 
This study has generated important new data, which may have implications for clinical 
practice, however more studies are required to influence policy changes. Data from the 
Vietnam study are required to confirm the findings of this study and provide conclusive 
evidence that may possibly change current policies on the treatment of TB patients co-
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The pharmacokinetics of rifabutin at 150mg daily and 150mg three times weekly 
with LPV/ritonavir were evaluated in TB-HIV co-infected patients. Intermittent 
rifabutin plus lopinavir/ritonavir results in sub-therapeutic rifabutin drug 









Background: Pharmacokinetic interactions between rifampicin and protease inhibitors 
complicate the management of HIV-associated tuberculosis. Rifabutin is an alternative 
rifamycin, preferred in patients requiring protease inhibitors (PIs). Despite recent 
studies suggesting that the current recommended dose of rifabutin in combination with 
boosted lopinavir (LPV/r) is suboptimal, there are insufficient pharmacokinetic data 
evaluating the interaction in patients treated with the film-coated tablet formulation of 
LPV/r. 
 
Methods and Findings: The pharmacokinetics of rifabutin was evaluated at two 
different doses in HIV co-infected African patients in Durban, South Africa, before and 
after administration of LPV/r (tablet formulation 400/100 mg 12 hourly)-based 
antiretroviral therapy (ART). Serial rifabutin and 25-O-desacetyl rifabutin 
concentrations were measured during a dose interval after 4 weeks of rifabutin 300 mg 
daily, after 4 weeks of 150 mg rifabutin daily with ART and after 4 weeks of rifabutin 
150 mg 3 times a week (TPW) with ART. The median AUC0-48 and Cmax, of rifabutin in 
patients taking 150mg rifabutin TPW was significantly reduced when compared to the 
other treatment arms. 86% of patients on this intermittent rifabutin arm had an AUC0-24 
< 4.5 μg.h/mL, which has been associated with acquired rifamycin resistance (ARR) in 
patients on twice weekly doses. Rifabutin was well tolerated at all doses and there 
were no grade 4 laboratory toxicities. One case of uveitis occurred prior to starting 







Conclusions: A daily 150 mg dose of rifabutin in combination with LPV/r safely 








Treating HIV associated tuberculosis remains a formidable challenge. In 2009, 12% of 
the 9.4 million incident cases of tuberculosis, and 22% of deaths from tuberculosis 
were in HIV-infected patients [1]. Combining efavirenz-based first-line antiretroviral 
therapy (ART) with rifampicin based tuberculosis chemotherapy significantly reduces 
mortality in these patients [2-4] and is safe and efficacious. However, as public sector 
ART expands, an increasing number of patients are developing virological failure and 
require second-line ART [5]. However, combining rifampicin and protease inhibitor-
based  second-line ART is problematic as rifampicin significantly reduces the 
bioavailability of protease inhibitors by accelerating their metabolism via induction of 
cytochrome 3A4 (CYP3A4) enzymes. Increasing the dose of the protease inhibitor or 
co-administering higher doses of a CYP3A4 inhibitor to ameliorate this adverse drug-
drug interaction have been thwarted by hepatotoxicity and other problems with 
tolerance [6].  
Rifabutin, a less potent inducer of CYP3A4 [7, 8], is recommended at 300 mg daily as 
prophylaxis and treatment of Mycobacterium avium complex (MAC) and for the 
treatment of drug susceptible tuberculosis (Mycobutin package insert). Plasma 
concentrations of rifabutin are increased in the presence of protease inhibitors [9] 
therefore dose adjustments are recommended when rifabutin is combined with a 
protease inhibitor. Current guidelines recommend dosing rifabutin 150 mg three times 
per week (TPW) in combination with a ritonavir-boosted protease inhibitor [10, 11]. 
However, recent reports suggested that this dosing in HIV-positive tuberculosis 







acquired rifamycin resistance (ARR) [15]. The present study was therefore undertaken 
to compare the bioavailability of two doses of rifabutin (150mg TPW and 150mg daily) 
with the standard 300mg dose in HIV-positive tuberculosis African patients in Durban, 
South Africa, initiating ART with LPV/r. 
Methods 
Study Design 
An open-label, three-period, crossover drug interaction study was undertaken to 
investigate the pharmacokinetics of rifabutin with and without PI-based ART. The 
secondary objective was to assess the tolerability and safety of rifabutin and lopinavir. 
The study was approved by the Biomedical Research Ethics Committees of the 
Universities of Kwa-Zulu Natal and Cape Town and the South African Medicines 
Control Council.  
Recruitment 
Patients were recruited from local tuberculosis clinics in Kwa-Zulu Natal, South Africa. 
Eligibility requirements were provision of written informed consent, a diagnosis of 
pulmonary tuberculosis confirmed by microscopy or culture, HIV infection with CD4 
lymphocyte count ≥ 50 and ≤ 200 cells/mm3, weight ≥ 50kg or a BMI ≥ 18, a Karnofsky 
score Q ≥ 80% and no grade 3 or 4 clinical or laboratory findings according to DAIDS 
tables [16]. Only patients who completed and adhered to 6 weeks of standard intensive 
phase chemotherapy and had not received ART therapy in the preceding three months 
were enrolled. Patients with a previous tuberculosis episode within three years prior to 







opportunistic infection requiring additional anti-microbial treatment, a formal 
contraindication to any trial medication, diabetes mellitus requiring treatment, 
recreational drug or alcohol abuse, , mental illness, total neutrophil count < 1200 
cells/L, hemoglobin < 6.8 g/dL, or liver function tests > grade 2, pregnancy or lactating 
women.  
Treatments under study  
At enrollment, six weeks after starting standard tuberculosis chemotherapy, rifampicin 
was switched to rifabutin 300 mg daily. After two weeks of rifabutin, pyrazinamide and 
ethambutol were stopped and patients continued with daily doses of rifabutin 300 mg 
in combination with isoniazid 300mg. After two more weeks, the first pharmacokinetic 
evaluation (PK1) was carried out and patients were randomized to one of two different 
rifabutin dose sequences together with daily doses of isoniazid and ART comprising 
LPV/r (400/100 mg) plus lamivudine (150mg bd) and stavudine (30mg bd). Half the 
patients received rifabutin 150 mg TPW for 4 weeks before being switched to rifabutin 
150 mg daily after a second pharmacokinetic evaluation (PK2). A third 
pharmacokinetic evaluation (PK3) took place after 4 weeks and they remained on this 
dose of rifabutin until completion of tuberculosis treatment. Half the patients received 
the two rifabutin doses in a reverse sequence. . Physical examinations and laboratory 
investigations were done at every pharmacokinetic evaluation and at the penultimate 
trial visit to assess safety and adverse events. Upon completion of the trial, patients 
were referred to local antiretroviral clinics for further management. Pfizer (South Africa) 
supplied the rifabutin (Mycobutin®) 150mg capsules and the new film-coated tablet 







Sample size   
The sample size was calculated on the basis that 16 enrolled participants would result 
in a minimum of 12 evaluable subjects. Based on the AUC0-24 for rifabutin determined 
in previous studies, it was estimated that a sample size of 12 participants had a power 
of 80% to detect a 20% difference between the mean AUC0-24 for rifabutin with and 
without ART.  
Pharmacokinetic Sampling 
All patients were admitted before each pharmacokinetic occasion and were fasted from 
midnight. A standard hospital breakfast was served 2h after drug ingestion. Blood 
draws were done at 0, 2, 3, 4, 5, 6, 8, 12, 24 and 48h after drug ingestion. The 
samples were placed on ice immediately and centrifuged at 3000 rpm at 40C for 10 




Rifabutin and 25-O-desacetylrifabutin were analyzed with a validated LC/MS/MS 
assay. Rifaximin was used as internal standard at a concentration of 100 ng/ml. 
Gradient chromatography was performed on a Phenomenex, Luna 5 μm PFP(2), 100 
A, 50 mm × 2 mm analytical column, using acetonitrile and 0.1% formic acid as mobile 
phase, and a flow rate of 500 µl/min.  An AB Sciex API 3200 mass spectrometer 







m/z 805.4 to the product ions at m/z 95.1 for 25-O-desacetylrifabutin, and at m/z 786.3 
to the product ions m/z 151.1 for Rifaximin. Rifabutin and 25-O-desacetylrifabutin 
accuracies were between 99.1% and 109.0% during inter-batch validation. The co-
efficient of variation during inter-batch validation was less than 9.2%. The calibration 
range for rifabutin was between 3.91 ng/ml and 1000 ng/ml, and for 25-O-
desacetylrifabutin between 0.780 ng/ml and 200 ng/ml. 
 
Lopinavir  
Plasma lopinavir concentrations were quantified by a validated LCMS/MS method 
using a modification of the method previously described by Chi et al [17]. The 
calibration curve was linear over the range from 0.05 to 20 mg/L. Samples with a 
concentration of > 20 mg/L, were diluted re-analyzed. Any sample below the LLQ was 
reported as 0.5 X LLQ for analysis. Accuracy ranged from 94.3% to 103.0%. The 
intraday and interday coefficient of variation (CV) ranged from 0.14% to 4.72% and 
from 1.61% to 4.22%, respectively.  
 
Pharmacokinetic Analysis 
The main pharmacokinetic measures for rifabutin, 25-O-desacetylrifabutin and 
lopinavir were derived by noncompartmental analysis using Stata (version 11). The 
peak concentration (Cmax), and time to Cmax (Tmax) were obtained directly from 







reported as Cmin and pre-dose concentrations as C0. The steady-state AUC from time 
0h to the last quantifiable sample at 24h (AUC0-24) or 48h (AUC0-48) for rifabutin and 
12h (AUC0-12) for LPV/r were calculated by the linear trapezoidal method. The apparent 




For statistical analysis, the AUC was log- transformed and log AUC was normally 
distributed. A linear mixed model with two doses (high and low), day (2 and 3), 
sequence and log AUC0-24 at baseline and id nested within sequence was used. As 
there was no significant effect of sequence, the two arms were pooled and the model 
was used to test the dose effect after adjusting for baseline differences.  A paired t-test 
was used to compare the AUC 150mg daily at 24 hours with baseline at 24 hours and 
the 150mg TPW at 48 hours  with  2 x baseline at 24 hours because the dosing interval 
is 48 hours for the TPW dose. 
To calculate geometric mean ratios (GMR) for AUC, log means and 90% confidence 
limits were back transformed and presented in their original units as geometric means. 
Geometric mean ratios for the AUC of rifabutin: 150 mg daily with LPV/r / 300mg daily, 
and 150 mg TPW with LPV/300mg daily, respectively, were computed. A P-value < 
0.05 was considered significant. Inter-patient variability was measured by   co-efficient 
of variation (%CV) which was calculated as {100X e(var est) -1)1/2}. Baseline and final log 










Sixteen patients received LPV/r therapy with rifabutin. Two patients were withdrawn 
from the pharmacokinetic analysis, one due to uveitis and another due to non-
compliance on trial medication. All patients were Black South Africans and (64%) were 
male. The evaluable subjects’ mean (SD) age was 31.5 (5.8) years, weight was 59.9 
(9.7) kg, height was 160 (7.7) cm, BMI was 23.3 (2.6), Karnofsky score Q was 100 % 
(100) and CD4+ lymphocyte count was 150.9 (12.1) cells/mm3. 
Pharmacokinetic Analysis 
Rifabutin 
The main pharmacokinetic parameters for rifabutin and 25-O-desacetylrifabutin are 
summarized in Table 1. The AUC0-24 of rifabutin 150 mg daily with LPV/r was 
significantly higher when compared to the AUC0-24 of rifabutin 300 mg daily in the 
absence of LPV/r (p = 0.004). In contrast, the AUC0-48 of rifabutin 150 mg TPW with 
lopinavir/r was significantly lower than the AUC0-48 of rifabutin 300 mg daily (p = 
0.0001). Wide inter-patient variability was observed in rifabutin AUC for all three doses 
(Table 2).  The %CV was 24% for the 300mg dose, 46% for rifabutin 150 mg daily plus 








The Cmax of rifabutin 150 mg TPW with LPV/r was also significantly lower when 
compared to the 150 mg daily dose with LPV/r (P = 0.01) and the 300 mg daily dose 
without LPV/r (P = 0.01). The median Cmin for rifabutin 300mg was 60.7 ng/mL (IQR, 
40.6-68.8 ng/mL). The Cmin values increased in the presence of LPV/r with daily dosing 
of rifabutin but dropped significantly with the intermittent dose. Rifabutin clearance was 
significantly reduced in the presence of LPV/r (p= 0.001 for daily and p = 0.002 
intermittent rifabutin dosing) compared to 300mg rifabutin given alone. 
 
25-O-Desacetylrifabutin 
Without lopinavir, 25-O-desacetylrifabutin concentrations were 11 % of the parent drug. 
Plasma 25-O-desacetylrifabutin concentrations increased 5-fold with intermittent 
rifabutin dosing and 15-fold with daily doses of rifabutin (Figure 2). The total 
antimicrobial moiety (combined AUC0-24 of rifabutin and metabolite) for rifabutin at 
150mg TPW with ART was 1.2 times greater than for 300mg rifabutin and 2.6 times 
greater than for 150mg daily with ART.  
 
Lopinavir Pharmacokinetics  
LPV/r pharmacokinetic measures are shown in Table 3 in Figure 3. Median LPV/r 
trough (C0) concentrations were above the recommended lower limit for ART-naïve 
patients of 1 µg/mL [18]. Although there was a trend to higher LPV/r concentrations 







two doses were not significant. Double peaks were observed in the lopinavir 
concentration-time profile with both doses of rifabutin. 
 
Response to TB/HIV Treatment  
Three patients were culture positive after two months of tuberculosis therapy and none 
culture positive at the end of therapy. The mean final CD4+ count at the end of 
tuberculosis therapy was 253.8 (42.4) cells/mm3, and significantly higher (p = 0.03) 
than baseline. The mean (SD) viral load dropped significantly (p < 0.001) by 2.7 log10 
copies and 8 patients had viral loads > 500 cells/L.  
Adverse Events 
Adverse events (AE) were analyzed for all sixteen patients. Rifabutin was well 
tolerated at all doses and there was only one withdrawal because of an adverse event 
(uveitis). There were two serious adverse events (bacterial meningitis and 
pyelonephritis), both unrelated to rifabutin. Grade 2 uveitis occurred in one patient after 
1 month of rifabutin, coinciding with the start of ART, and resolved with no sequelae 
after withdrawal.  Her AUC0-24 and Cmax values for rifabutin were within the interquartile 
range. The commonest laboratory AE was neutropenia. Grade 3 neutropenia occurred 
on six occasions in 4 patients. There were 2 grade 3 elevations in transaminases and 









The currently recommended dose of rifabutin for the treatment of pulmonary 
tuberculosis is 300mg daily but there are few pharmacokinetic data, especially from 
HIV infected African tuberculosis patients. The median rifabutin AUC0-24 and Cmax 
values from this study are comparable to previous studies of rifabutin 300mg daily in 
HIV-infected patients [12, 19-21].  
 
Previous studies of the pharmacokinetic interaction of rifabutin with LPV/r in HIV 
infected individuals have been small case series or involved an adaptive design in 
which only selected patients were exposed to the higher dose of rifabutin. In addition, 
no previous studies have reported on the rifabutin pharmacokinetics in combination 
with the most widely used tablet formulation of LPV/r (Aluvia). We adopted a cross-
over design in which all patients received 3 full pharmacokinetic assessments with 
rifabutin alone and at two different rifabutin doses in combination with ART allowing us 
to formally compare the different dosing strategies. We found the AUC0-24 and Cmax of 
rifabutin when 150mg was given intermittently with ART, to be significantly lower than 
daily dosing or dosing at 300mg daily without ART.  
 
The reduced bioavailability of intermittent dosing of rifabutin at 150mg with LPV/r could 
result in suboptimal tuberculosis therapy, although the pharmacodynamic-
pharmacokinetic (PKPD) relationship for rifabutin has not been comprehensively 
studied. It is still uncertain if Cmax or AUC is the critical pharmacodynamic measure for 







PKPD measure, whereas subsequent murine and hollow fibre models [24] [25], and 
early bactericidal activity studies in humans[26] found that the AUC0-24/MIC ratio was a 
superior parameter.  
 
Despite a lack of conventional efficacy data in support of a particular dose of RBT, 
there is convincing evidence that intermittent rifamycin therapy is associated with 
tuberculosis relapse and ARR, especially in subjects with low CD4 counts [28-30]. In 
TBTC study 23 [15], TB-HIV co-infected patients who had lower AUC0–24  of < 4.5 
μg.h/mL plasma concentrations of rifabutin were at risk of ARR. 83% of patients who 
relapsed or failed therapy developed ARR as opposed to only 33% who had AUC’s 
above this threshold value. We found 71% patients on rifabutin 150mg daily and 14% 
on rifabutin TPW had AUC0-24 values > 4.5 μg.h/mL.   
 
The AUC0-24 and Cmax of 25-O-desacetylrifabutin were significantly increased in the 
presence of LPV/r in keeping with previous studies [9, 31 - 34]. The exposure to the 
metabolite increased approximately 5- and 15-fold when rifabutin150 mg was given 
intermittently or daily with LPV/r. 25-O-desacetylrifabutin is known to have significant 
antimycobacterial activity and could contribute to regimen efficacy. Interestingly, when 
rifabutin and the metabolite were combined the AUC0-24 on the 150mg daily dose with 
LPV/r was significantly increased compared to both the other arms. The therapeutic 
index of 25-O-desacetylrifabutin is unknown and it is possible that elevations of the 







plasma rifabutin and 25-O-desacetylrifabutin concentrations and adverse events was 
not seen although the numbers of patients are few.   
 
There has been a reluctance to recommend a higher dose of rifabutin partly based on 
early experience with rifabutin and CYP3A4 inhibitors [35-39]. An advantage of this 
study is that patients remained on study doses up to six months allowing a safety 
evaluation to be made over a longer duration. In this study the combinations of rifabutin 
and LPV/r were generally well tolerated with no grade 4 toxicities apart from 2 clinical 
serious adverse events unrelated to rifabutin. Neutropenia was a common adverse 
event and has been reported predominantly in previous studies on healthy volunteers, 
but there were no grade 4 cases. There was a significant fall in the neutrophil count but 
most of this decline occurred in the first few weeks of rifabutin therapy prior to the 
initiation of ART and no significant association between neutropenia and plasma 
rifabutin concentrations was found. Neutropenia is also the most common side effect of 
cotrimoxazole therapy [40] and all patients in the present study received cotrimoxazole 
960 mg daily. The majority of the patients started cotrimoxazole at enrollment and this 
would have contributed to the declining neutrophil count seen in this study.  
 
We also evaluated the pharmacokinetics of LPV/r in the presence of rifabutin. The 
median LPV/r AUC0-12, Cmax, C0 and C12 obtained in this study when LPV/r was 
administered with two different doses of rifabutin are comparable to those reported by 







were observed in the time-concentration profiles of LPV/r, usually within 4 hours of 
drug ingestion, similar to patterns observed in other studies. In both dosing arms, 
median LPV/r trough (C0) concentrations at steady state were above the 
recommended lower limit for ART-naïve patients of 1 µg/mL [18] and therapeutic LPV/r 
trough (C0) and Cmin (C12) concentrations were achieved in all participants with both 
doses of rifabutin [41].  
 
In conclusion this study supports an alteration to the current guidelines for the dosing 
of rifabutin in combination with LPV/r. The high proportion of participants on the 150mg 
TPW arm who failed to achieve rifabutin concentrations that prevented the emergence 
of drug resistance when the drug is dosed twice weekly is concerning. Although 
escalating the rifabutin dose after therapeutic drug monitoring is a viable option in 
resource rich settings it is impractical in many regions of the world where HIV and TB 
are endemic. Our study was too small to address all concerns about the toxicity of the 
higher dose rifabutin with LPV/r, most notably the decrease in neutrophil count, which 
requires further evaluation. However the 150 mg daily dose was well tolerated and 
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Table	  1.	  Main	  pharmacokinetic	  parameters	  median	  (interquartile	  range)	  
for	  rifabutin	  and	  25-­‐O-­‐desacetylrifabutin	  derived	  by	  non-­‐compartmental	  
analysis	  for	  each	  of	  the	  study	  treatments:	  rifabutin	  300mg	  daily,	  rifabutin	  
150	  mg	  thrice	  weekly	  (TPW)	  plus	  lopinavir/ritonavir	  (LPV/r),	  and	  
rifabutin	  150	  mg	  daily	  plus	  LPV/r.	  
*	  calculated	  by	  2	  X	  AUC0-­‐24	  
RBT	  =	  rifabutin;	  d-­‐RBT	  =	  25-­‐O-­‐deacetylrifabutin;	  LPV/r	  =	  lopinavir/ritonavir;	  TPW	  =	  three	  times	  per	  week;	  AUC	  =	  area	  
under	  the	  curve;	  Cmax	  =	  maximum	  concentration	  in	  plasma;	  Tmax	  =	  time	  at	  which	  maximum	  plasma	  attained;	  CL/F	  =	  








Treatment	  period	   Rifabutin	  300mg	   Rifabutin	  150	  mg	  TPW	  
plus	  LPV/r	  
Rifabutin	  150	  mg	  daily	  
plus	  LPV/r	  
Rifabutin	  (n=14)	   	   	   	  












Cmax	  (ng/mL)	   291.5	  (250.0-­‐377.0)	   167.5	  (87.8-­‐294.0)	   311.0	  (258.0-­‐376.0)	  
Tmax	  (h)	   3.0	  (3.0-­‐4.0)	   3.5	  (3.0-­‐5.0)	   3.0	  (3.0-­‐4.0)	  
C0	  (ng/mL)	   59.0	  (36.4	  -­‐	  78.6)	   49.1	  (27.7-­‐58.9)	   176.5	  (149.0	  –	  195.0)	  
Cmin	  24h	  (ng/mL)	   60.7	  (40.6	  -­‐68.8)	   70.7	  (45.7	  –	  96.6)	   133.0	  (105.0	  –	  191.0)	  
Cmin	  48h	  (ng/mL)	   -­‐	   37.0	  (26.6-­‐70.0)	   -­‐	  






	  (2424.6	  –	  6772.7)	  
8753.0	  
	  (7771.7	  –	  11	  505.0)	  



















77.2	  (58.6-­‐128)	   236.5	  (159.0-­‐274.0)	  
Tmax	  (h)	   3.0	  (3.0-­‐4.0)	   5.0	  (4.0-­‐6.0)	   4.0	  (3.0-­‐3.0)	  
C0	  (ng/mL)	   5.1	  (2.7-­‐6.6)	   44.6	  (31.7-­‐68.9)	   186.0	  (115.0-­‐232.0)	  
Cmin	  24h	  (ng/mL)	   5.0	  (3.4	  -­‐5.8	   63.9	  (42.7-­‐101.0)	   155.0	  (53.6-­‐206.0)	  






Table	  2.	  	  Comparison	  of	  	  geometric	  mean	  ratios	  (GMR)	  for	  rifabutin	  when	  
rifabutin	  150	  mg	  is	  administered	  three	  times	  per	  week	  (TPW)	  or	  daily	  with	  
lopinavir/r	  vs.	  rifabutin	  300	  mg	  daily	  without	  lopinavir/ritonavir	  and	  
comparison	  of	  rifabutin	  150mg	  TPW	  with	  lopinavir/ritonavir	  vs	  rifabutin	  
150mg	  daily	  with	  lopinavir/ritonavir	  
	  
	   GMR	  	  (90%	  CI)	  




RBT	  150mg	  daily	  
with	  ART/	  RBT	  
300mg	  daily	  
RBT	  150mg	  daily	  
with	  ART/RBT	  
150mg	  TPW	  with	  
ART	  
AUC0-­‐24	   1.3	  (1.3	  -­‐2.1)	   1.6	  (0.1	  -­‐2.5)	   2.04	  (1.1	  -­‐3.9)	  
AUC0-­‐48	   1.6	  (1.0	  –	  2.6)	   1.6	  (1.0	  -­‐2.4)	   2.6	  (1.5	  -­‐4.5)	  






















Table	  3.	  Table	  3.	  Lopinavir	  pharmacokinetic	  parameters	  derived	  from	  the	  
non-­‐compartmental	  analysis	  when	  lopinavir/ritonavir	  was	  given	  in	  
combination	  with	  two	  different	  doses	  of	  rifabutin.	  
	   Median	  (Interquartile	  range)	  
Parameter	   RBT	  150mg	  TPW	  plus	  
LVP/r	  
RBT	  150mg	  daily	  plus	  
LPV/r	  
AUC0-­‐12	  (µg.h/mL)	   139.5	  (103.8	  –	  163.9)	   160.1	  (129.1	  –	  181.9)	  
Cmax	  (ng/mL)	   15.8	  (12.9	  –	  17.1)	   18.1	  (14.5-­‐19.6)	  
Tmax	  (h)	   2.0	  (2.0	  –	  3.0)	   2.0	  (2.0-­‐3.0)	  
C0(µg/mL)	   9.8	  (3.5	  –	  14.0)	   11.4	  (9.9	  –	  15.2)	  
C12	  (µg/mL)	   7.4	  (4.5	  –	  10.0)	   9.4	  (7.2	  –	  11.6)	  
RBT	  =	  rifabutin;	  LPV/r	  =	  lopinavir/ritonavir;	  TPW	  =	  three	  times	  per	  week;	  AUC	  =	  area	  under	  the	  curve;	  Cmax	  =	  maximum	  
concentration	  in	  plasma;	  Tmax	  =	  time	  at	  which	  maximum	  plasma	  attained;	  C0	  =	  pre-­‐dose	  concentration;	  C12	  =	  trough	  
concentration	  
 
